
<html lang="en"     class="pb-page"  data-request-id="2cf637a0-1d32-46d8-b869-e58da7878620"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-13;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.9b00439"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors" /></meta><meta name="dc.Creator" content="Marian C.  Bryan" /></meta><meta name="dc.Creator" content="Joy  Drobnick" /></meta><meta name="dc.Creator" content="Alberto  Gobbi" /></meta><meta name="dc.Creator" content="Aleksandr  Kolesnikov" /></meta><meta name="dc.Creator" content="Yongsheng  Chen" /></meta><meta name="dc.Creator" content="Naomi  Rajapaksa" /></meta><meta name="dc.Creator" content="Chudi  Ndubaku" /></meta><meta name="dc.Creator" content="Jianwen  Feng" /></meta><meta name="dc.Creator" content="Willy  Chang" /></meta><meta name="dc.Creator" content="Ross  Francis" /></meta><meta name="dc.Creator" content="Christine  Yu" /></meta><meta name="dc.Creator" content="Edna F.  Choo" /></meta><meta name="dc.Creator" content="Kevin  DeMent" /></meta><meta name="dc.Creator" content="Yingqing  Ran" /></meta><meta name="dc.Creator" content="Le  An" /></meta><meta name="dc.Creator" content="Claire  Emson" /></meta><meta name="dc.Creator" content="Zhiyu  Huang" /></meta><meta name="dc.Creator" content="Swathi  Sujatha-Bhaskar" /></meta><meta name="dc.Creator" content="Hans  Brightbill" /></meta><meta name="dc.Creator" content="Antonio  DiPasquale" /></meta><meta name="dc.Creator" content="Jonathan  Maher" /></meta><meta name="dc.Creator" content="John  Wai" /></meta><meta name="dc.Creator" content="Brent S.  McKenzie" /></meta><meta name="dc.Creator" content="Patrick J.  Lupardus" /></meta><meta name="dc.Creator" content="Ali A.  Zarrin" /></meta><meta name="dc.Creator" content="James R.  Kiefer" /></meta><meta name="dc.Description" content="A series of pyrazolopyrimidine inhibitors of IRAK4 were developed from a high-throughput screen (HTS). Modification of an HTS hit led to a series of bicyclic heterocycles with improved potency and ..." /></meta><meta name="Description" content="A series of pyrazolopyrimidine inhibitors of IRAK4 were developed from a high-throughput screen (HTS). Modification of an HTS hit led to a series of bicyclic heterocycles with improved potency and ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 13, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00439" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00439" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00439" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00439" /></link>
        
    
    

<title>Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00439" /></meta><meta property="og:title" content="Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0015.jpeg" /></meta><meta property="og:description" content="A series of pyrazolopyrimidine inhibitors of IRAK4 were developed from a high-throughput screen (HTS). Modification of an HTS hit led to a series of bicyclic heterocycles with improved potency and kinase selectivity but lacking sufficient solubility to progress in vivo. Structure-based drug design, informed by cocrystal structures with the protein and small-molecule crystal structures, yielded a series of dihydrobenzofurans. This semisaturated bicycle provided superior druglike properties while maintaining excellent potency and selectivity. Improved physicochemical properties allowed for progression into in vivo experiments, where lead molecules exhibited low clearance and showed target-based inhibition of IRAK4 signaling in an inflammation-mediated PK/PD mouse model." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="A series of pyrazolopyrimidine inhibitors of IRAK4 were developed from a high-throughput screen (HTS). Modification of an HTS hit led to a series of bicyclic heterocycles with improved potency and kinase selectivity but lacking sufficient solubility to progress in vivo. Structure-based drug design, informed by cocrystal structures with the protein and small-molecule crystal structures, yielded a series of dihydrobenzofurans. This semisaturated bicycle provided superior druglike properties while maintaining excellent potency and selectivity. Improved physicochemical properties allowed for progression into in vivo experiments, where lead molecules exhibited low clearance and showed target-based inhibition of IRAK4 signaling in an inflammation-mediated PK/PD mouse model." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0015.jpeg" /></meta><meta name="twitter:title" content="Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00439"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00439">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00439&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00439&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00439&amp;href=/doi/10.1021/acs.jmedchem.9b00439" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 6223-6240</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00519" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00525" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Marian C. Bryan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marian C. Bryan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#1476666d757a3a7975667d757a5473717a713a777b79"><span class="__cf_email__" data-cfemail="f89a8a819996d695998a919996b89f9d969dd69b9795">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marian+C.++Bryan">Marian C. Bryan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3138-6888" title="Orcid link">http://orcid.org/0000-0002-3138-6888</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Joy Drobnick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joy Drobnick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joy++Drobnick">Joy Drobnick</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Alberto Gobbi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alberto Gobbi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alberto++Gobbi">Alberto Gobbi</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Aleksandr Kolesnikov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aleksandr Kolesnikov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aleksandr++Kolesnikov">Aleksandr Kolesnikov</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yongsheng Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongsheng Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi Apptec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongsheng++Chen">Yongsheng Chen</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Naomi Rajapaksa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Naomi Rajapaksa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Naomi++Rajapaksa">Naomi Rajapaksa</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Chudi Ndubaku</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chudi Ndubaku</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chudi++Ndubaku">Chudi Ndubaku</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4183-0417" title="Orcid link">http://orcid.org/0000-0003-4183-0417</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jianwen Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianwen Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianwen++Feng">Jianwen Feng</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1221-7605" title="Orcid link">http://orcid.org/0000-0003-1221-7605</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Willy Chang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Willy Chang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Willy++Chang">Willy Chang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ross Francis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ross Francis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ross++Francis">Ross Francis</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Christine Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christine Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christine++Yu">Christine Yu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Edna F. Choo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Edna F. Choo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Edna+F.++Choo">Edna F. Choo</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4200-8302" title="Orcid link">http://orcid.org/0000-0003-4200-8302</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Kevin DeMent</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin DeMent</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++DeMent">Kevin DeMent</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yingqing Ran</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingqing Ran</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingqing++Ran">Yingqing Ran</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Le An</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Le An</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Le++An">Le An</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Claire Emson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claire Emson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claire++Emson">Claire Emson</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Zhiyu Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiyu Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiyu++Huang">Zhiyu Huang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Swathi Sujatha-Bhaskar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Swathi Sujatha-Bhaskar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Swathi++Sujatha-Bhaskar">Swathi Sujatha-Bhaskar</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Hans Brightbill</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hans Brightbill</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hans++Brightbill">Hans Brightbill</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Antonio DiPasquale</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Antonio DiPasquale</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Antonio++DiPasquale">Antonio DiPasquale</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jonathan Maher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jonathan Maher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan++Maher">Jonathan Maher</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">John Wai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Wai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi Apptec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Wai">John Wai</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Brent S. McKenzie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brent S. McKenzie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brent+S.++McKenzie">Brent S. McKenzie</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Patrick J. Lupardus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick J. Lupardus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick+J.++Lupardus">Patrick J. Lupardus</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ali A. Zarrin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ali A. Zarrin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ali+A.++Zarrin">Ali A. Zarrin</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">James R. Kiefer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James R. Kiefer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Kiefer">James R. Kiefer</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00439&amp;href=/doi/10.1021%2Facs.jmedchem.9b00439" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 6223â6240</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 13, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 March 2019</li><li><span class="item_label"><b>Published</b> online</span>13 May 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 July 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00439" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00439</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6223%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMarian%2BC.%2BBryan%252C%2BJoy%2BDrobnick%252C%2BAlberto%2BGobbi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D13%26contentID%3Dacs.jmedchem.9b00439%26title%3DDevelopment%2Bof%2BPotent%2Band%2BSelective%2BPyrazolopyrimidine%2BIRAK4%2BInhibitors%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6240%26publicationDate%3DJuly%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00439"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3252</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00439" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Marian&quot;,&quot;last_name&quot;:&quot;C. Bryan&quot;},{&quot;first_name&quot;:&quot;Joy&quot;,&quot;last_name&quot;:&quot;Drobnick&quot;},{&quot;first_name&quot;:&quot;Alberto&quot;,&quot;last_name&quot;:&quot;Gobbi&quot;},{&quot;first_name&quot;:&quot;Aleksandr&quot;,&quot;last_name&quot;:&quot;Kolesnikov&quot;},{&quot;first_name&quot;:&quot;Yongsheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Naomi&quot;,&quot;last_name&quot;:&quot;Rajapaksa&quot;},{&quot;first_name&quot;:&quot;Chudi&quot;,&quot;last_name&quot;:&quot;Ndubaku&quot;},{&quot;first_name&quot;:&quot;Jianwen&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Willy&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Ross&quot;,&quot;last_name&quot;:&quot;Francis&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Edna&quot;,&quot;last_name&quot;:&quot;F. Choo&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;DeMent&quot;},{&quot;first_name&quot;:&quot;Yingqing&quot;,&quot;last_name&quot;:&quot;Ran&quot;},{&quot;first_name&quot;:&quot;Le&quot;,&quot;last_name&quot;:&quot;An&quot;},{&quot;first_name&quot;:&quot;Claire&quot;,&quot;last_name&quot;:&quot;Emson&quot;},{&quot;first_name&quot;:&quot;Zhiyu&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Swathi&quot;,&quot;last_name&quot;:&quot;Sujatha-Bhaskar&quot;},{&quot;first_name&quot;:&quot;Hans&quot;,&quot;last_name&quot;:&quot;Brightbill&quot;},{&quot;first_name&quot;:&quot;Antonio&quot;,&quot;last_name&quot;:&quot;DiPasquale&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;Maher&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Wai&quot;},{&quot;first_name&quot;:&quot;Brent&quot;,&quot;last_name&quot;:&quot;S. McKenzie&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;J. Lupardus&quot;},{&quot;first_name&quot;:&quot;Ali&quot;,&quot;last_name&quot;:&quot;A. Zarrin&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Kiefer&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;6223-6240&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00439&quot;},&quot;abstract&quot;:&quot;A series of pyrazolopyrimidine inhibitors of IRAK4 were developed from a high-throughput screen (HTS). Modification of an HTS hit led to a series of bicyclic heterocycles with improved potency and kinase selectivity but lacking sufficient solubility to progress in vivo. Structure-based drug design, informed by cocrystal structures with the protein and small-molecule crystal structures, yielded a series of dihydrobenzofurans. This semisaturated bicycle provided superior druglike properties while maintaining excellent potency and selectivity. Improved physicochemical properties allowed for progression into in vivo experiments, where lead molecules exhibited low clearance and showed target-based inhibition of IRAK4 signaling in an inflammation-mediated PK/PD mouse model.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00439&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00439" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00439&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00439" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00439&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00439" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00439&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00439&amp;href=/doi/10.1021/acs.jmedchem.9b00439" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00439" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00439" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00439%26sid%3Dliteratum%253Aachs%26pmid%3D31082230%26genre%3Darticle%26aulast%3DBryan%26date%3D2019%26atitle%3DDevelopment%2Bof%2BPotent%2Band%2BSelective%2BPyrazolopyrimidine%2BIRAK4%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D13%26spage%3D6223%26epage%3D6240%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/13" title="Go to Volume 62, Issue 13"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/jmcmar.2019.62.issue-13/20190711/jmcmar.2019.62.issue-13.largecover.jpg" alt="Go to Volume 62, Issue 13"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of pyrazolopyrimidine inhibitors of IRAK4 were developed from a high-throughput screen (HTS). Modification of an HTS hit led to a series of bicyclic heterocycles with improved potency and kinase selectivity but lacking sufficient solubility to progress in vivo. Structure-based drug design, informed by cocrystal structures with the protein and small-molecule crystal structures, yielded a series of dihydrobenzofurans. This semisaturated bicycle provided superior druglike properties while maintaining excellent potency and selectivity. Improved physicochemical properties allowed for progression into in vivo experiments, where lead molecules exhibited low clearance and showed target-based inhibition of IRAK4 signaling in an inflammation-mediated PK/PD mouse model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The innate immune system forms a first line of response to infection in mammals. This system is required to sensitively distinguish between self- and nonself-antigens and immediately respond to infections and injuries. Receptors, both on the cell surface and in endosomal compartments, are critical sensors of innate immunity, recognizing pathogens and initiating signaling cascades to mount immune responses.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Two such examples are the IL-1 receptor (IL-1R) family and toll-like receptors (TLRs), transmembrane pattern recognition receptors (PRRs) critical in the detection of pathogen-associated molecular patterns (PAMPs) of foreign microbes. Together with the IL-1R family, TLRs enable cells to recognize molecular structures present in pathogens and quickly respond to them by initiating and amplifying the pro-inflammatory cytokine response.</div><div class="NLM_p">While this system is critically important to the innate immune system, dysregulation of TLR signaling in particular has been implicated in autoinflammatory diseases such as rheumatoid arthritis (RA) and several others.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> In RA for example, multiple TLR family members are upregulated when compared to healthy individuals. Stimulation of these receptors leads to production of the inflammatory cytokines such as IL-6 and tissue-destructive matrix metaloproteins.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> TLR family members are also implicated in the pathophysiology of systemic lupus erythematosus (SLE), another debilitating autoimmune disease. SLE is characterized by chronic systemic inflammation of the joints and kidneys among other organs.</div><div class="NLM_p">Ligand binding to either IL-1R or TLR family members leads to dimerization and recruitment of adaptor molecules to a conserved motif on the cytoplasmic domain of the receptor called the toll/IL-1R (TIR) domain.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Binding then leads to recruitment of MyD88 and formation of the myddosome complex, which includes the interleukin-1 receptor activated kinase (IRAK) family.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7 ref8 ref9">(4â9)</a> This family of kinases then plays the crucial role of signal transduction propagating the innate immune response. Autophosphorylation of IRAK4, the first step in the pathway, leads to IRAK1 phosphorylation, which in turn leads to downstream signaling through multiple cascades, ultimately altering gene transcription and initiation of the inflammatory response.</div><div class="NLM_p">The IRAK kinase family is composed of four members, IRAK1 and IRAK4, which perform scaffolding functions in addition to being active kinases, and IRAK2 and IRAK3 (also called IRAKm), which are catalytically inactive.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Of the two family members with kinase activity, IRAK4 has been called the âmaster IRAKâ and is the most upstream kinase required for IL-1R and TLR signaling.<a onclick="showRef(event, 'ref8 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref10">(8,10)</a></div><div class="NLM_p">IRAK4âs role in the innate immune response has led to both interest in it as a target for therapeutic intervention in autoinflammatory diseases and concerns of safety due to its role as a critical node. While IRAK4-deficient patients show increased susceptibility to certain pyogenic infections, adults show no increased risk, derisking IRAK4 as a therapeutic target to an extent, and interest in targeting IRAK4 has grown. Several reports of small-molecule kinase inhibitors targeting the IRAK4 kinase domain, including those shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, have been published recently, including the clinical candidate PF-06650833 (<b>1</b>), pyridine indazole <b>2</b>, BMS-986126 (<b>3</b>), and aminopyridine <b>4</b>.<a onclick="showRef(event, 'ref2 ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref2 ref9 ref11">(2,9,11)</a> Lactam <b>1</b> was advanced into Phase II in RA, although results have not yet been disclosed (NCT02996500). This molecule and others continue to undergo clinical evaluation.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of IRAK4 kinase inhibitors PF-06650833 (<b>1</b>), indazole <b>2</b>, 1,6-naphthyridine <b>3</b>, and aminopyridine <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05246" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05246" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">From a high-throughput screening campaign, we identified hits <b>5</b> and <b>6</b>, differing only in piperidine substitution, as starting points from which to design potent and selective IRAK4 inhibitors. Both of these quinolines showed excellent biochemical potency against IRAK4 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and reasonable LLE based on cLogP.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Both molecules possessed selectivity over IRAK1. While IRAK1 plays important scaffolding roles in the cell, its kinase activity has been reported as unnecessary for homeostasis, and several studies have highlighted the integral role of IRAK4 alone in toll-like receptor (TLR)-mediated immune responses.<a onclick="showRef(event, 'ref3 ref14'); return false;" href="javascript:void(0);" class="ref ref3 ref14">(3,14)</a> As there is a high degree of sequence homology between the ATP binding sites of IRAK1 and IRAK4,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> we hypothesized that measured selectivity of >200-fold against IRAK1 would provide a useful initial kinase selectivity triage parameter. Evaluation of compounds <b>5</b> and <b>6</b> against a broad kinase panel showed compound <b>5</b> inhibited â¥70% of the activity of 34 of 236 kinases at 1 Î¼M inhibitor concentration, while compound <b>6</b> inhibited 22 of 220 kinases tested.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Profile of High-Throughput Screening Hits, Quinolines <b>5</b> and <b>6</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0008.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center"><b>5</b></th><th class="colsep0 rowsep0" align="center"><b>6</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LLE<sub>cLogP</sub><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>/calcâd p<i>K</i><sub>a</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">6.78/9.3</td><td class="colsep0 rowsep0" align="left">6.54/7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LogÂ <i>D</i>/K.Â Sol.<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> (Î¼M)</td><td class="colsep0 rowsep0" align="left">0.79/22</td><td class="colsep0 rowsep0" align="left">3.1/1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IRAK4 <i>K</i><sub>i</sub>Â (nM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">2Â Â±Â 0.71 (<i>n</i>Â =Â 183)</td><td class="colsep0 rowsep0" align="left">1.7Â Â±Â 0.73 (<i>n</i>Â =Â 6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IRAK1 <i>K</i><sub>i</sub>Â (nM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">510Â Â±Â 110 (<i>n</i>Â =Â 172)</td><td class="colsep0 rowsep0" align="left">400Â Â±Â 110 (<i>n</i>Â =Â 5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NFkB cell IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">41Â Â±Â 2.5 (<i>n</i>Â =Â 133)</td><td class="colsep0 rowsep0" align="left">35Â Â±Â 4.1 (<i>n</i>Â =Â 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H/R/MLM<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">4.5/14/51</td><td class="colsep0 rowsep0" align="left">12/43/75</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Moka v.2.6.5.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Kinetic solubility: experimental procedures for kinetic solubility experiments can be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Data are the geometric mean of at least two independent experiments Â± standard deviation of the average for the number (<i>n</i>) of experiments conducted.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">H/R/MLM defined as predicted hepatic clearance in liver microsomes for human (H), rat (R), and mouse (M). Reported in units of mL/min/kg.</p></div></div></div><div class="NLM_p">Both compounds showed strong inhibition of NFkB reporter gene activity (41 and 35 nM, respectively, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) in a THP1-XBlue stable cell line. As a secondary readout, cell viability was assayed in this cell line, and no inhibition of proliferation was seen at up to 20 Î¼M concentrations for either compound. The proliferation assay was also used to give a preliminary indication of kinase selectivity, as inhibition of IRAK4 alone should not lead to target-related cytotoxicity due to the previously mentioned safety rationale. While both compounds were potent in the biochemical and cellular assays, the scaffold presented challenges that needed to be addressed, including kinase selectivity compatible with chronic dosing and in vitro absorption, distribution, metabolism, and excretion (ADME) properties.</div><div class="NLM_p">To understand their binding mode to enable structureâactivity relationship (SAR) development, we obtained a 2.5 Ã resolution X-ray cocrystal structure of <b>5</b> with fully phosphorylated IRAK4 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A and Figure S2 in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Compound <b>5</b> binds to the hinge through the backbone of Met265 and Val263 via the amide carbonyl and the C2 hydrogen of the pyrazolopyrimidine, referred to as the âhinge binding elementâ (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a>This was of interest to the team as the pyrazolopyrimidine moiety is known to bind to hinge residues in an alternate configuration. In an example from the JAK kinase family, the N1-nitrogen of the pyrazolopyrimidine core makes a hydrogen bond with a backbone NH and the amide carbonyl forms a hydrogen bond with a water molecule.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> This binding configuration has also been reported for other IRAK4 inhibitors.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The leading edge of this fused 5,6-ring system forms van der Waals contacts and potentially Ï-stacking interactions with the kinase âgatekeeperâ residue Tyr262, an amino acid relatively unique to the IRAK family among protein tyrosine kinases.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structures of IRAK4 initial lead inhibitors. The 2.5 Ã resolution cocrystal structure of <b>5</b> (A, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O9D">6O9D</a>) bound in the IRAK4 active site reveals three polarized functional groups forming hydrogen bonds to the protein. Further annotation (B) shows the subregions together with key molecule features and their interactions. The solvent-accessible surface of the binding site (C) shows substantial van der Waals contacts made between nonpolar (green mesh) protein residues and the inhibitor as well as focal polar (pink mesh) contact points. Regions above and below the plane of the quinoline ring (dotted circles) are potentially accessible through elaboration of the inhibitor linker. A 2.0 Ã resolution cocrystal structure of <b>17</b> (D, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O94">6O94</a>) shows that the inhibitor benzimidazole forms an additional polar interaction with the protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The quinoline system, referred to as the âlinkerâ in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B, stacks under Met192 and forms multiple additional van der Waals interactions to residues of the P-loop and floor of the kinase binding site (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). Finally, the methylamine substitution on the piperidine, occupying the ATP ribose pocket, forms a hydrogen bond with the backbone carbonyl of Ala315 and proximal solvent molecules.</div><div class="NLM_p">Analysis of the protein-inhibitor contacts in the cocrystal structure of <b>5</b> and comparison of them to known IRAK4 small-molecule inhibitors (SMIs) revealed additional potential interactions and vectors toward the solvent front that could be exploited for optimization of the linker region of the compound.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> As such, we synthesized a set of 6,6- and 5,6-ring systems (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Truncation of the ribose pocket group to methyl ether <b>7</b> led to a 30-fold loss in activity and a 5-fold loss in selectivity when compared to <b>6</b>, although it allowed for rapid development of linker SAR. Replacement or movement of the quinoline N to yield naphthalene <b>8</b> and isomeric quinoline <b>9</b>, respectively, lost significant potency when compared to parent <b>7</b>. The dramatic erosion in potency of <b>9</b> was presumably due to a repulsion between the N lone pair and a backbone carbonyl.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. 6,6- versus 5,6-Linkers</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0009.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Data are the geometric mean of at least two independent experiments Â± standard deviation of the average for the number (<i>n</i>) of experiments conducted. ND = not determined.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Assay conditions and experimental data for these molecules were reported in WO2012007375A1.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></p></div></div><div></div></div><div class="NLM_p">Substitution at R1 was then undertaken with morpholine <b>11</b>. The morpholine moiety was selected due to its presence in a number of known IRAK SMI.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> This compound lost potency compared to parent <b>10</b>. To understand if this was due to steric interference, we generated the smaller dimethylamino analogue (<b>12</b>) and modified the angle by introduction of a second nitrogen to the linker to give quinazoline <b>13</b>. While removal of some of the morpholine bulk was able to regain some of the potency (26 nM for <b>12</b> versus 8 nM for <b>10</b>), quinazoline <b>13</b> was equipotent to quinoline <b>11</b>, and none of these changes to the 6,6-biaryl systems were able to improve LLE<sub>cLogP</sub> compared to the initial HTS hit <b>6</b>.</div><div class="NLM_p">At this point we shifted focus to optimize the linker to 5,6-ring systems. Indole <b>14</b> was analogous to naphthalene <b>8</b>, highlighting the same trend toward a requirement for a critical H-bond acceptor in the quinoline linker. Unsubstituted benzimidazole <b>15</b> was 4Ã less potent than the quinolone <b>6</b> in the biochemical assay with similar LLE<sub>cLogP</sub> but continued to experience a larger cell shift (45Ã vs 20Ã). Appending a morpholine R<sup>1</sup> substituent resulted in compound <b>16</b>, which was equipotent to <b>6</b> in a biochemical context with improved LLE<sub>cLogP</sub> but continued to show a sizable shift in cellular potency. Capping the NH of the benzimidazole with a methyl group (<b>17</b>) led to a compound that was both potent and selective over IRAK1. This kinase selectivity was recapitulated when the molecule was assessed against a broader kinase panel as shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, where the molecule inhibited â¥70% the activity of only 13 of 220 kinases when measured at 1 Î¼M (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> Table S1). Introduction of an additional methylene (<b>18</b>) eroded both of these potency and selectivity gains, presumably due to steric clashes with the protein backbone. Alternate 5,6-linker systems such as benzoxazole <b>19</b> and benzothiazole <b>20</b> either maintained or improved potency relative to initial molecule <b>6</b>, with morpholine <b>20</b> being 3â4Ã more potent in the assays. Trimming the morpholine to a dimethylamine (<b>21</b>) retained enzymatic potency but negatively impacted the cellular potency (52 vs 8 nM). In addition, while selectivity over IRAK1 was improved with compound <b>21</b> relative to <b>20</b>, evaluation in broader panels revealed that dimethylamine <b>21</b> inhibited 23 kinases (in addition to IRAK4) in a panel of 41 to â¥70% activity at 1 Î¼M, while morpholine <b>20</b> inhibited only 15 additional kinases to the same degree against a much broader panel of 220 at the same concentration (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> Table S1).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro and In Vivo PK of <b>17</b>, <b>20</b>, and <b>22</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" align="center">mouse IV PK</th><th class="rowsep1 colsep0" colspan="4" align="center">mouse PO PK</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd no.</th><th class="colsep0 rowsep0" align="center">H/MLM<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> H/MÂ CLhep<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">MDCK <i>P</i><sub>app</sub>Â (A-B)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">PPB (H/M)</th><th class="colsep0 rowsep0" align="center">kinase count<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">CL<sub>p</sub>/<i>V</i><sub>ss</sub> (L/kg)<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub>Â (Î¼M)</th><th class="colsep0 rowsep0" align="center">AUC<sub>â</sub> (Î¼MÂ h)</th><th class="colsep0 rowsep0" align="center"><i>F</i>Â (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="center"><b>17</b></td><td class="colsep0 rowsep0" align="center">7.4/33</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">2.4</td><td class="colsep0 rowsep0" rowspan="2" align="center">88/95</td><td class="colsep0 rowsep0" rowspan="2" align="center">13/220</td><td class="colsep0 rowsep0" rowspan="2" align="center">23/0.4</td><td class="colsep0 rowsep0" rowspan="2" align="center">5<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" rowspan="2" align="center">0.2</td><td class="colsep0 rowsep0" rowspan="2" align="center">0.5</td><td class="colsep0 rowsep0" rowspan="2" align="center">3%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">15/21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="center"><b>20</b></td><td class="colsep0 rowsep0" align="center">8.5/42</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">8.4</td><td class="colsep0 rowsep0" rowspan="2" align="center">98/99</td><td class="colsep0 rowsep0" rowspan="2" align="center">16/220</td><td class="colsep0 rowsep0" rowspan="2" align="center">18/0.4</td><td class="colsep0 rowsep0" rowspan="2" align="center">5<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" rowspan="2" colspan="3" align="center">BLOD<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">18/47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="center"><b>22</b></td><td class="colsep0 rowsep0" align="center">7.6/46</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">12</td><td class="colsep0 rowsep0" rowspan="4" align="center">95/99</td><td class="colsep0 rowsep0" rowspan="4" align="center">9/221</td><td class="colsep0 rowsep0" rowspan="4" align="center">17/0.9</td><td class="colsep0 rowsep0" align="center">5<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">0.2</td><td class="colsep0 rowsep0" align="center">0.6</td><td class="colsep0 rowsep0" align="center">5%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="center">7.5/21</td><td class="colsep0 rowsep0" align="center">10<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="center">1.3</td><td class="colsep0 rowsep0" align="center">12</td><td class="colsep0 rowsep0" align="center">25%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">30<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="center">2.0</td><td class="colsep0 rowsep0" align="center">11</td><td class="colsep0 rowsep0" align="center">12%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">100<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="center">3.3</td><td class="colsep0 rowsep0" align="center">40</td><td class="colsep0 rowsep0" align="center">6%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">H/MLM defined as predicted hepatic clearance in liver microsomes for human (H) and mouse (M). Reported in units of mL/min/kg.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">H/M CLhep defined as predicted hepatic clearance in hepatocytes for human (H) and mouse (M). Reported in units of mL/min/kg.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">A-B, apical-to-basolateral permeability as measured in MadinâDarby canine kidney (MDCK) cells. Reported in units of Ã10<sup>â6</sup> cm/s; PPB = plasma protein binding, % bound.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Ratio of number of kinases inhibited at â¥70% against the total number of kinases assessed at 1 Î¼M.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Cl<sub>p</sub> = blood clearance. Reported in units of mL/min/kg. Compound dosed IV (1 mg/kg) as a solution in dimethylsulfoxide (DMSO)/Cremophor/saline (30:10:60).</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">Compound dosed po as a suspension in MCT.</p></div><div class="footnote" id="t3fn7"><sup><sup>g</sup></sup><p class="last">Compound dosed po as a nanosuspension in MCT.</p></div><div class="footnote" id="t3fn8"><sup><sup>h</sup></sup><p class="last">BLOD = below the limit of detection.</p></div></div></div><div class="NLM_p">Analysis of the 2.0 Ã resolution cocrystal structure of benzimidazole <b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D and Figure S2 in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) shows that the compound maintains the same key hinge interactions of <b>5</b> and projects its morpholine toward solvent, forming additional van der Waals interactions with the protein. The bismorpholine inhibitor <b>22</b> lost cellular potency compared to <b>20</b> but importantly improved kinase selectivity, reducing the number of off-target kinases with activity inhibited â¥70% to 9 of 221 at 1 Î¼M including IRAK4 (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> Table S1).</div><div class="NLM_p">With comparably promising biochemical and cellular potency, as well as reasonable kinase selectivity, molecules <b>17</b>, <b>20</b>, and <b>22</b> were examined in in vitro metabolic stability assays. These analogues were predicted to be stable-to-moderate in mouse and human based on liver microsomes (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, 7.4â8.5 mL/min/kg in HLM and 33â46.4 mL/min/kg in MLM) but differentiated when advanced to hepatocytes. Benzimidazole <b>17</b> and benzothiazole <b>20</b> both showed heightened lability in human hepatocytes with predicted clearances of >70% of liver blood flow (LBF) (15.3 and 17.8 mL/min/kg, respectively), although <b>17</b> appeared stable in mouse hepatocytes at <30% LBF (MH = 20.7 mL/min/kg). Only compound <b>22</b> remained relatively stable in human hepatocytes and showed improved predicted stability in mouse hepatocytes (7.5 and 20.7 mL/min/kg, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>22</b> also exhibited higher permeability when compared to <b>17</b> and <b>20</b> (12.4 versus 8.4 and 2.4 cm/s Ã 10<sup>â6</sup>, respectively), although benzimidazole <b>17</b> was less plasma protein bound in both species (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_p">When dosed intravenously in mice, all three compounds (<b>17</b>, <b>20</b>, and <b>22</b>) were stable, with clearance below 30% of liver blood flow. Upon oral dosing, benzothiazole <b>20</b> was not detected (<i>F</i> below the level of detection), while <b>17</b> and <b>22</b> showed only marginal bioavailability (<i>F</i> = 3% and 5%). While morpholine <b>22</b> initially showed submicromolar concentrations at <i>C</i><sub>max</sub> and low bioavailability, this was improved upon formulation as a nanosuspension (at low dose). Given its improved in vitro stability profile relative to <b>17</b> and <b>20</b>, <b>22</b> was advanced into further studies. Unfortunately, compound <b>22</b> showed limited increase in exposure (AUC and <i>C</i><sub>max</sub>) in dose-escalating mouse PK study as a result of dose-limited absorption due to low solubility, despite a high in vitro permeability measurement and low observed clearance. Analysis of the material properties of <b>22</b> along with other members of the 5,6-series revealed crystalline material with high melting points (>200 Â°C), resulting in poor solubility across a range of pH,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and several crystal packing interactions for the fused biaryl linker, leading to extensive Ï-stacking interactions in the crystal lattice (see small-molecule crystal structures in Figure S4 in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Despite many changes probing exploration of the solvent front and ribose pocket of this and related biaryl systems, we were not able to see measurable improvements in solubility. Therefore, we next designed molecules incorporating a reduction in linker aromaticity and planarity to drive solubility and bioavailability improvements.</div><div class="NLM_p">Similar to other kinases, most of the active site of IRAK4 is a relatively flat, narrow pocket; however, the solvent front adjacent to the hinge region (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C) broadens and can accommodate three-dimensional ligand topology; thus, we sought to introduce more sp<sup>3</sup> character into this region of the molecules in order to improve solubility.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Docking studies with semisaturated systems suggested that they would complement the protein shape, and their enhanced 3-dimensionality could disrupt the crystal packing observed in the small molecule X-ray structures, while maintaining the key vectors to the ribose pocket and solvent front regions. Additionally, for dihydrobenzofuran linkers, the docking pose suggested that the oxygen atom would occupy a comparable position to the conserved hydrogen bond acceptor functionality observed in the previous scaffolds, such as <b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D). This feature could maintain a water mediated hydrogen bond with the protein, previously observed to enhance potency (e.g., the pyridine N of <b>7</b> compared with the CH of <b>8</b>, <i>K</i><sub>i</sub> = 52 and 613 nM, respectively, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The design also provided flexibility to introduce modifications to the hinge and ribose pocket groups.</div><div class="NLM_p">The first molecule synthesized in this series validated the hypothesis by demonstrating that a dihydrobenzofuran linker provided biochemical and cellular potency within an order of magnitude of previous leads <b>20</b> and <b>22</b> though with lower efficiency (LLE<sub>cLogP</sub> = 5.7 and 5.6 vs 6.9 and 7.1, respectively). Both <b>23</b> and <b>24</b> also maintained or improved in vitro permeability. Although <b>23</b> remained poorly soluble (kinetic sol. = 1 Î¼M), modification of the ribose pocket group in <b>24</b> improved kinetic solubility (kinetic sol. = 95 Î¼M) while maintaining potency and improving permeability. Furthermore, these molecules maintained excellent selectivity over IRAK1 (220Ã and 210Ã, respectively).</div><div class="NLM_p">To swiftly assess kinase selectivity without requiring a full screen of >200 kinases, we profiled off-target kinases that either routinely showed significant inhibition with our core scaffold, were also involved in the cytokine production pathway which would complicate on-target efficacy evaluation, or whose inhibition would lead to known safety liabilities. This group formed a core panel of 27 kinases that could be rapidly screened. A kinase selectivity ratio (KS27) was developed for rank-ordering molecules on selectivity, with a lower value correlating to inhibition of fewer off-target kinases inhibited at â¥70% at 1 Î¼M. Evaluation of <b>23</b> and <b>24</b> along with the previous lead molecules provided a range of KS27 ratios with initial quinoline <b>6</b> showing a KS27 = 0.52 reflecting its inhibition of 14 kinases out of 27 and 22 out of 220 when screened at 1 Î¼M. Improvements in kinase selectivity for benzothiazoles <b>20</b> and <b>22</b> also translated to an improved KS27 (KS27 = 0.44 and 0.26, respectively). Gratifyingly, <b>23</b> and <b>24</b> demonstrated improved kinase selectivity with a KS27âs of 0.15 and 0.22, respectively.</div><div class="NLM_p">To this point, no changes had been undertaken on the pyrazolopyrimidine. However, we were interested in the ability of pyrazolopyrimidine substitution to impact selectivity given the relative rarity of the tyrosine gatekeeper. Modification of the pyrazolopyrimidine of <b>23</b>, selected for synthetic feasibility over hydroxymethylpiperidine <b>24</b>, was then undertaken (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The only example of substitution at C7, hydroxypyridine <b>25</b>, lost measurable potency while C6 substitution was well tolerated in the biochemical assay with hydroxyl-substituted pyrimidine <b>26</b> being equipotent to the parent pyrimidine <b>23</b> with the lowered lipophilicity reflected in the improved LLE<sub>cLogP</sub>. Moieties with increased lipophilicity at R<sup>4</sup> led to 6-fold loss in biochemical potency and lower lipophilic efficiency as seen with <b>27</b>â<b>29</b> despite differences in steric bulk or hydrogen bond donating/accepting capabilities. This is particularly interesting for <b>26</b> when compared to <b>28</b>. Both have the potential for hydrogen bond donation but <b>28</b> loses an order of magnitude in biochemical potency. Modifications with comparable or improved lipophilicity, such as nitrile <b>30</b> and primary amide <b>31</b>, maintained biochemical potency with superior cellular potency. However, these groups led to poor permeability with low solubility and no improvement on KS27 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The one modification that appeared universally beneficial was the hydroxymethyl substituent in <b>32</b>. This molecule maintained biochemical potency and permeability while improving solubility, in vitro stability and kinase selectivity (K. Sol. = 15 Î¼M, H/MLM = <3.9/57 mL/min/kg, KS27 = 0.074, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Initial Efforts toward Reducing Planarity with Semisaturated 5,6-Ring Systems and Modification of the Pyrazolopyrimidine Hinge Binding Element</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0010.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd no.</th><th class="colsep0 rowsep0" align="center">IRAK4 <i>K</i><sub>i</sub>Â (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (LLE<sub>cLogP</sub>)</th><th class="colsep0 rowsep0" align="center">NFkB cell IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">K.Â Sol.<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> (Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">KS27 ratio<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">MDCK P<sub>app</sub>(A-B)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">H/MLM<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>23</b></td><td class="colsep0 rowsep0" align="center">5.3Â Â±Â 2.1 (<i>n</i>Â =Â 4) (5.7)</td><td class="colsep0 rowsep0" align="center">170Â Â±Â 38 (<i>n</i>Â =Â 4)</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="center">14</td><td class="colsep0 rowsep0" align="center">5.3/81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>24</b></td><td class="colsep0 rowsep0" align="center">1.5Â Â±Â 0.5 (<i>n</i>Â =Â 5) (5.6)</td><td class="colsep0 rowsep0" align="center">38Â Â±Â 6.7 (<i>n</i>Â =Â 4)</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="center">16</td><td class="colsep0 rowsep0" align="center">9.5/74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>25</b></td><td class="colsep0 rowsep0" align="center">>8400 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="center">>20000 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">--</td><td class="colsep0 rowsep0" align="center">13/26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>26</b></td><td class="colsep0 rowsep0" align="center">3.2Â Â±Â 0.4 (<i>n</i>Â =Â 4) (6.3)</td><td class="colsep0 rowsep0" align="center">330Â Â±Â 34 (<i>n</i>Â =Â 4)</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="center">14</td><td class="colsep0 rowsep0" align="center">3.9/44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>27</b></td><td class="colsep0 rowsep0" align="center">34Â Â±Â 11 (<i>n</i>Â =Â 4) (4.4)</td><td class="colsep0 rowsep0" align="center">>20000 (<i>n</i>Â =Â 4)</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">0.6</td><td class="colsep0 rowsep0" align="center">15/58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>28</b></td><td class="colsep0 rowsep0" align="center">31Â Â±Â 11 (<i>n</i>Â =Â 4) (5.4)</td><td class="colsep0 rowsep0" align="center">1200Â Â±Â 1000 (<i>n</i>Â =Â 4)</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">--</td><td class="colsep0 rowsep0" align="center">10/56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>29</b></td><td class="colsep0 rowsep0" align="center">35Â Â±Â 9.0 (<i>n</i>Â =Â 7) (4.0)</td><td class="colsep0 rowsep0" align="center">>20000 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">--</td><td class="colsep0 rowsep0" align="center">7.4/54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>30</b></td><td class="colsep0 rowsep0" align="center">6.1Â Â±Â 0.4 (<i>n</i>Â =Â 4) (5.9)</td><td class="colsep0 rowsep0" align="center">84Â Â±Â 10 (<i>n</i>Â =Â 4)</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="center">2.7</td><td class="colsep0 rowsep0" align="center">14/47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>31</b></td><td class="colsep0 rowsep0" align="center">1.1Â Â±Â 0.4 (<i>n</i>Â =Â 4) (7.5)</td><td class="colsep0 rowsep0" align="center">56Â Â±Â 9.7 (<i>n</i>Â =Â 4)</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="center">0.7</td><td class="colsep0 rowsep0" align="center">12/49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>32</b></td><td class="colsep0 rowsep0" align="center">6.5Â Â±Â 0.9 (<i>n</i>Â =Â 8) (6.4)</td><td class="colsep0 rowsep0" align="center">66Â Â±Â 5.2 (<i>n</i>Â =Â 4)</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.074</td><td class="colsep0 rowsep0" align="center">18</td><td class="colsep0 rowsep0" align="center">3.9/57</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Data are the geometric mean of at least two independent experiments Â± standard deviation of the average for the number (<i>n</i>) of experiments conducted. ND = not determined.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Kinetic solubility: experimental procedures for kinetic solubility experiments in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">KS27 ratio defined in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">A-B, apical-to-basolateral permeability as measured in MadinâDarby canine kidney (MDCK) cells. Reported in units of Ã10<sup>â6</sup> cm/s.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">H/MLM defined as predicted hepatic clearance in liver microsomes for human (H) and mouse (M). Reported in units of mL/min/kg.</p></div></div></div><div class="NLM_p">While only modest improvements were obtained through modifying the hinge binding element, we were interested in the ability of the ribose pocket to allow for polar moieties given the polar surface area shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C and the interaction between the primary amine of <b>5</b> and the backbone carbonyl of Ala315 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Related chemotypes such as those in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> or disclosed elsewhere either had aryl groups in this region or very small moieties.<a onclick="showRef(event, 'ref2 ref9 ref11 ref16'); return false;" href="javascript:void(0);" class="ref ref2 ref9 ref11 ref16">(2,9,11,16)</a> We envisioned that the ribose group could be used to tailor the overall physicochemical properties and indeed significant improvements in multiple parameters including solubility and stability were seen through alternate groups in the ribose pocket as was established for <b>23</b> vs <b>24</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Several saturated ring systems were tolerated by the ribose pocket of the IRAK4 ATP binding site. Contraction of the morpholine to a pyrrolidine (<b>33</b>), modification to a piperazine (<b>34</b>), substitution or oxidation of the hydroxymethylene (<b>35</b> and <b>36</b>) and expansion to an azepane (<b>37</b>) all led to analogues within 4-fold biochemical potency to each other (<i>K</i><sub>i</sub> = 3.2â13 nM). None of these modifications improved either IRAK4 or the cellular potency compared to <b>24</b>, although all 6-membered ring modifications gave improved in vitro metabolic stability with piperazine <b>34</b> showing modest gains in solubility as well (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Appending hydrogen-bond donors via N-linked substitution of <b>34</b> gave <b>38</b>â<b>40</b>, with biochemical and cellular potency comparable to <b>24</b>. This is presumably due to forming similar hydrogen bonding interactions as discussed with <b>5</b> earlier. However, potency gains seen with primary amide <b>39</b> appeared to be at the cost of permeability and selectivity (<i>P</i><sub>app</sub> = 2.6, KS27 = 0.3).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Diversification of the Ribose Pocket Moiety</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0011.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0012.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Data are the geometric mean of at least two independent experiments Â± standard deviation of the average for the number (<i>n</i>) of experiments conducted. ND = not determined.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Kinetic solubility: experimental procedures for kinetic solubility experiments in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">KS27 ratio defined in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">A-B, apical-to-basolateral permeability as measured in MadinâDarby canine kidney (MDCK) cells. Reported in units of Ã10<sup>â6</sup> cm/s.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">H/MLM defined as predicted hepatic clearance in liver microsomes for human (H) and mouse (M). Reported in units of mL/min/kg.</p></div></div><div></div></div><div class="NLM_p">Having explored the SAR on the ribose pocket group and hinge binding element with the dihydrobenzofuran linker, we sought to introduce further changes to the solvent front leading to molecules with a combination of improved potency, PK properties, and selectivity. Replacing a methyl in the solvent front with a hydroxymethyl (<b>41</b> and <b>42</b>) improved the solubility of the scaffold (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Resolution of the enantiomers revealed <b>41</b> to be equipotent with <b>23</b> with maintained selectivity and improved mouse metabolic stability, while <b>42</b> lost roughly 2â3Ã potency in the biochemical and cellular systems and suffered from slightly reduced kinase selectivity.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Modification of the Dihydrobenzofuran Linker Substitution</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0013.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Data are the geometric mean of at least two independent experiments Â± standard deviation of the average for the number (<i>n</i>) of experiments conducted.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Kinetic solubility: experimental procedures for kinetic solubility experiments in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">KS27 ratio defined in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">A-B, apical-to-basolateral permeability as measured in MadinâDarby canine kidney (MDCK) cells. Reported in units of Ã10<sup>â6</sup> cm/s.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">H/MLM defined as predicted hepatic clearance in liver microsomes for human (H) and mouse (M). Reported in units of mL/min/kg.</p></div></div><div></div></div><div class="NLM_p">Further disruption to the planarity of the molecule with introduction of the tertiary alcohol (<b>43</b>) or 1-oxa-8-azaspiro[4.5]decane <b>44</b> greatly improved the solubility and predicted mouse metabolic stability, either maintained or improved permeability, and maintained selectivity and potency. X-ray cocrystal structures of <b>23</b> and <b>41</b> with IRAK4 confirmed that these substitutions along the solvent front added to the van der Waals contacts to the protein without perturbing the binding mode of the inhibitors (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Additionally, the hydroxymethyl substituent of <b>41</b> formed hydrogen bonds to a network of water molecules at the solvent front.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structures of dihydrobenzofuran IRAK4 inhibitors. (A, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8U">6O8U</a>) Cocrystal structure of <b>23</b> (1.8 Ã resolution) bound in the IRAK4 active site revealed three hydrogen bonds formed to the protein or solvent molecules and the protrusion of the <i>gem</i>-dimethyl moiety into the region of the site unoccupied by inhibitor atoms in the cocrystal structure of <b>5</b> with IRAK4. (B, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O95">6O95</a>) Crystal structure of <b>41</b> (1.8 Ã resolution) revealed additional polar contacts made by the hydroxymethyl substituent that further fills a previously unoccupied region, also adding 3-dimensional vectors to the compound. (C) Solvent-accessible surface for <b>41</b>, colored as in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To understand if these changes to solubility and other properties improved in vivo properties relative to the 5,6-fused heteroaryl systems, <b>41</b> was taken first into PK studies. Gratifyingly, initial in vivo PK data showed an order of magnitude improvement in the <i>C</i><sub>max</sub>, AUC and bioavailability for mouse when compared to compound <b>22</b>, with in vivo CL in line with the in vitro CL observed across species (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Dose escalating PK studies in mice showed a less than dose proportional increase in exposure between 10 and 100 mg/kg, though all doses were sufficient to cover IC<sub>50</sub> for at least part of the 1 h time course for PK/PD (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Modification of formulation also led to improved bioavailability and exposure as shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. With this superior PK in hand, we advanced <b>41</b> into an interleukin-6 (IL-6) PK/PD mouse model.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. PK Profile of <b>41</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">LM<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a>/CLhep<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">PPBÂ (%)</th><th class="colsep0 rowsep0" align="center">IV CL<sub>p</sub><a class="ref internalNav" href="#t7fn3" aria-label="c">c</a>/V<sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub>Â (Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>â</sub> (Î¼MÂ h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i>Â (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub>Â (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="7" align="left">mouse</td><td class="colsep0 rowsep0" rowspan="7" align="center">56/51</td><td class="colsep0 rowsep0" rowspan="7" align="char" char=".">86</td><td class="colsep0 rowsep0" rowspan="7" align="center">54/1.1<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">5<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">59%</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">10<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">30<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">100<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">15.1</td><td class="colsep0 rowsep0" align="char" char=".">19%</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">100<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="char" char=".">9.7</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">49%</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">300<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="char" char=".">22%</td><td class="colsep0 rowsep0" align="char" char=".">23.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">300<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">340</td><td class="colsep0 rowsep0" align="char" char=".">33%</td><td class="colsep0 rowsep0" align="char" char=".">42.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="center">8.1/10</td><td class="colsep0 rowsep0" align="char" char=".">79</td><td class="colsep0 rowsep0" align="center">6.6/2.3<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">1<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">42%</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="center">8.8/7.8</td><td class="colsep0 rowsep0" align="char" char=".">66</td><td class="colsep0 rowsep0" align="center">9.3/8<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">1<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">30%</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="center">6.7/8.8</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="center">11/4.4<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">1<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">85%</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="center"><4.3/<6.2</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">LM defined as predicted hepatic clearance in liver microsomes. Reported in units of mL/min/kg.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">CLhep defined as predicted hepatic clearance in hepatocytes. Reported in units of mL/min/kg.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Cl<sub>p</sub> = plasma clearance. Reported in units of mL/min/kg; PPB = plasma protein binding, % bound.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">Compound dosed IV (1 mg/kg) as a solution in PEG400/EtOH/H<sub>2</sub>O (35:5:60).</p></div><div class="footnote" id="t7fn5"><sup><sup>e</sup></sup><p class="last">Compound dosed IV (0.3 mg/kg) as a solution in PEG400/EtOH/H<sub>2</sub>O (60:5:35).</p></div><div class="footnote" id="t7fn6"><sup><sup>f</sup></sup><p class="last">Compound dosed po as a suspension in MCT.</p></div><div class="footnote" id="t7fn7"><sup><sup>g</sup></sup><p class="last">Compound dosed po as a suspension in 10% captisol.</p></div></div></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cytokine inhibition upon treatment with <b>41</b> in a CpG-stimulated mouse PK/PD model. (A) IL-6 response, (B) TNFÎ± response, and (C) plasma compound PK. Model design: 5 mice per group were enrolled. Single dose of the compound or vehicle was given orally at â1 h; the stimulus CpG1826 or phosphate-buffered saline (PBS) was dosed intravenously at 0 h; and whole blood was collected at 1 h post CpG1826 for plasma PK and serum cytokines (IL-6 and TNFa) measured by MSD. Plasma compound PK is from blood samples collected from the same experiment of the cytokine analysis as shown in (A) and (B). One-way ANOVA analysis comparing all groups to the stimulus group (Group 2: vehicle + GpG1826) was performed. *<i>P</i> < 0.05; **<i>P</i> < 0.01; ***<i>P</i> < 0.001; ***<i>P</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Attenuation of pro-inflammatory cytokines upon treatment with IRAK4 inhibitors in a PK/PD model was of critical interest to the project as many efficacy models for autoimmune disease are both time- and material-consuming. While both vertebrates and bacteria store critical genomic information in DNA using the same bases, there are slight but immunologically important differences.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> Unmethylated CpG dinucleotide (CpG) is one such motif found in bacterial and viral DNA but not mammalian DNA.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Immunocompetent cells such as dendritic cells (DCs) and macrophages recognize this ânonselfâ motif through TLR9,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> leading to pro-inflammatory cytokine release including TNF-Î± and IL-6 along with other interleukins and interferons. As recognition and activation of TLR9 in the innate immune system may contribute to the pathogenesis of SLE, inhibition of TLR9âs downstream signaling and cytokine stimulation by IRAK4 inhibition has strong potential for therapeutic intervention.</div><div class="NLM_p last">To validate the hypothesis of IRAK4 involvement in cytokine release, mice were treated with <b>41</b> 1 h prior to CpG1826 stimulation. Blockade of TLR9 signaling via inhibition of IRAK4 should lead to suppression of both IL-6 and TNFÎ±, as they are downstream of TLR9. After 1 h, blood and serum samples were collected for cytokine and PK analysis. Statistically significant inhibition of both IL-6 (69%) and TNFÎ± (39%) induction were observed at a 10 mg/kg dose (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A and B). Increasing the dose yielded increasing exposure up to 100 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C), with this top dose level resulting in 91% inhibition of IL-6 induction and 89% inhibition of TNFÎ± (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A and B).</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83502" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83502" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A synthetic route amenable to diversifying multiple portions of the molecules and applicable to both the 5,6- and 6,6-biaryl systems was derived. The 5,6-biaryl systems were prepared via a similar route, allowing diversification of the ribose pocket group and installation of the pyrazolopyrimidine hinge binder. Routes for the benzothiazole and benzoxazole cores have been previously disclosed.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Synthesis of benzimidazole linker <b>C</b> is shown below (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Addition of 4-chloro-5-nitrobenzene-1,2-diamine (<b>45</b>) to a nitrile containing the desired substitution (<b>I1</b>) promoted by ytterbium amides provides an efficient one-step synthesis of benzimidazole core <b>I2</b> via an <i>N</i>-arylamidine intermediate,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> which could be further manipulated with alkylation of the imidazole nitrogen to give intermediate <b>I3</b>. Extrapolating this to all the 5,6-biaryl systems gave late-stage intermediate <b>I4</b>. Nucleophilic aromatic substitution with various secondary amines proceeded in high yield to give intermediate <b>I5</b>. Reduction of the nitro group via palladium-catalyzed hydrogenation with subsequent amide coupling then yielded final targets <b>15</b>â<b>22</b>. Routes to quinoline and naphthyridine cores to provide <b>5</b>â<b>13</b> as well as indole <b>14</b> have been reported previously.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Benzimidazole Intermediates and Final 5,6-Biaryl Molecules<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ytterbium triflate, xylenes, 140 Â°C, 48 h; (b) MeI/EtBr, Cs<sub>2</sub>CO<sub>3</sub>, dimethylformamide (DMF), 90 min; (c) NHR<sup>3</sup>R<sup>4</sup>, 100 Â°C, 4 h; (d) Pd/C, MeOH; (e) hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DMF.</p></p></figure><div class="NLM_p">The semisaturated dihydrobenzofuran core was obtained through multiple routes. The original synthetic route provided a direct approach to initial lead <b>23</b> via late-stage intermediate <b>49</b> as well as targets <b>25</b>â<b>32</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Etherification of 3-chloro-4-nitrophenol <b>46</b> with 3-bromo-2-methylprop-1-ene followed by nucleophilic aromatic substitution with morpholine provided 4-(5-((2-methylallyl)oxy)-2-nitrophenyl)morpholine <b>47</b> in high yield over two steps. Claisen rearrangementârearomatization under microwave conditions provided a complex mixture including desired alcohol <b>48</b>, regioisomer <b>50</b>, cyclized furan <b>51</b>, and recovered starting material (27%). <i>gem</i>-Dimethyl dihydrobenzofuran <b>49</b> was then generated from phenol <b>48</b> under acidic conditions. Hydrogenation of the nitro group followed by amide coupling then gave furan <b>23</b> with poor overall conversion. The analogous route also provided hydroxymethylpiperidine <b>24</b>.</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Initial Route for Generating Dihydrobenzofuran <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, MeCN, 55 Â°C, quant.; (b) K<sub>2</sub>CO<sub>3</sub>, DMSO, 100 Â°C, 30 min, 93% yield; (c) Î¼w, DMF, 220 Â°C, 60 min; (d) 35% aqueous HCl in MeOH, 65% yield; (e) H<sub>2</sub>, Pd/C, MeOH; (f) PyAOP, 2,4,6-trimethylpyridine, DMF (45% yield).</p></p></figure><div class="NLM_p">Through further optimization, two synthetic routes were identified that allowed for scaffold diversification. The first route (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, route A) involved epoxidation of intermediate <b>48</b> with <i>meta</i>-chloroperoxybenzoic acid (<i>m</i>CPBA), which was accompanied by cyclization to generate the hydroxymethyl dihydrobenzofuran, which could then be elaborated to pyrazolopyrimidine IRAK4 inhibitors following the same transformations described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> (compound <b>49</b> to <b>23</b>). However, the epoxidationâcyclization sequence was low yielding. An improved route to the dihydrobenzofurans allowed for increased flexibility beginning with bromide <b>52</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, route B). Bromide <b>52</b> was converted to the corresponding Grignard reagent and reacted with methyl 2-oxopropanoate to afford tertiary alcohol <b>53</b>, which could be cyclized under basic conditions to give acid <b>54</b>. Nitration proceeded selectively at the C3 position to give intermediate <b>55</b>, which, after reduction using borane, provided the versatile hydroxymethyl dihydrobenzofuran intermediate <b>I6</b>. This intermediate allowed for modification of the ribose pocket group as well as diversification of the hinge binding element via nitro reduction and amide formation analogous to those shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Revised Route to Dihydrobenzofuran Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) <i>m</i>CPBA, dichloromethane (DCM), 20% yield; (b) H<sub>2</sub>, Pd/C; (c) PyAOP, 65% yield; (d) Mg, cat. I<sub>2</sub>, Et<sub>2</sub>O, Î then methyl 2-oxopropanoate; tetrahydrofuran (THF), â78 Â°C to rt, 2 h, 51% yield; (e) <i>t</i>BuOK, THF, 60 Â°C, 12 h, 64% yield; (f) HNO<sub>3</sub>, DCM, rt, 5 min, 54% yield; (g) BH<sub>3</sub>, THF, rt, 2 h, 32% yield. Highest resolution shell; n.d., parameter not determined.</p></p></figure><div class="NLM_p last">Modification of 1-(bromomethyl)-4-chloro-2-fluorobenzene <b>52</b> and carboxylic acid <b>55</b> also allowed for modification of the solvent front and linker regions. The synthetic details of additional intermediates and characterization details are provided in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> and the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35378" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35378" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have identified a series of highly potent and selective IRAK4 inhibitors through a structure-based design approach. Initial molecules contained either 6,6- or 5,6-biaryl linker systems. While the 5,6-biaryl ring systems such as benzimidazoles and benzothiazoles provided potent and stable molecules in rodents, poor oral exposure was uniformly seen due to the formation of poorly soluble, highly stable crystals. Reducing planarity while maintaining key hydrogen-bond interactions was hypothesized as a path forward to improve the physicochemical properties of inhibitors. This approach led to a new dihydrobenzofuran linker that was optimized to provide <b>41</b>. This was the first molecule from the pyrazolopyrimidine class to show improved stability and oral exposure across species. Most gratifyingly, <b>41</b> was also able to inhibit production of two cytokines that are critical to autoinflammatory response, IL-6 and TNFÎ±, after TLR induction. Given this precedence for scaffold hopping and the accompanying strategy for generating inhibitors with improved exposure, further development is being pursued and will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17126" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17126" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All chemicals were purchased from commercial suppliers and used as received. <sup>1</sup>H NMR spectra were recorded on Bruker Avance 400 or 500 spectrometers. Chemical shifts are expressed in Î´ ppm referenced to an internal standard, tetramethylsilane (Î´ = 0 ppm). Abbreviations used in describing peak signals are br = broad signal, s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet. All final compounds were purified to have purity higher than 95% by reverse-phase high-performance liquid chromatography (HPLC), supercritical fluid chromatography (SFC), or normal-phase silica gel flash chromatography. The purity was assessed by reverse-phase HPLC with an isocratic gradient of 5â95% acetonitrile in water (with either acid or base modifier) and monitored by diode array ultraviolet detection at 254 nm. Low-resolution mass spectra were recorded on a liquid chromatographyâmass spectrometer in electrospray positive (ES+) mode. High-resolution mass spectrometry (HRMS) experiments were performed on a Dionex LC Ultimate3000 coupled with a ThermoScientific Q Exactive orbitrap mass spectrometer using electrospray ionization (ESI) as the ionization source and a Phenomenex XB-C18, 1.7 mm, 50 mm Ã 2.1 mm column with a 0.7 mL/min flow rate at 40 Â°C for LC separation. Solvent A was 0.1% formic acid (FA) in water, and solvent B was 0.1% FA in acetonitrile. The gradient consisted of 2â98% solvent B over 7 min and held at 98% B for 1.5 min following equilibration for 1.0 min. The LC was monitored by UV absorbance at 220 and 254 nm. MS full scans with 10â¯000 resolution were applied to all experiments. Examples <b>5</b>â<b>14</b> were prepared by procedures described in the patent in ref <a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a>.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Procedure for the Synthesis of Benzimidazoles <b>I2</b> As Used toward 4-(5-Chloro-6-nitro-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)morpholine</h3><div class="NLM_p last">A sealed tube equipped with a stir bar was charged with 4-chloro-5-nitro-<i>O</i>-phenylenediamine, <b>45</b> (1.30 g, 6.93 mmol), ytterbium(III) trifluoromethanesulfonate (1.42 g, 2.29 mmol), xylenes (0.133 M, 52 mL, 418 mmol), and 4-morpholinecarbonitrile (785 mg, 6.93 mmol). The reaction mixture was then sealed and heated to 105 Â°C. After stirring for 48 h at this temperature, the reaction mixture was cooled to room temperature, diluted with dichloromethane/ethyl acetate/<i>p</i>-dioxane, and transferred to 500 mL of RBF. The mixture was then concentrated under reduced pressure. The crude residue was purified with flash column chromatography on silica gel (80 g gold column, 0â100% ethyl acetate in heptane) to afford 4-(5-chloro-6-nitro-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)morpholine (636 mg, 2.25 mmol, 33% yield). <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 7.86 (s, 1H), 7.39 (s, 1H), 3.74â3.71 (m, 4H), 3.58â3.54 (m, 4H). MS (ESI): <i>m</i>/<i>z</i> = 282.9 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure for the Synthesis of Intermediates <b>I3</b> As Used toward 4-(5-Chloro-1-methyl-6-nitrobenzimidazol-2-yl)morpholine</h3><div class="NLM_p last">To a solution of 4-(5-chloro-6-nitro-1<i>H</i>-benzimidazol-2-yl)morpholine (500 mg, 1.40 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (10 mL, 0.14 M) was added iodomethane (299 mg, 2.11 mmol) and cesium carbonate (686 mg, 2.11 mmol). The reaction mixture was stirred at room temperature for 1.5 h then extracted with ethyl acetate (50 mL), and the organics were washed with 3 Ã 20 mL saturated brine solution. The organics were then separated and dried over MgSO<sub>4</sub>. The organic layer was concentrated to dryness in vacuo to obtain a crude residue that was purified via chiral HPLC to obtain 4-(5-chloro-1-methyl-6-nitro-benzimidazol-2-yl)morpholine (353 mg, 1.19 mmol, 85% yield). <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 8.24 (s, 1H, 7.66 (s, 1H), 3.80â3.75 (m, 4H), 3.69 (s, 3H), 3.44â3.37 (m, 4H). MS (ESI): <i>m</i>/<i>z</i> = 297.1 [M + 1]<sup>+</sup>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Procedure for the Synthesis of Intermediates <b>I5</b> As Used toward [1-(6-Amino-1-methyl-2-morpholinobenzimidazol-5-yl)-4-piperidyl]methanol</h3><div class="NLM_p">A solution of 4-(5-chloro-1-methyl-6-nitrobenzimidazol-2-yl)morpholine (150 mg, 0.506 mmol) in 4-piperidinylmethanol (1.50 g, 13.0 mmol) was stirred overnight at 110 Â°C. The reaction was taken up in DCM (100 mL), and the organics were washed with water. The organics were then separated and dried over Na<sub>2</sub>SO<sub>4</sub> before concentration in vacuo. The crude residue was then purified by flash column chromatography eluting 3% MeOH in DCM to afford [1-(1-methyl-2-morpholino-6-nitro-benzimidazol-5-yl)-4-piperidyl]methanol (180 mg, 0.388 mmol, 77% yield) as a brown solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 8.03 (s, 1H), 7.82 (s, 1H), 3.94 (m, 4H), 3.69 (m, 5H), 3.58 (m, 2H), 3.29 (m, 2H), 2.83 (m, 2H), 1.83 (m, 5H), 1.55 (m, 2H). MS (ESI): <i>m</i>/<i>z</i> = 376.3 [M + 1]<sup>+</sup>. [1-(1-Methyl-2-morpholino-6-nitrobenzimidazol-5-yl)-4-piperidyl]methanol (1.76 g, 4.70 mmol) was dissolved in ethanol (23 mL). To the mixture was added palladium (10% on activated carbon) (500 mg, 0.470 mmol), and the flask was put under a hydrogen atmosphere after 3Ã vacuum/purge cycles. The reaction mixture was stirred for 2.5 h at room temperature, opened to air, and filtered through a short pad of Celite. The solution was concentrated in vacuo to afford [1-(6-amino-1-methyl-2-morpholinobenzimidazol-5-yl)-4-piperidyl]methanol as a dark red solid (1.58 g, 4.57 mmol, 97% yield) that was carried on without further purification.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (6-Chloro-2-methyl-5-nitro-3<i>H</i>-benzofuran-2-yl)methanol (<b>I6</b>)</h4><div class="NLM_p last">A mixture of 6-chloro-2-methyl-5-nitro-3<i>H</i>-benzofuran-2-carboxylic acid (1.93 g, 7.5 mmol) and borane (1 M in tetrahydrofuran, 14.0 mL, 14 mmol) in tetrahydrofuran (75 mL) was stirred at 25 Â°C for 2 h. Methanol (10 mL) was slowly added, and the reaction was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting 1:1 ethyl acetate/petroleum ether) to afford (6-chloro-2-methyl-5-nitro-3<i>H</i>-benzofuran-2-yl)methanol (580 mg, 32%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 7.84 (s, 1H), 6.99 (s, 1H), 6.60â5.80 (m, 1H), 3.68 (d, <i>J =</i> 16.8 Hz, 1H), 3.23 (d, <i>J =</i> 16.8 Hz, 1H), 1.80 (s, 3H). MS (ESI): <i>m</i>/<i>z</i> = 244.1 [M + 1]<sup>+</sup>. Examples <b>14</b>â<b>16</b> and example <b>18</b> were prepared using an analogous method to <b>17</b>.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(5-Methoxy-1<i>H</i>-indol-6-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>14</b>)</h4><div class="NLM_p last">MS (ESI): <i>m</i>/<i>z</i> = 308.12 [M + 1]<sup>+</sup>.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-(5-(4-(Hydroxymethyl)piperidin-1-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-6-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>15</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 12.36 (m, 1H), 10.94 (m, 1H), 9.39 (m, 1H), 8.94 (m, 1H), 8.79 (m, 1H), 8.74 (s, 1H), 8.13 (s, 1H), 7.59 (s, 1H), 7.36 (m, 1H), 4.61 (m,1H), 3.44 (m, 2H), 2.99 (m, 2H), 2.74 (m, 2H), 1.76 (m, 2H), 1.68â1.65 (m, 3H). MS (ESI): <i>m</i>/<i>z</i> = 392.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(5-(4-(Hydroxymethyl)piperidin-1-yl)-2-morpholino-1<i>H</i>-benzo[<i>d</i>]imidazol-6-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>16</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 11.75 (s, 1H), 10.81 (s, 1H), 9.36 (m, 1H), 8.92 (m, 1H), 8.71 (s, 1H), 8.55 (s, 1H), 7.34 (m, 1H), 7.20 (s, 1H), 4.59 (s, 1H), 3.74 (m, 4H), 3.45 (m, 4H), 3.33 (m, 2H), 2.94 (m, 2H), 2.71 (m, 2H), 1.75 (m, 2H), 1.64 (m, 3H). MS (ESI): <i>m</i>/<i>z</i> = 477.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(5-(4-(Hydroxymethyl)piperidin-1-yl)-1-methyl-2-morpholino-1<i>H</i>-benzo[<i>d</i>]imidazol-6-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>17</b>)</h4><div class="NLM_p last">A solution of [1-(6-amino-1-methyl-2-morpholinobenzimidazol-5-yl)-4-piperidyl]methanol (75.0 mg, 0.210 mmol), pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acid (41.4 mg, 0.250 mmol), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (165.2 mg, 0.320 mmol), and diisopropylethylamine (81.9 mg, 0.630 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (5 mL) was stirred at 25 Â°C for 2 h and then purified by prep-HPLC to give the target compound <i>N</i>-[6-[4-(hydroxymethyl)-1-piperidyl]-3-methyl-2-morpholinobenzimidazol-5-yl]pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (70.0 mg, 0.140 mmol, 66% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 10.89 (s, 1H), 9.37 (m, 1H), 8.94 (m, 1H), 8.70 (s, 1H), 8.58 (s, 1H), 7.40 (s, 1H), 7.35 (m, 1H), 4.59 (m, 1H), 3.79 (m, 4H), 3.60 (s, 3H), 3.44 (m, 2H), 3.19 (m, 4H), 2.95 (m, 2H), 2.73 (m, 2H), 1.71 (m, 5H). MS (ESI): <i>m</i>/<i>z</i> = 491.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(1-Ethyl-5-(4-(hydroxymethyl)piperidin-1-yl)-2-morpholino-1<i>H</i>-benzo[<i>d</i>]imidazol-6-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>18</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 11.00 (s, 1H), 8.86â8.79 (m, 4H), 7.55 (s, 1H), 7.02 (m, 1H), 4.11 (m, 2H), 3.90 (m, 4H), 3.68 (m, 2H), 3.29 (m, 4H), 3.12 (m, 2H), 2.79 (m, 2H), 1.83â1.63 (m, 5H), 1.49 (m, 3H). MS (ESI): <i>m</i>/<i>z</i> = 505.3 [M + 1]<sup>+</sup>. Examples <b>19</b>â<b>22</b> were prepared by procedures described in the patent in ref <a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>.</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(2,2-Dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>23</b>)</h4><div class="NLM_p">A mixture of 4-(2,2-dimethyl-5-nitro-3<i>H</i>-benzofuran-6-yl)morpholine <b>49</b> (60 mg, 0.22 mmol) and 10% palladium on carbon (30 mg) in methanol (8 mL) was stirred under a hydrogen atmosphere at 25 Â°C for 1 h. After filtration through a plug of Celite and concentration, 2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-amine (50 mg) was afforded as a yellow oil, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 249.2 [M + 1]<sup>+</sup>.</div><div class="NLM_p">A solution of pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acid (370 mg, 2.1 mmol) in dimethylformamide (6.2 mL) under nitrogen and cooled to 0 Â°C was treated with (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (1.1 g, 2.1 mmol) followed by 2,4,6-trimethylpyridine (0.27 mL, 2.1 mmol). 2,2-Dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-amine (460 mg, 1.9 mmol) was then introduced, and the reaction was allowed to warm to ambient temperature and was stirred for 18 h. The reaction mixture was filtered through a plug of silica and washed with a solution of 20% methanol in dichloromethane, and the filtrate was concentrated and purified via Prep-HPLC (Gemini-NX 50*30 mm c18, 5um, 110A; acetonitrile 20â60% (0.1% NH<sub>4</sub>OH in water)) to afford 330 mg of the title compound as an off-white solid. <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 10.43 (s, 1H), 9.41â9.32 (m, 1H), 8.98â8.91 (m, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.34 (dd, <i>J</i> = 7.0, 4.2 Hz, 1H), 6.71 (s, 1H), 3.89â3.77 (m, 4H), 3.04â2.96 (m, 2H), 2.86â2.78 (m, 4H), 1.42 (s, 6H). MS (ESI): <i>m</i>/<i>z</i> = 394.2 [M + 1]<sup>+</sup>.</div><div id="sec5_3_7_b" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> <i>N</i>-(6-(4-(Hydroxymethyl)piperidin-1-yl)-2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>24</b>)</h5><div class="NLM_p">A mixture of 6-chloro-2,2-dimethyl-5-nitro-3<i>H</i>-benzofuran (1.14 g, 5.01 mmol)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and 4-piperidinylmethanol (5.77 g, 50.08 mmol) was stirred at 110 Â°C for 18 h. The reaction was concentrated to dryness, and the residue was purified by silica gel chromatography (eluting gradient 1:4 to 2:3 ethyl acetate/petroleum ether) to afford [1-(2,2-dimethyl-5-nitro-3<i>H</i>-benzofuran-6-yl)-4-piperidyl]methanol (1.53 g, 97%) as an orange oil. MS (ESI): <i>m</i>/<i>z</i> = 307.2 [M + 1]<sup>+</sup>.</div><div class="NLM_p">A mixture of [1-(2,2-dimethyl-5-nitro-3<i>H</i>-benzofuran-6-yl)-4-piperidyl]methanol (1.16 g, 3.75 mmol) and 10% palladium on carbon (116 mg) in methanol (30 mL) was stirred at 25 Â°C under a hydrogen atmosphere for 2 h. The reaction was concentrated under reduced pressure to afford [1-(5-amino-2,2-dimethyl-3<i>H</i>-benzofuran-6-yl)-4-piperidyl]methanol (1.29 g) as an orange oil, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 277.2 [M + 1]<sup>+</sup>.</div><div class="NLM_p last">A mixture of [1-(5-amino-2,2-dimethyl-3<i>H</i>-benzofuran-6-yl)-4-piperidyl]methanol (990.0 mg, 3.58 mmol) and triethylamine (1087.4 mg, 10.75 mmol) in dichloromethane (10 mL) was stirred at 0 Â°C. To the mixture was added a solution of pyrazolo[1,5-<i>a</i>]pyrimidine-3-carbonyl chloride (example 3, step B) (975.67 mg, 5.37 mmol) in dichloromethane (10 mL), and the reaction was stirred at 25 Â°C for 1 h and concentrated under reduced pressure. The residue was purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10um; (A) acetonitrile 45â55%; (B) 10 mM ammonium bicarbonate in water) to afford <i>N</i>-[6-[4-(hydroxymethyl)-1-piperidyl]-2,2-dimethyl-3<i>H</i>-benzofuran-5-yl]pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (916 mg, 61%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.50 (s, 1H), 8.82â8.72 (m, 3H), 8.43 (s, 1H), 7.01 (dd, <i>J</i> = 4, 6.8 Hz, 1H), 6.65 (s, 1H), 3.67â3.57 (m, 2H), 3.14â3.06 (m, 2H), 3.03 (s, 2H), 2.72â2.61 (m, 2H), 1.82â1.61 (m, 5H), 1.48 (s, 6H). MS (ESI): <i>m</i>/<i>z</i> = 422.1 [M + 1]<sup>+</sup>.</div></div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(2,2-Dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-7-hydroxypyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>25</b>)</h4><div class="NLM_p">To a solution of 7-hydroxypyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acid (800 mg, 4.47 mmol) in dichloromethane (30 mL) was added <i>N</i>,<i>N</i>-dimethylformamide (0.34 mL, 4.47 mmol) and ethanedioyl dichloride (1.13 mL, 13.4 mmol) at 0 Â°C. The mixture was warmed to room temperature and stirred for 2 h. The solution was concentrated to afford crude 7-hydroxypyrazolo[1,5-<i>a</i>]pyrimidine-3-carbonyl chloride (800 mg,4.049 mmol, 90.7% yield) as a yellow solid. The product was directly used for the next step.</div><div class="NLM_p last">A mixture of 2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-amine (188.52 mg, 0.7600 mmol) and 7-hydroxypyrazolo[1,5-<i>a</i>]pyrimidine-3-carbonyl chloride (300.0 mg, 1.52 mmol) in pyridine (5 mL) was stirred at room temperature for 2 h. Thin-layer chromatography (TLC) (5% MeOH in DCM, Rf = 0.3) showed that the reaction was completed. The solution was concentrated in vacuo, and the resulting residue was purified by reverse-phase chromatography (acetonitrile 25â35/0.1% HCl in water) to afford <i>N</i>-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)-7-hydroxypyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (20.5 mg, 0.0496 mmol, 3.3% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 12.15 (s, 1H), 9.37 (s, 1H), 8.62 (s, 1H), 7.80 (s, 1H), 7.56 (s, 1H), 6.65 (s, 1H), 5.90 (d, <i>J</i> = 7.1 Hz, 1H), 3.76 (s, 4H), 2.98 (s, 2H), 2.88 (s, 4H), 1.42 (s, 6H). LCMS (ESI): <i>m</i>/<i>z</i> = 410.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(2,2-Dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-hydroxypyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>26</b>)</h4><div class="NLM_p last">To a solution of 6-bromo-<i>N</i>-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (200 mg, 0.42 mmol) in methanol (10 mL) was added potassium hydroxide (143 mg, 2.54 mmol). The mixture was stirred at 65 Â°C for 72 h and concentrated. The residue was dissolved in water (20 mL) and washed with dichloromethane (30 mL Ã 3). The aqueous phase was acidified to pH = 3 with 2 N HCl aqueous solution and extracted with 20% methanol in dichloromethane (20 mL Ã 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford <i>N</i>-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-hydroxypyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (40 mg, 22%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.33 (s, 1H), 8.76â8.72 (m, 2H), 8.49 (s, 1H), 8.29 (s, 1H), 6.70 (s, 1H), 3.82 (s, 4H), 2.99 (s, 2H), 2.80 (s, 4H), 1.41 (s, 6H). LCMS (ESI): <i>m</i>/<i>z</i> = 410.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 6-(Difluoromethoxy)-<i>N</i>-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>27</b>)</h4><div class="NLM_p last">To a solution of <i>N</i>-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-hydroxypyrazolo [1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>26</b>) (180 mg, 0.44 mmol) in DMF (8 mL) and water (0.8 mL) was added cesium carbonate (172 mg, 0.53 mmol) and sodium chlorodifluoroacetate (134 mg, 0.88 mmol). The mixture was heated at 100 Â°C for 16 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (50 mL), and washed with H<sub>2</sub>O (20 mL Ã 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by prep-TLC (2% methanol in dichloromethane) to afford 6-(difluoromethoxy)-<i>N</i>-(2,2- dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (26 mg, 12%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.37 (s, 1H), 8.82â8.81 (m, 2H), 8.72 (d, <i>J</i> = 2.4 Hz, 1H), 8.43 (s, 1H), 6.90â6.43 (m, 2H), 4.09â3.88 (m, 4H), 3.05 (s, 2H), 2.99â2.86 (m, 4H), 1.49 (s, 6H). LCMS (ESI): <i>m</i>/<i>z</i> = 460.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 6-(Difluoromethyl)-<i>N</i>-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>28</b>)</h4><div class="NLM_p">A mixture of 5-amino-1<i>H</i>-pyrazole-4-carboxylic acid (0.5 g, 3.93 mmol), methane tricarbaldehyde (0.47 g, 4.7 mmol), and acetic acid (1 mL) in ethanol (6 mL) was stirred under an atmosphere of nitrogen at 15 Â°C for 1 h followed by 70 Â°C for 15 h. The suspension was filtered, and the precipitate was washed with ethanol (10 mL). The solid was collected and dried to give 6-formylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acid (0.47 g, 63% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 12.68 (s, 1H), 10.06 (s, 1H), 9.92 (s, 1H), 9.11 (d, <i>J</i> = 2.4 Hz, 1H), 8.78 (s, 1H).</div><div class="NLM_p">A solution of 6-formylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acid (example 75, step A) (191 mg, 1.0 mmol), 2-(7-aza-1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (750 mg, 1.97 mmol), and diisopropylethylamine (0.5 mL, 3.0 mmol) was stirred in dimethylformamide (2 mL) at room temperature for 10 min. To this mixture was added 2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-amine (245 mg, 0.98 mmol) in dimethylformamide (1 mL), and the reaction was stirred for an additional 16 h. The mixture was poured into water (20 mL) and extracted with ethyl acetate (50 mL). The organic phase was washed with water and brine and dried over sodium sulfate before concentration to dryness. The residue was purified by silica gel chromatography (eluent 1:10 ethyl acetate/petroleum ether) to afford <i>N</i>-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)-6-formylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (283 mg, 61%) as a yellow solid. MS (ESI): <i>m</i>/<i>z</i> = 422.2 [M + 1]<sup>+</sup>.</div><div class="NLM_p last">To a solution of <i>N</i>-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)-6-formylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (120 mg, 0.28 mmol) in dichloromethane (8 mL) at 0 Â°C was added diethylaminosulfurtrifluoride (0.17 mL, 1.28 mmol). The mixture was stirred at 25 Â°C for 8 h, concentrated to dryness, and purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10um; acetonitrile 30â70% (10 mM ammonium bicarbonate) in water) to afford 6-(difluoromethyl)-<i>N</i>-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (10.1 mg, 7.4%) as a brown solid. <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 10.36 (s, 1H), 9.75 (d, <i>J</i> = 1.6 Hz, 1H), 9.12 (d, <i>J</i> = 1.6 Hz, 1H), 8.80 (s, 1H), 8.30 (s, 1H), 7.32 (t, <i>J</i> = 54.6 Hz, 2H), 6.73 (s, 1H), 3.90â3.78 (m, 4H), 3.01 (s, 2H), 2.87â2.73 (m, 4H), 1.42 (s, 6H). MS (ESI): <i>m</i>/<i>z</i> = 444.2 [M + 1].</div></div><div id="sec5_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 6-Cyclopropyl-<i>N</i>-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>29</b>)</h4><div class="NLM_p">To a mixture of ethyl 3-amino-1<i>H</i>-pyrazole-4-carboxylate (3.0 g, 19.34 mmol) and 2-bromomalonaldehyde (3.21 g, 21.26 mmol) in ethanol (10 mL) was added acetic acid (30 mL). The mixture was stirred for 2 h at 70 Â°C. The reaction was concentrated to dryness. The residue was brought up in ethyl acetate and washed with saturated sodium bicarbonate solution, dried over sodium sulfate, filtered, and concentrated to dryness. The residue was then purified by silica gel chromatography (eluent 1:3 ethyl acetate/petroleum ether) to afford ethyl 6-bromopyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylate (3.3 g, 63%) as a white solid. MS (ESI): <i>m</i>/<i>z</i> = 270.0 [M + 1]<sup>+</sup>.</div><div class="NLM_p">A mixture of ethyl 6-bromopyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylate (400 mg, 1.48 mmol), cyclopropylboronic acid (200 mg, 2.33 mmol), palladium diacetate (56 mg, 0.25 mmol), triphenylphosphine (168 mg, 0.60 mmol), and potassium phosphate (1260 mg, 5.94 mmol) in toluene (6 mL) and water (1 mL) in a sealed tube was stirred under N<sub>2</sub> atmosphere at 120 Â°C for 2 h. The mixture was poured onto water (30 mL), and the aqueous phase was extracted with ethyl acetate (100 mL). The organic phase was washed with water and brine and dried over sodium sulfate before concentration to dryness. The residue was purified by preparative TLC (eluent 1:3 ethyl acetate/petroleum ether) to afford ethyl 6-cyclopropylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylate (205 mg, 60%) as a yellow solid. MS(ESI): <i>m</i>/<i>z</i> = 232.1 [M + 1]<sup>+</sup>.</div><div class="NLM_p">The mixture of ethyl 6-cyclopropylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylate (60 mg, 0.26 mmol) and lithium hydroxide (12 mg, 0.29 mmol) in tetrahydrofuran (3 mL), methanol (3 mL), and water (3 mL) was stirred at 100 Â°C for 10 min. The mixture was neutralized with 1 N hydrogen chloride solution and extracted with ethyl acetate (20 mL). The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford 6-cyclopropylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acid (52 mg) as a yellow solid, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 204.1 [M + 1]<sup>+</sup>.</div><div class="NLM_p last">To a mixture of 6-cyclopropylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acid (61 mg, 0.30 mmol) and diisopropylethylamine (0.11 mL, 0.66 mmol) in dimethylformamide (2 mL) was added 2-(7-aza-1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (154 mg, 0.41 mmol), and the mixture was stirred at 25 Â°C for 20 min. To this was added a solution of 2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-amine (50 mg, 0.20 mmol) in dimethylformamide (2 mL), and the mixture was stirred at 25 Â°C for 16 h. The reaction was filtered, and the precipitate was washed with methanol to afford 6-cyclopropyl-<i>N</i>-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (61 mg, 70%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.41 (s, 1H), 8.70 (s, 1H), 8.65 (d, <i>J</i> = 2.0 Hz, 1H), 8.50 (dd, <i>J</i> = 0.8 Hz, 2.0 Hz, 1H), 8.43 (s, 1H), 6.65 (s, 1H), 3.97 (t, <i>J</i> = 4.4 Hz, 4H), 3.04 (s, 2H), 2.92 (t, <i>J</i> = 4.4 Hz, 4H), 2.09â2.00 (m, 1H), 1.49 (s, 6H), 1.20â1.13 (m, 2H), 0.86â0.79 (m, 2H). MS (ESI): <i>m</i>/<i>z</i> = 434.1 [M + 1]<sup>+</sup>.</div></div><div id="sec5_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 6-Cyano-<i>N</i>-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>30</b>)</h4><div class="NLM_p">To a stirred solution of <i>N</i>-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)-6-formylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (0.15 g, 0.35 mmol) in ethanol (5 mL) was added hydroxylamine hydrochloride (97 mg, 1.4 mmol) and sodium acetate (0.11 g, 1.4 mmol). The mixture was stirred at 20 Â°C for 2 h under an atmosphere of nitrogen. Water (10 mL) was added, and the mixture was extracted with dichloromethane (50 mL Ã 4), dried over sodium sulfate, and concentrated under reduced pressure to give <i>N</i>-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-((hydroxyimino)methyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (155 mg, 99% yield) as a yellow solid. LCMS (ESI): <i>m</i>/<i>z</i> = 437.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last">To a stirred solution of <i>N</i>-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)-6-((hydroxyimino)methyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (180 mg, 0.41 mmol) in carbon tetrachloride (5 mL) was added thionyl chloride (0.15 mL, 2.06 mmol). The mixture was stirred at 65 Â°C for 2 h under an atmosphere of nitrogen. Water (10 mL) was added, and the mixture was extracted with dichloromethane (20 mL Ã 3). The combined organic phases were washed with saturated sodium bicarbonate (20 mL), dried over sodium sulfate, and concentrated to dryness. The residue was purified by column chromatography (eluent 3% methanol/dichloromethane) followed by recrystallization in methanol to give 6-cyano-<i>N</i>-(2,2-dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (53 mg, 29% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.33 (s, 1H), 9.20 (d, <i>J</i> = 2.0 Hz, 1H), 8.95 (s, 1H), 8.85 (d, <i>J</i> = 2.0 Hz, 1H), 8.40 (s, 1H), 6.68 (s, 1H), 3.94 (t, <i>J</i> = 4.0 Hz, 4H), 3.05 (s, 2H), 2.91 (t, <i>J</i> = 4.0 Hz, 4H), 1.50 (s, 6H). LCMS (ESI): <i>m</i>/<i>z</i> = 419.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i><sup>3</sup>-(2,2-Dimethyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3,6-dicarboxamide (<b>31</b>)</h4><div class="NLM_p">A solution of 6-bromo-<i>N</i>-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (150 mg, 0.3 mmol), triethylamine (96 mg, 1.0 mmol), and 1,1â²-bis(diphenylphosphino)ferrocene palladium dichloride (23 mg, 0.03 mmol) in anhydrous ethanol (25 mL) was stirred at 80 Â°C for 20 h under CO atmosphere (40 psi). The reaction mixture was concentrated, and the residue was purified by prep-TLC (4% methanol in dichloromethane) to afford ethyl 3-[(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)carbamoyl]pyrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylate (120.0 mg, 81%) as a yellow solid. LCMS (ESI): <i>m</i>/<i>z</i> = 466.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">To ethyl 3-[(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)carbamoyl]pyrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylate (120.0 mg, 0.3 mmol) was added anhydrous ethanol (30 mL) saturated with ammonia (22.0 mg, 1.3 mmol). The mixture was stirred at 100 Â°C for 48 h and concentrated. The crude product was triturated with 10% methanol in dichloromethane twice to give <i>N</i>-3-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3,6-dicarboxamide (37.1 mg, 32%) as a reddish purple solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.42 (s, 1H), 9.76 (d, <i>J</i> = 2.0 Hz, 1H), 9.26 (d, <i>J</i> = 2.0 Hz, 1H), 8.79 (s, 1H), 8.41 (s, 1H), 8.32 (s, 1H), 7.92 (s, 1H), 6.73 (s, 1H), 3.87â3.84 (m, 4H), 3.01 (s, 2H), 2.83â2.81 (m, 4H), 1.41 (s, 6H). LCMS (ESI): <i>m</i>/<i>z</i> = 437.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-(2,2-Dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)-6-(hydroxymethyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>32</b>)</h4><div class="NLM_p last">To a solution of 6-bromo-<i>N</i>-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (100 mg, 0.21 mmol) in 1,4-dioxane (3 mL) and water (0.30 mL) was added potassium acetoxymethyl(trifluoro)boron (115 mg, 0.64 mmol), sodium carbonate (68 mg, 0.64 mmol), 2-dicyclohexylphosphino-2â²,6â²-di-i-propoxy-1,1â²-biphenyl (60 mg, 0.13 mmol), and Ruphos-Pd-G2 (44 mg, 0.06 mmol). The reaction mixture was stirred at 120 Â°C for 0.5 h under microwave irradiation. The reaction mixture was filtered and concentrated. The residue was purified by prep-TLC (5% methanol in dichloromethane) to afford <i>N</i>-(2,2-dimethyl-6-morpholino-3<i>H</i>-benzofuran-5-yl)-6-(hydroxymethyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (48 mg, 53%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) 10.42 (s, 1H), 9.22 (s, 1H), 8.95 (s, 1H), 8.65 (s, 1H), 8.32 (s, 1H), 6.72 (s, 1H), 5.64 (t, <i>J</i> = 5.6 Hz, 1H), 4.70 (d, <i>J</i> = 5.6 Hz, 2H), 3.90â3.80 (m, 4H), 3.00 (s, 2H), 2.90â2.80 (m, 4H), 1.41 (s, 6H). LCMS (ESI): <i>m</i>/<i>z</i> = 424.1 [M + H]<sup>+</sup>. The following examples were made in a manner similar to that for examples <b>24</b> and <b>38</b>.</div></div><div id="sec5_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-(2,2-Dimethyl-6-(pyrrolidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>33</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 10.13 (s, 1H), 9.37 (dd, <i>J</i> = 7.0, 1.6 Hz, 1H), 8.85 (dd, <i>J</i> = 4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.08 (s, 1H), 7.31 (dd, <i>J</i> = 7.0, 4.2 Hz, 1H), 6.59 (s, 1H), 3.00 (m, 4H), 2.98 (s, 2H), 1.98â1.86 (m, 4H), 1.41 (s, 6H). MS (ESI): <i>m</i>/<i>z</i> = 378.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(2,2-Dimethyl-6-(piperazin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>34</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.34 (s, 1H), 9.39 (dd, <i>J</i> = 6.8 Hz, 1.6 Hz, 1H), 9.02 (dd, <i>J</i> = 4.0 Hz, 1.2 Hz, 1H), 8.70 (s, 1H), 8.34 (s, 1H), 7.39 (dd, <i>J</i> = 6.8 Hz, 4.4 Hz, 1H), 6.70 (s, 1H), 4.17â4.13 (m, 1H), 3.32â3.28 (m, 2H), 3.16 (d, <i>J</i> = 5.6 Hz, 2H), 3.07â3.00 (m, 6H), 1.41 (s, 6H). LCMS (ESI): <i>m</i>/<i>z</i> = 393.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-(2,2-Dimethyl-6-(4-(2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>35</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 10.51 (s, 1H), 9.35 (dd, <i>J</i> = 7.0, 1.7 Hz, 1H), 8.99 (dd, <i>J</i> = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.37 (s, 1H), 7.33 (dd, <i>J</i> = 7.0, 4.2 Hz, 1H), 6.69 (s, 1H), 6.38 (d, <i>J</i> = 2.6 Hz, 1H), 3.94 (s, 1H), 2.99 (s, 2H), 2.95 (d, <i>J</i> = 11.4 Hz, 2H), 2.74â2.59 (m, 2H), 1.98â1.83 (m, 2H), 1.80â1.72 (m, 2H), 1.66 (d, <i>J</i> = 12.3 Hz, 1H), 1.41 (s, 6H). MS (ESI): <i>m</i>/<i>z</i> = 490.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-[6-(4-Carbamoyl-1-piperidyl)-2,2-dimethyl-3<i>H</i>-benzofuran-5-yl]pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>36</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.71 (s, 1H), 9.19 (dd, <i>J</i> = 4.0, 1.6 Hz, 1H), 8.79â8.77 (m, 2H), 8.55 (s, 1H), 7.08 (dd, <i>J</i> = 7.2, 4.4 Hz, 1H), 6.63 (s, 1H), 5.54â5.52 (m, 1H), 5.31â5.29 (m, 1H), 3.14â3.11 (m, 2H), 3.04 (s, 2H), 2.73â2.67 (m, 2H), 2.35â2.30 (m, 3H), 1.92â1.90 (m, 2H), 1.49 (s, 6H). LCMS (ESI): <i>m</i>/<i>z</i> = 435.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-[6-(4-Hydroxyazepan-1-yl)-2,2-dimethyl-3<i>H</i>-benzofuran-5-yl]pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>37</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 10.45 (s, 1H), 9.36 (dd, <i>J</i> = 7.0, 1.6 Hz, 1H), 8.93 (dd, <i>J</i> = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.26 (d, <i>J</i> = 1.0 Hz, 1H), 7.34 (dd, <i>J</i> = 7.0, 4.2 Hz, 1H), 6.64 (s, 1H), 4.54 (d, <i>J</i> = 3.7 Hz, 1H), 3.98â3.87 (m, 1H), 3.03â2.80 (m, 6H), 2.04 (m, 1H), 1.99â1.80 (m, 3H), 1.80â1.57 (m, 2H), 1.40 (s, 6H). LCMS (ESI) <i>m</i>/<i>z</i>: 422.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-[6-[4-(2-Hydroxyethyl)piperazin-1-yl]-2,2-dimethyl-3<i>H</i>-benzofuran-5-yl]pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>38</b>)</h4><div class="NLM_p">A mixture of 6-chloro-2,2-dimethyl-5-nitro-3<i>H</i>-benzofuran (100 mg, 0.44 mmol) and 1-piperazine ethanol (572 mg, 4.39 mmol) in dimethyl sulfoxide (1 mL) was stirred at 110 Â°C for 16 h. The mixture was poured into water, and the reaction was extracted by ethyl acetate (100 mL). The organic phase was washed with water and brine, dried over sodium sulfate, and filtered before concentration to dryness. The residue was purified by preparative TLC (eluent 1:20 methanol/dichloromethane) to afford 2-[4-(2,2-dimethyl-5-nitro-3<i>H</i>-benzofuran-6-yl)piperazin-1-yl]ethanol (110 mg, 78%) as a brown oil. MS (ESI): <i>m</i>/<i>z</i> = 322.1 [M + 1]<sup>+</sup>.</div><div class="NLM_p">A mixture of 2-[4-(2,2-dimethyl-5-nitro-3<i>H</i>-benzofuran-6-yl)piperazin-1-yl]ethanol (59 mg, 0.18 mmol) and 10% palladium on carbon (29 mg) in methanol (8 mL) was stirred under a hydrogen atmosphere at 20 Â°C for 1 h. After filtration and concentration, 2-[4-(5-amino-2,2-dimethyl-3<i>H</i>-benzofuran-6-yl)piperazin-1-yl]ethanol (50 mg) was afforded as a brown oil, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 392.2 [M + 1]<sup>+</sup>.</div><div class="NLM_p last">To a mixture of pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acid (42 mg, 0.26 mmol) and diisopropylethylamine (0.09 mL, 0.52 mmol) in dimethylformamide (2 mL) was added 2-(7-aza-1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (131 mg, 0.34 mmol), and the mixture was stirred at 25 Â°C for 15 min. To this was added a solution of 2-[4-(5-amino-2,2-dimethyl-3<i>H</i>-benzofuran-6-yl)piperazin-1-yl]ethanol (50 mg, 0.17 mmol) in dimethylformamide (2 mL), and the resulting mixture was stirred at 25 Â°C for 16 h. The mixture was purified by preparative HPLC (Xbridge 21.2*250 mm c18, 10um; (A) acetonitrile 10â70%; (B) 10 mM ammonium bicarbonate in water) to afford <i>N</i>-[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2,2-dimethyl-3<i>H</i>-benzofuran-5-yl]pyrazolo[1,5-6<i>a</i>]pyrimidine-3-carboxamide (45 mg, 60%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 10.42 (s, 1H), 9.37 (dd, <i>J</i> = 1.6, 7.2 Hz, 1H), 8.92 (dd, <i>J</i> = 1.6, 4.4 Hz, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 7.36 (dd, <i>J</i> = 4.4,7.2 Hz, 1H), 6.69 (s, 1H), 4.45 (t, <i>J</i> = 5.2 Hz, 1H), 3.54 (q, <i>J</i> = 5.6 Hz, 2H), 3.00 (s, 2H), 2.84â2.78 (m, 4H), 2.74â2.61 (m, 4H), 2.50 (t, <i>J</i> = 5.6 Hz, 2H), 1.41 (s, 6H). MS (ESI): <i>m</i>/<i>z</i> = 437.3 [M + 1]<sup>+</sup>.</div></div><div id="sec5_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-[6-[4-(2-Amino-2-oxoethyl)piperazin-1-yl]-2,2-dimethyl-3<i>H</i>-benzofuran-5-yl]pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>39</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 10.42 (s, 1H), 9.36 (dd, <i>J</i> = 7.0, 1.6 Hz, 1H), 8.97 (dd, <i>J</i> = 4.2, 1.7 Hz, 1H), 8.67 (s, 1H), 8.33 (s, 1H), 7.35 (dd, <i>J</i> = 7.0, 4.2 Hz, 1H), 7.19 (d, <i>J</i> = 29.3 Hz, 2H), 6.68 (s, 1H), 3.01 (m, 4H), 2.85 (m, 4H), 2.73 (m, 4H), 1.41 (s, 6H). LCMS (ESI) <i>m</i>/<i>z</i>: 450.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(6-Methyl-2-morpholino-7-oxo-6,7-dihydro-5<i>H</i>-pyrrolo[3,4-<i>b</i>]pyridin-3-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>40</b>)</h4><div class="NLM_p">A mixture of 6-chloro-2,2-dimethyl-5-nitro-3<i>H</i>-benzofuran (10.0 g, 43.9 mmol), piperazine (4.16 g, 48.3 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (25.4 mL, 154 mmol) in dimethyl sulfoxide (133 mL) was heated at 45 Â°C for 12 h. The mixture was diluted with water, brine, and dichloromethane. The phases were separated, and the aqueous phase was extracted into dichloromethane. The combined organic phases were dried over sodium sulfate, concentrated under reduced pressure, and purified by silica gel chromatography (eluting gradient 0â20% methanol/dichloromethane) to afford 1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazine (5.96 g, 49% yield) as a bright orange foam. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 7.83 (s, 1H), 6.57 (s, 1H), 3.00 (d, <i>J</i> = 1.1 Hz, 2H), 2.91 (d, <i>J</i> = 10.5 Hz, 8H), 1.44 (s, 6H).</div><div class="NLM_p">A mixture of 1-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazine (5.96 g, 21.5 mmol), potassium carbonate (4.46 g, 32.3 mmol), and ethyl 2-bromoacetate (2.55 mL, 22.6 mmol) in dimethylformamide (100 mL) was stirred at ambient temperature for 18 h. The mixture was diluted with water, brine, and isopropyl acetate. The layers were separated, and the aqueous phase was extracted with isopropyl acetate. The combined organic phases were dried over sodium sulfate, concentrated under reduced pressure, and purified by silica gel chromatography (eluting gradient 0â100% isopropyl acetate/heptane) to afford ethyl 2-(4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)acetate (7.74 g, 99% yield) as an orange oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 7.82 (t, <i>J</i> = 1.2 Hz, 1H), 6.59 (s, 1H), 4.09 (q, <i>J</i> = 7.1 Hz, 2H), 3.27 (s, 2H), 3.00 (d, <i>J</i> = 1.0 Hz, 2H), 2.99â2.93 (m, 4H), 2.68â2.58 (m, 4H), 1.44 (s, 6H), 1.24â1.14 (m, 4H).</div><div class="NLM_p">A mixture of ethyl 2-(4-(2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)acetate (7.74 g, 21.3 mmol) and 10% palladium on carbon (2.27 g, 2.13 mmol) in ethanol (100 mL) was stirred for 18 h under an atmosphere of hydrogen. The mixture was filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel chromatography (eluting gradient 0â5% methanol/dichloromethane) to afford ethyl 2-(4-(5-amino-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)piperazin-1-yl)acetate (6.36 g, 90% yield).<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 6.52 (s, 1H), 6.34 (s, 1H), 4.17 (s, 2H), 4.10 (q, <i>J</i> = 7.1 Hz, 2H), 3.25 (s, 2H), 2.83 (s, 2H), 2.74 (d, <i>J</i> = 4.4 Hz, 4H), 2.63 (s, 4H), 1.34 (s, 6H), 1.24â1.14 (m, 3H).</div><div class="NLM_p">Ethyl 2-[4-(5-amino-2,2-dimethyl-3<i>H</i>-benzofuran-6-yl)piperazin-1-yl]acetate (200 mg, 0.60 mmol) in pyridine (10 mL) was treated with pyrazolo[1,5-<i>a</i>]pyrimidine-3-carbonyl chloride (120 mg, 0.66 mmol) and stirred at 25 Â°C for 4 h. The reaction was concentrated and purified by silica gel chromatography (eluting gradient 0â10% methanol/dichloromethane) to afford ethyl 2-[4-[2,2-dimethyl-5-(pyrazolo[1,5-<i>a</i>]pyrimidine-3-carbonylamino)-3<i>H</i>-benzofuran-6-yl]piperazin-1-yl]acetate (280 mg, 98% yield) as a brown solid. LCMS (ESI): <i>m</i>/<i>z</i> = 479.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Ethyl 2-[4-[2,2-dimethyl-5-(pyrazolo[1,5-<i>a</i>]pyrimidine-3-carbonylamino)-3<i>H</i>-benzofuran-6-yl]piperazin-1-yl]acetate (280 mg, 0.59 mmol) was treated with 2 M methylamine in tetrahydrofuran (10 mL, 20 mmol), stirred at 100 Â°C for 36 h under autoclave, concentrated, and purified by preparatory TLC (eluent: 10% methanol in dichloromethane) to afford <i>N</i>-[2,2-dimethyl-6-[4-[2-(methylamino)-2-oxo-ethyl]piperazin-1-yl]-3<i>H</i>-benzofuran-5-yl]pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (93.6 mg, 33% yield) as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.42 (s, 1H), 9.40â9.35 (m, 1H), 8.97â8.95 (m, 1H), 8.67 (s, 1H), 8.33 (s, 1H), 7.75â7.74 (m, 1H), 7.36 (dd, <i>J</i> = 7.2, 4.4 Hz, 1H), 6.67 (s, 1H), 3.04 (s, 2H), 3.00 (s, 2H), 2.85â2.84 (m, 4H), 2.72â2.68 (m, 4H), 2.64 (d, <i>J</i> = 4.8 Hz, 3H), 1.41 (s, 6H). LCMS (ESI) <i>m</i>/<i>z</i>: 464.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>R</i>)-<i>N</i>-(2-(Hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>41</b>) and (<i>S</i>)-<i>N</i>-(2-(Hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>42</b>)</h4><div class="NLM_p">A mixture of (6-chloro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol (<b>I6</b>) (900 mg, 3.70 mmol) was stirred in morpholine (5 mL) at 120 Â°C for 18 h. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (eluent 1:1 ethyl acetate/petroleum ether) to afford (2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)methanol (780 mg, 72%) as a yellow oil. MS (ESI): <i>m</i>/<i>z</i> = 295.1 [M + 1]<sup>+</sup>.</div><div class="NLM_p">A mixture of (2-methyl-6-morpholino-5-nitro-3<i>H</i>-benzofuran-2-yl)methanol (780 mg, 2.65 mmol) and 10% palladium on carbon (200 mg) in methanol (30 mL) was stirred at 25 Â°C under a hydrogen atmosphere for 1 h. The reaction was filtered, and the filtrate was concentrated under reduced pressure to afford (5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)methanol (550 mg) as a light green oil, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 265.1 [M + 1]<sup>+</sup>.</div><div class="NLM_p">A mixture of (5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)methanol (550 mg, 2.08 mmol), pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (407 mg, 2.5 mmol), (3-hydroxy-3<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinato-<i>O</i>)tri-1-pyrrolidinylphosphonium hexafluorophosphate (1.63 g, 3.12 mmol), and diisopropyethylamine (756 mg, 6.24 mmol) in dimethylformamide (10 mL) was stirred at 25 Â°C for 3 h. Water was added, and the reaction was extracted with ethyl acetate (2 Ã 50 mL). The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluent 3:100 methanol in dichloromethane) to afford <i>N</i>-[2-(hydroxymethyl)-2-methyl-6-morpholino-3<i>H</i>-benzofuran-5-yl]pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (490 mg, 58%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.47 (s, 1H), 8.83 (dd, <i>J</i> = 1.5, 7.2 Hz, 1H), 8.78 (s, 1H), 8.77 (dd, <i>J</i> = 1.6, 4.0 Hz, 1H), 7.07 (dd, <i>J</i> = 4.0, 7.2 Hz, 1H), 6.67 (s, 1H), 3.94â3.96 (m, 4H), 3.67 (d, <i>J</i> = 5.6 Hz, 2H), 3.25 (d, <i>J</i> = 15.6 Hz, 1H), 2.95 (d, <i>J</i> = 15.6 Hz, 1H), 2.91â2.93 (m, 4H), 1.46 (s, 3H). MS (ESI): <i>m</i>/<i>z</i> = 410.1 [M + 1]<sup>+</sup>.</div><div class="NLM_p"><i>N</i>-(2-(Hydroxymethyl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (example <b>6</b>) was resolved via chiral SFC (PIC 100 SFC (Lux Cellulose-3, 21.1*150 mm, 5um), 25% methanol isocratic (0.1% NH<sub>4</sub>OH in CO<sub>2</sub>)) to afford the title compounds as solids. Stereochemistry was arbitrarily assigned based on peak elution.</div><div class="NLM_p">Example <b>41</b>, peak 1: <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 10.43 (s, 1H), 9.37 (dd, <i>J</i> = 7.0, 1.6 Hz, 1H), 8.94 (dd, <i>J</i> = 4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.29 (s, 1H), 7.34 (dd, <i>J</i> = 7.0, 4.2 Hz, 1H), 6.70 (s, 1H), 5.10â4.98 (m, 1H), 3.91â3.74 (m, 4H), 3.43 (t, <i>J</i> = 5.7 Hz, 2H), 3.20 (dd, <i>J</i> = 15.9, 0.7 Hz, 1H), 2.90â2.73 (m, 5H), 1.34 (s, 3H). MS (ESI): <i>m</i>/<i>z</i> = 410.2 [M + 1]<sup>+</sup>. <sup>13</sup>C NMR (400 MHz, DMSO) Î´ 159.32, 155.49, 152.97, 146.95, 145.26, 142.17, 138.23, 127.16, 123.14, 117.29, 110.67, 106.20, 102.54, 89.80, 67.15, 67.06, 52.77, 40.63, 40.42, 40.22, 40.01, 39.80, 39.59, 39.38, 38.04, 24.07.</div><div class="NLM_p last">Example <b>42</b>, peak 2: <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 10.43 (s, 1H), 9.37 (dd, <i>J</i> = 7.0, 1.6 Hz, 1H), 8.94 (dd, <i>J</i> = 4.2, 1.6 Hz, 1H), 8.68 (s, 1H), 8.29 (s, 1H), 7.34 (dd, <i>J</i> = 7.0, 4.2 Hz, 1H), 6.70 (s, 1H), 5.10â4.98 (m, 1H), 3.91â3.74 (m, 4H), 3.43 (t, <i>J</i> = 5.7 Hz, 2H), 3.20 (dd, <i>J</i> = 15.9, 0.7 Hz, 1H), 2.90â2.73 (m, 5H), 1.34 (s, 3H). MS (ESI): <i>m</i>/<i>z</i> = 410.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_3_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>R</i>)-<i>N</i>-(2-(2-Hydroxypropan-2-yl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide and (<i>S</i>)-<i>N</i>-(2-(2-Hydroxypropan-2-yl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>43</b>)</h4><div class="NLM_p">To a solution of methyl 6-fluoro-2-methyl-3<i>H</i>-benzofuran-2-carboxylate (877 mg, 4.17 mmol) in anhydrous tetrahydrofuran (20 mL) under a nitrogen atmosphere at â78 Â°C was added dropwise methylmagnesium bromide (3 M in ditheyl ether, 4.17 mL, 12.52 mmol), and the solution was maintained at that temperature for 1 h. The mixture was quenched with saturated ammonium chloride solution. Ethyl acetate (50 mL) was added, and the organic phase was separated, dried over sodium sulfate, and concentrated to afford 2-(6-fluoro-2-methyl-2,3-dihydrobenzofuran-2-yl)propan-2-ol (800 mg) as a colorless oil, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 193.1 [M â 17]<sup>+</sup>.</div><div class="NLM_p">To a mixture of 2-(6-fluoro-2-methyl-2,3-dihydrobenzofuran-2-yl)propan-2-ol (400 mg, 1.9 mmol) in dichloromethane (15 mL) was added concentrated nitric acid (60â70 wt %, 0.5 mL). The mixture was stirred at room temperature for 1 h, poured into ice water, and extracted with dichloromethane (30 mL). The organic phase was separated, dried over sodium sulfate, and concentrated. The residue was purified by silica gel chromatography (eluent: 1:4 ethyl acetate/petroleum ether) to afford 2-(6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)propan-2-ol (320 mg, 59%) as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.94 (d, <i>J</i> = 7.8 Hz, 1H), 6.61 (d, <i>J</i> = 12.8 Hz, 1H), 3.54 (d, <i>J</i> = 15.6 Hz, 1H), 2.82 (d, <i>J</i> = 15.6 Hz, 1H), 1.38 (s, 3H), 1.24 (s, 6H).</div><div class="NLM_p">Morpholine (218 mg, 2.51 mmol), 2-(6-fluoro-2-methyl-5-nitro-2,3-dihydrobenzofuran-2-yl)propan-2-ol (320 mg, 1.25 mmol), and potassium carbonate (346 mg, 2.51 mmol) were stirred at room temperature in acetonitrile (20 mL) for 3 h. Water was added, and the mixture was extracted with ethyl acetate (50 mL). The organic phase was isolated, dried over sodium sulfate, and concentrated to afford 2-(2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)propan-2-ol (318 mg) as a yellow oil, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 323.2 [M + 1]<sup>+</sup>.</div><div class="NLM_p">A mixture of palladium on carbon (100 mg, 10 wt %) and 2-(2-methyl-6-morpholino-5-nitro-2,3-dihydrobenzofuran-2-yl)propan-2-ol (300 mg, 0.93 mmol) in methanol (30 mL) was stirred at room temperature under a hydrogen atmosphere for 1 h. After filtration and concentration under reduced pressure, 2-(5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)propan-2-ol (280 mg) was obtained as a green oil, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 293.2 [M + 1]<sup>+</sup>.</div><div class="NLM_p">A mixture of pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acid (174 mg, 1.07 mmol), (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate (695 mg, 1.33 mmol), <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (323 mg, 2.67 mmol), and 2-(5-amino-2-methyl-6-morpholino-2,3-dihydrobenzofuran-2-yl)propan-2-ol (260 mg, 0.89 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (10 mL) was stirred at room temperature for 2 h. The crude reaction was purified by preparative HPLC (Gilson 281, Xbridge 21.2*250 mm c18, 10um; (A) acetonitrile, 25â55%, (B) 10 M ammonium bicarbonatein water) to afford <i>N</i>-(2-(2-hydroxypropan-2-yl)-2-methyl-6-morpholino-2,3-dihydrobenzofuran-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (100 mg) as a yellow solid. The product was resolved by chiral preparatory SFC (column: AD 20*250 mm, 5um (Dacel); mobile phase: CO<sub>2</sub>/0.5% ammonia in 7 M methanol = 70/30) to afford <i>N</i>-[(2<i>R</i>)-2-(1-hydroxy-1-methylethyl)-2-methyl-6-morpholino-3<i>H</i>-benzofuran-5-yl]pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide and <i>N</i>-[(2<i>S</i>)-2-(1-hydroxy-1-methylethyl)-2-methyl-6-morpholino-3<i>H</i>-benzofuran-5-yl]pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (45 mg, 45%; 50 mg, 50%) as yellow solids with absolute stereochemistry assigned arbitrarily.</div><div class="NLM_p last">Example <b>43</b>, peak 1: <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 10.43 (s, 1H), 9.37 (dd, <i>J</i> = 7.2, 1.6 Hz, 1H), 8.94 (dd, <i>J</i> = 4.0, 1.6 Hz, 1H), 8.68 (s. 1H), 8.29 (s, 1H), 7.34 (dd, <i>J</i> = 7.2, 4.0 Hz, 1H), 6.71 (s, 1H), 4.53 (s, 1H), 3.85â3.83 (m, 4H), 3.46 (d, <i>J</i> = 16.0 Hz, 1H), 2.83â2.81 (m, 4H), 2.73 (d, <i>J</i> = 16.0 Hz, 1H), 1.32 (s, 3H), 1.17 (d, <i>J</i> = 5.2 Hz, 6H). MS (ESI): <i>m</i>/<i>z</i> = 438.3 [M + 1]<sup>+</sup>.</div></div><div id="sec5_3_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-(1â²-Methyl-6-morpholino-3<i>H</i>-spiro[benzofuran-2,4â²-piperidine]-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>44</b>)</h4><div class="NLM_p">To a solution of magnesium (2.40 g, 100 mmol) and iodine (180 mg, 0.71 mmol) in diethyl ether (25 mL) at reflux was slowly added 1-(bromomethyl)-2,4-difluorobenzene (8.20 g, 39.61 mmol), and the resulting mixture was stirred for 30 min. This solution was then added to <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (6.50 g, 32.62 mmol) in diethyl ether (200 mL) at â78 Â°C prior to warming to room temperature for 2 h. Water and ethyl acetate (200 mL) were added, and the organic phase was separated and dried over sodium sulfate. After concentration, the residue was purified by silica gel chromatography (eluting gradient 4:1 to 2:1 petroleum ether/ethyl acetate) to afford <i>tert</i>-butyl 4-[(2,4-difluorophenyl)methyl]-4-hydroxypiperidine-1-carboxylate (9.50 g, 73%) as a white solid. MS (ESI): <i>m</i>/<i>z</i> = 350.1 [M + 23]<sup>+</sup>.</div><div class="NLM_p"><i>tert</i>-Butyl 4-[(2,4-difluorophenyl)methyl]-4-hydroxypiperidine-1-carboxylate (818.0 mg, 2.5 mmol) and potassium <i>tert</i>-butanolate (700.95 mg, 6.25 mmol) in tetrahydrofuran (50 mL) were stirred at 65 Â°C for 3 h. Water was added, and the mixture was extracted with ethyl acetate (100 mL). The organic phase was isolated, dried over sodium sulfate, and concentrated to dryness to afford <i>tert</i>-butyl 6-fluorospiro[3<i>H</i>-benzofuran-2,4â²-piperidine]-1â²-carboxylate (644 mg, crude) as a yellow solid, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 252.2 [M â 55]<sup>+</sup>.</div><div class="NLM_p">To a solution of <i>tert</i>-butyl 6-fluorospiro[3<i>H</i>-benzofuran-2,4â²-piperidine]-1â²-carboxylate (644.0 mg, 2.1 mmol) in dichloromethane (20 mL) was added trifluoroacetic acid (2 mL). The reaction was stirred for 2 h at room temperature. To this was added saturated sodium hydrogen carbonate (20 mL), and the mixture was extracted with dichloromethane (2 Ã 20 mL). The combined organic phases were washed with brine and dried over anhydrous magnesium sulfate. After removal of the solvent, 6-fluorospiro[3<i>H</i>-benzofuran-2,4â²-piperidine] (429 mg) was afforded as a yellow solid, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 208.2 [M + 1]<sup>+</sup>.</div><div class="NLM_p">To a solution of 6-fluorospiro[3<i>H</i>-benzofuran-2,4â²-piperidine] (429.0 mg, 1.51 mmol) in methanol (40 mL) was added formaldehyde (28 wt % in water, 1.5 mL) at room temperature. The reaction solution was stirred for 30 min at room temperature. Sodium borohydride (574.22 mg, 15.11 mmol) was added slowly, and the reaction was stirred for 2 h at room temperature. Saturated ammonium chloride (200 mL) was added, and the mixture was extracted with ethyl acetate (2 Ã 200 mL). The combined organic phases were washed with brine and dried over anhydrous magnesium sulfate. After concentration, 6-fluoro-1â²-methylspiro[3<i>H</i>-benzofuran-2,4â²-piperidine] (402 mg) was afforded as a yellow oil, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 222.2 [M + 1]<sup>+</sup>.</div><div class="NLM_p">To a solution of 6-fluoro-1â²-methyl-spiro[3<i>H</i>-benzofuran-2,4â²-piperidine] (402.0 mg, 1.82 mmol) in dichloromethane (30 mL) was slowly added fuming nitric acid (1.7 mL, 27.25 mmol). The mixture was stirred at room temperature for 30 min. Water (50 mL) was added followed by sodium bicarbonate to reach pH 7. The mixture was extracted with dichloromethane (50 mL), and the organic phase was isolated, dried over sodium sulfate, and concentrated to afford 6-fluoro-1â²-methyl-5-nitro-3<i>H</i>-spiro[benzofuran-2,4â²-piperidine] (399 mg) as a yellow solid, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 267.1 [M â 55]<sup>+</sup>.</div><div class="NLM_p">A mixture of 6-fluoro-1â²-methyl-5-nitrospiro[3<i>H</i>-benzofuran-2,4â²-piperidine] (399.0 mg, 1.5 mmol), morpholine (195.82 mg, 2.25 mmol), and potassium carbonate (516.64 mg, 3.75 mmol) in acetonitrile (10 mL) was stirred at 25 Â°C overnight. Water was added, and the mixture was extracted with ethyl acetate (2 Ã 20 mL). The combined organic phases were washed with saturated brine and dried over anhydrous magnesium sulfate. After concentration, 1â²-methyl-6-morpholino-5-nitro-3<i>H</i>-spiro[benzofuran-2,4â²-piperidine] (467 mg) was obtained as a yellow solid, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 334.2 [M + 1]<sup>+</sup>.</div><div class="NLM_p">A mixture of 10 wt % palladium on carbon (70.0 mg) and 1â²-methyl-6-morpholino-5-nitro-3<i>H</i>-spiro[benzofuran-2,4â²-piperidine] (467.0 mg, 1.4 mmol) in methanol (40 mL) was stirred at room temperature under a hydrogen atmosphere for 2 h. After filtration and concentration under reduced pressure, 1â²-methyl-6-morpholino-3<i>H</i>-spiro[benzofuran-2,4â²-piperidin]-5-amine (419 mg) was obtained as a brown solid, which was used without further purification. MS (ESI): <i>m</i>/<i>z</i> = 304.3 [M + 1]<sup>+</sup>.</div><div class="NLM_p">To a mixture of pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acid (109.69 mg, 0.6700 mmol), (3-hydroxy-3<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinato-<i>O</i>)tri-1-pyrrolidinylphosphonium hexafluorophosphate (385.62 mg, 0.74 mmol), and <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (260.7 mg, 2.02 mmol) in <i>N,N</i>-dimethylformanide (5 mL) at 0 Â°C was added 1â²-methyl-6-morpholino-spiro[3<i>H</i>-benzofuran-2,4â²-piperidine]-5-amine (204.0 mg, 0.6700 mmol) in <i>N,N</i>-dimethylformanide (2 mL), and the reaction was stirred at room temperature overnight. The reaction was concentrated under reduced pressure and purified by reverse-phase chromatography (Xbridge Prep C18 10 um OBD, 19*250 mm; (A) acetonitrile 30â60%; (B) 0.01 wt % ammonium hydroxide and 10 mM ammonium carbonate in water) to afford <i>N</i>-(1â²-methyl-6-morpholino-3<i>H</i>-spiro[benzofuran-2,4â²-piperidine]-5-yl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (121 mg, 40%) as a yellow solid. <sup>1</sup>H NMR (400 MHz,CDCl<sub>3</sub>) Î´ 10.46 (s, 1H), 8.83 (dd, <i>J</i> = 1.6, 6.8 Hz, 1H), 8.78 (s, 1H), 8.77 (dd, <i>J</i> = 1.6, 4.4 Hz, 1H), 8.43 (s, 1H), 7.06 (dd, <i>J</i> = 4.4, 7.2 Hz, 1H), 6.69 (s, 1H), 3.99â3.91 (m, 4H), 3.02 (s, 2H), 2.94â2.88 (m, 4H), 2.66â2.44 (m, 4H), 2.35 (s, 3H), 2.05â1.95 (m, 2H), 1.89â1.79 (m, 2H). MS (ESI): <i>m</i>/<i>z</i> = 449.3 [M + 1]<sup>+</sup>.</div><div id="sec5_3_26_b" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> Synthesis of 4-(5-((2-Methylallyl)oxy)-2-nitrophenyl)morpholine (<b>47</b>)</h5><div class="NLM_p last">To a solution of 3-chloro-4-nitrophenol (<b>46</b>) (25.2 g, 145 mmol) in acetonitrile (184 mL) was added 3-bromo-2-methylpropene (16.1 mL, 159 mmol) and potassium carbonate (28.0 g, 203 mmol). The reaction mixture was stirred at 55 Â°C overnight. The mixture was diluted with iPrOAc, and the solids were filtered off and washed with iPrOAc and DCM. The filtrates were combined and evaporated in vacuo onto Celite for purification via flash column chromatography (220 g gold column, 0â40% 3:1 iPrOAc/MeOH in heptanes, 34 min) to afford 2-chloro-4-(2-methylallyloxy)-1-nitro-benzene as a light yellow oil (32.71 g, 99%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.10 (d, <i>J</i> = 9.1 Hz, 1H), 7.34 (d, <i>J</i> = 2.7 Hz, 1H), 7.14 (dd, <i>J</i> = 9.2, 2.7 Hz, 1H), 5.13â5.03 (m, 1H), 5.05â4.97 (m, 1H), 4.66 (s, 2H), 1.83â1.68 (m, 3H). The morpholine (1.15 mL, 13.2 mmol) was added to a mixture of 2-chloro-4-(2-methylallyloxy)-1-nitrobenzene (3.01 g, 13.2 mmol) and potassium carbonate (6.03 g, 43.7 mmol) in dimethyl sulfoxide (0.66 M, 20.0 mL, 280 mmol). The mixture was heated to 100 Â°C for 1 h, cooled to room temperature, and diluted with water and ethyl acetate. The organic layer was washed with saturated NaHCO<sub>3(aq)</sub>, and then the aqueous layer was back-extracted three times with EtOAc. The combined organics were then washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude oil residue was purified via flash chromatography on silica gel (40 g gold column, 0â50% iPrOAc in heptane) to afford 4-(5-((2-methylallyl)oxy)-2-nitrophenyl)morpholine (<b>47</b>) as a bright yellow solid (3.22 g, 88%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 7.90 (d, <i>J</i> = 9.0 Hz, 1H), 6.71 (d, <i>J</i> = 2.6 Hz, 1H), 6.68 (dd, <i>J</i> = 9.0, 2.6 Hz, 1H), 5.08 (d, <i>J</i> = 0.8 Hz, 1H), 4.99 (s, 1H), 4.59 (s, 2H), 3.76â3.63 (m, 4H), 3.06â2.95 (m, 4H), 1.82â1.72 (m, 3H).</div></div></div><div id="sec5_3_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Synthesis of 2-(2-Methylallyl)-5-morpholino-4-nitrophenol (<b>48</b>)</h4><div class="NLM_p">In a sealed tube was heated 4-(5-((2-methylallyl)oxy)-2-nitrophenyl)morpholine (5.00 g, 18.0 mmol) in dimethylformamide (15 mL) at 220 Â°C for 1 h to obtain a 1:1 mixture of <b>48</b> to <b>47</b>. The reaction was repeated 6 times on this scale. Further heating will proceed to the undesired regioisomer. The six reactions were combined, and the DMF solvent was removed in vacuo. The crude residue was extracted into iPrOAc and washed with water to remove any residual DMF. The aqueous layer was back-extracted into iPrOAc three times. The combined organic layers were dried over sodium sulfate, filtered, and absorbed onto Celite. The material was purified via flash column chromatography (0â25%, then 25â50% iPrOAc in heptanes) to recover 4-(5-((2-methylallyl)oxy)-2-nitrophenyl)morpholine (<b>47</b>, 8.16 g, 29.31 mmol) and a mixture of <b>50</b> and <b>51</b> (â¼6.0 g). The following peaks were isolated cleanly from the column conditions.</div><div class="NLM_p">Peak 1 (<b>50</b>): 4.69 g, 16.84 mmol, 16% yield. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i><sub>6</sub>) Î´ 7.56 (d, <i>J</i> = 8.9 Hz, 1H), 6.72 (d, <i>J</i> = 8.9 Hz, 1H), 5.60 (s, 1H), 4.93 (p, <i>J</i> = 1.4 Hz, 1H), 4.68 (d, <i>J</i> = 0.6 Hz, 1H), 3.86â3.66 (m, 4H), 3.56 (s, 2H), 1.91â1.81 (m, 3H), 1.53 (d, <i>J</i> = 12.4 Hz, 3H). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.50 (s, 1H), 7.58 (d, <i>J</i> = 8.9 Hz, 1H), 6.75 (d, <i>J</i> = 8.9 Hz, 1H), 4.65 (s, 1H), 4.27â4.14 (m, 1H), 3.63 (s, 4H), 3.36 (s, 2H), 2.86 (s, 4H), 1.80 (s, 3H).</div><div class="NLM_p">Peak 2 (<b>48</b>): 3.53 g, 12.7 mmol, 12% yield. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i><sub>6</sub>) Î´ 7.82 (s, 1H), 6.54 (d, <i>J</i> = 11.8 Hz, 1H), 5.91 (s, 1H), 5.00 (d, <i>J</i> = 4.0 Hz, 1H), 4.94 (s, 1H), 3.93â3.82 (m, 4H), 3.36 (s, 2H), 3.05 (dd, <i>J</i> = 5.6, 3.6 Hz, 4H), 1.75 (s, 3H). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.72 (s, 1H), 7.74 (s, 1H), 6.59 (s, 1H), 4.80â4.74 (m, 1H), 4.67â4.60 (m, 1H), 3.71 (q, <i>J</i> = 4.0, 3.6 Hz, 4H), 3.20 (s, 2H), 2.95â2.90 (m, 4H), 1.66 (s, 3H).</div><div class="NLM_p last">Peak 3 (<b>51</b>): 2.52 g, 9.05 mmol, 8% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 7.66 (d, <i>J</i> = 8.7 Hz, 1H), 6.55 (d, <i>J</i> = 8.7 Hz, 1H), 3.68â3.60 (m, 4H), 3.14 (s, 2H), 3.05â2.98 (m, 4H), 1.45 (s, 6H).</div></div><div id="sec5_3_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 4-(2,2-Dimethyl-5-nitro-2,3-dihydrobenzofuran-6-yl)morpholine (<b>49</b>)</h4><div class="NLM_p last">2-(2-Methylallyl)-5-morpholino-4-nitrophenol (1.0 g, 3.6 mmol) was dissolved in methanol (12 mL) and cooled to 0 Â°C. A solution of 35% aqueous HCl (12 mL) was added, and the reaction mixture was allowed to warm to ambient temperature and then heated at reflux for 60 h. The reaction was cooled to room temperature, neutralized with saturated sodium bicarbonate, and extracted with isopropyl acetate. The organic phase was dried over sodium sulfate, filtered, and absorbed onto Celite under reduced pressure. The crude residue was purified by silica gel chromatography (eluting gradient 0â30% isopropyl acetate in heptanes) to afford the title compound as a yellow foam (520 mg, 1.87 mmol, 52%). <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide-<i>d</i><sub>6</sub>) Î´ 7.85 (t, <i>J</i> = 1.2 Hz, 1H), 6.60 (s, 1H), 3.76â3.61 (m, 4H), 3.01 (d, <i>J</i> = 1.1 Hz, 2H), 2.98â2.90 (m, 4H), 1.44 (s, 6H). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 7.85 (t, <i>J</i> = 1.2 Hz, 1H), 6.44 (s, 1H), 3.90â3.79 (m, 4H), 3.05â3.01 (m, 4H), 3.00 (d, <i>J</i> = 1.1 Hz, 2H), 1.51 (s, 6H).</div></div><div id="sec5_3_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Synthesis of (2-Methyl-6-morpholino-5-nitro-3<i>H</i>-benzofuran-2-yl)methanol (As Shown in Scheme 3, Route A)</h4><div class="NLM_p last">To a solution of 2-(2-methylallyl)-5-morpholino-4-nitrophenol (48, 813 mg, 2.92 mmol) in dichloromethane (13.21 mL) cooled to 0 Â°C was carefully added <i>m</i>-chloroperoxybenzoic acid (851 mg, 3.80 mmol). After 30 min at 0 Â°C, the reaction mixture was warmed to room temperature. The solution slowly became a slurry and was allowed to stir at room temperature for 2 days. The reaction was filtered. The filtrate was washed with 10% w/v sodium thiosulfate and brine. The organic layer was dried over sodium sulfate and filtered. Silica gel was added to the solution, and the mixture was stirred at room temperature for 4 h. The crude reaction mixture was absorbed onto Celite and purified via flash column chromatography [80 g, 40â100% iPrOAc in heptanes] to afford (2-methyl-6-morpholino-5-nitro-3<i>H</i>-benzofuran-2-yl)methanol (202 mg, 0.686 mmol, 24% yield) as an orange oil. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i><sub>6</sub>) Î´ 7.85 (t, <i>J</i> = 1.2 Hz, 1H), 6.47 (s, 1H), 3.91â3.80 (m, 4H), 3.74 (d, <i>J</i> = 11.9 Hz, 1H), 3.64 (d, <i>J</i> = 11.9 Hz, 1H), 3.26 (dd, <i>J</i> = 15.7, 1.2 Hz, 1H), 3.03 (dd, <i>J</i> = 5.5, 3.7 Hz, 4H), 2.89 (dd, <i>J</i> = 15.7, 1.1 Hz, 1H), 1.47 (s, 3H). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 7.83 (t, <i>J</i> = 1.2 Hz, 1H), 6.59 (s, 1H), 5.12 (t, <i>J</i> = 5.7 Hz, 1H), 3.73â3.65 (m, 4H), 3.54â3.39 (m, 2H), 3.20 (dd, <i>J</i> = 16.0, 1.2 Hz, 1H), 2.99â2.89 (m, 4H), 2.84 (dd, <i>J</i> = 16.0, 1.1 Hz, 1H), 1.36 (s, 3H).</div></div><div id="sec5_3_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Methyl 3-(4-Chloro-2-fluorophenyl)-2-hydroxy-2-methylpropanoate (<b>53</b>)</h4><div class="NLM_p last">To a solution of magnesium (1350.0 mg, 56.25 mmol) and iodine (100.0 mg, 0.39 mmol) in diethyl ether (50 mL) heated at reflux was added 1-(bromomethyl)-4-chloro-2-fluoro-benzene <b>52</b> (5.0 g, 22.4 mmol) dropwise. The reaction was stirred for 30 min. The solution was then added to a solution of methyl pyruvate (2.3 g, 22.5 mmol) in diethyl ether (50 mL) at â78 Â°C and stirred for 30 min followed by warming to room temperature for 2 h. Saturated ammonium chloride and ethyl acetate (200 mL) were added, and the organic phase was separated and dried over sodium sulfate. The reaction was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting gradient 1:20 to 1:10 ethyl acetate/petroleum ether) to afford methyl 3-(4-chloro-2-fluorophenyl)-2-hydroxy-2-methylpropanoate (2.8 g, 51%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.33â7.25 (m, 1H), 7.18â7.09 (m, 2H), 3.73 (s, 3H), 3.03 (s, 2H), 1.39 (s, 3H).</div></div><div id="sec5_3_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 6-Chloro-2-methyl-3<i>H</i>-benzofuran-2-carboxylic acid (<b>54</b>)</h4><div class="NLM_p last">A mixture of methyl 3-(4-chloro-2-fluoro-phenyl)-2-hydroxy-2-methylpropanoate (493.0 mg, 2 mmol) and potassium <i>tert</i>-butanolate (561.0 mg, 5 mmol) in tetrahydrofuran (10 mL) was stirred at 60 Â°C for 18 h. After cooling to room temperature, water and a 1 N hydrogen chloride solution were added until pH = 3. Ethyl acetate (20 mL) was added, and the organic phase was separated and dried over sodium sulfate. The reaction was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting gradient 1:1 to 2:1 ethyl acetate/petroleum ether) to afford 6-chloro-2-methyl-3<i>H</i>-benzofuran-2-carboxylic acid (271 mg, 64%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.95â10.24 (m, 1H), 7.04 (d, <i>J</i> = 8.0 Hz, 1H), 6.87 (dd, <i>J</i> = 1.6, 9.2 Hz, 1H), 6.85 (s, 1H), 3.59 (d, <i>J</i> = 16 Hz, 1H), 3.13 (d, <i>J</i> = 16 Hz, 1H), 1.73, (s, 3H).</div></div><div id="sec5_3_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 6-Chloro-2-methyl-5-nitro-3<i>H</i>-benzofuran-2-carboxylic acid (<b>55</b>)</h4><div class="NLM_p last">To a solution of 6-chloro-2-methyl-3<i>H</i>-benzofuran-2-carboxylic acid (230.0 mg, 1.08 mmol) in dichloromethane (10 mL) at 25 Â°C was slowly added fuming nitric acid (0.5 mL). The resulting solution was stirred for 5 min. Water and ethyl acetate (20 mL) were added, and the organic phase was separated and dried over sodium sulfate. The reaction was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting gradient 1:4 to 1:3 ethyl acetate/petroleum ether) to afford 6-chloro-2-methyl-5-nitro-3<i>H</i>-benzofuran-2-carboxylic acid (150 mg, 54%) as an orange solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.84 (s, 1H), 6.99 (s, 1H), 3.68 (d, <i>J</i> = 16.8 Hz, 1H), 3.23 (d, <i>J</i> = 16.8 Hz, 1H), 1.80 (s, 3H).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00439" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76128" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76128" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00439" class="ext-link">10.1021/acs.jmedchem.9b00439</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings, synthetic procedures, biochemical and cellular assay conditions, metabolic stability assay conditions, kinase selectivity data, crystallography details, pharmacokinetic study conditions, and PK/PD study conditions (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00439/suppl_file/jm9b00439_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">List of compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00439/suppl_file/jm9b00439_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00439/suppl_file/jm9b00439_si_001.pdf">jm9b00439_si_001.pdf (2.19 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00439/suppl_file/jm9b00439_si_002.csv">jm9b00439_si_002.csv (2.2 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates and structure factors are deposited at the Protein Data Bank with codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O9D">6O9D</a> (<b>5</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O94">6O94</a> (<b>17</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8U">6O8U</a> (<b>23</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O95">6O95</a> (<b>41</b>).</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00439" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marian C. Bryan</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3138-6888" title="Orcid link">http://orcid.org/0000-0002-3138-6888</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a7c5d5dec6c989cac6d5cec6c9e7c0c2c9c289c4c8ca"><span class="__cf_email__" data-cfemail="debcaca7bfb0f0b3bfacb7bfb09eb9bbb0bbf0bdb1b3">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joy Drobnick</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alberto Gobbi</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aleksandr Kolesnikov</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongsheng Chen</span> - <span class="hlFld-Affiliation affiliation">WuXi
Apptec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R.
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naomi Rajapaksa</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chudi Ndubaku</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span>Present Address:
                        C.N.: Aduro BioTech, Inc., 626 Bancroft Way, 3C Berkeley, California 94710, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4183-0417" title="Orcid link">http://orcid.org/0000-0003-4183-0417</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianwen Feng</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span>Present Address:
                        J.F.: Denali Therapeutics, Inc., Therapeutic Discovery, 1501 Oyster Pt Boulevard, South San Francisco, California 94080, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1221-7605" title="Orcid link">http://orcid.org/0000-0003-1221-7605</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Willy Chang</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span>Present Address:
                        W.C.: Televerde, 4636 E University Dr # 150, Phoenix, Arizona 85034, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ross Francis</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Yu</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edna F. Choo</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4200-8302" title="Orcid link">http://orcid.org/0000-0003-4200-8302</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin DeMent</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span>Present Address:
                        K.D.: Takeda Bio Development Center Ltd., 9625 Towne Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingqing Ran</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Le An</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claire Emson</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span>Present Address:
                        C.E.: Medimmune, Inc., 1 Medimmune Way, Gaithersburg, Maryland 20878, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiyu Huang</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Swathi Sujatha-Bhaskar</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hans Brightbill</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonio DiPasquale</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan Maher</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Wai</span> - <span class="hlFld-Affiliation affiliation">WuXi
Apptec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R.
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brent S. McKenzie</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick J. Lupardus</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span>Present Address:
                        P.J.L.: Synthekine, Inc., 1700 Owens Street, Suite 500, San Francisco, California 94157, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ali A. Zarrin</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Kiefer</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., One DNA Way, South San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare the following competing financial interest(s): All research funded by Genentech.<br /></br></p></li></ul></div><div class="ack" id="ACK-d7e5466-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33208" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33208" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to the Biomolecular Resources department for protein expression and cloning and to Shamrock Structures LLC for assistance with X-ray data acquisition. Macromolecular diffraction data were collected at the Advanced Photon Source and at the Advanced Light Source. This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract no. DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (Grant 085P1000817). Crystal diffraction data were collected at Southeast Regional Collaborative Access Team (SER-CAT) 22-ID (or 22-BM) beamline at the Advanced Photon Source, Argonne National Laboratory. SER-CAT is supported by its member institutions (see <a href="http://www.ser-cat.org/members.html" class="extLink">www.ser-cat.org/members.html</a>), and equipment grants (S10_RR25528 and S10_RR028976) were from the National Institutes of Health. Diffraction data were collected at beamline 5.0.2 of the Advanced Light Source. The Berkeley Center for Structural Biology is supported in part by the Howard Hughes Medical Institute. The Advanced Light Source is a Department of Energy Office of Science User Facility under Contract no. DE-AC02-05CH11231.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">IL-1R</td><td class="NLM_def"><p class="first last">IL-1 receptor</p></td></tr><tr><td class="NLM_term">IRAK</td><td class="NLM_def"><p class="first last">interleukin-1 receptor-associated kinase</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">ligand-lipophilicity efficiency</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">MadinâDarby canine kidney cells</p></td></tr><tr><td class="NLM_term">PAMP</td><td class="NLM_def"><p class="first last">pathogen-associated molecular patterns</p></td></tr><tr><td class="NLM_term">PPR</td><td class="NLM_def"><p class="first last">pattern recognition receptors</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">SMI</td><td class="NLM_def"><p class="first last">small-molecule inhibitor</p></td></tr><tr><td class="NLM_term">TIR</td><td class="NLM_def"><p class="first last">toll/IL-1R</p></td></tr><tr><td class="NLM_term">TLR</td><td class="NLM_def"><p class="first last">toll-like receptor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52610" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52610" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K.</span></span> <i>Janewayâs Immunobiology</i>, <span class="NLM_edition">8</span>th ed.; <span class="NLM_publisher-name">Garland Science, Taylor & Francis Group, LLC</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2012</span>; p  <span class="NLM_fpage">888</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=888&author=K.+Murphy&title=Janeway%E2%80%99s+Immunobiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DK.%26btitle%3DJaneway%25E2%2580%2599s%2520Immunobiology%26pub%3DGarland%2520Science%252C%2520Taylor%2520%2526%2520Francis%2520Group%252C%2520LLC%26date%3D2012%26spage%3D888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">96</span>â <span class="NLM_lpage">110</span>, <span class="refDoi">Â DOI: 10.1021/jm5016044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5016044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCjsLzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=96-110&issue=1&author=D.+Chaudharyauthor=S.+Robinsonauthor=D.+L.+Romero&title=Recent+advances+in+the+discovery+of+small+molecule+inhibitors+of+interleukin-1+receptor-associated+kinase+4+%28IRAK4%29+as+a+therapeutic+target+for+inflammation+and+oncology+disorders&doi=10.1021%2Fjm5016044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders</span></div><div class="casAuthors">Chaudhary, Divya; Robinson, Shaughnessy; Romero, Donna L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-110</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  IRAK4, a serine/threonine kinase, plays a key role in both inflammation and oncol. diseases.  Herein, we summarize the compelling biol. surrounding the IRAK4 signaling node in disease, review key structural features of IRAK4 including selectivity challenges, and describe efforts to discover clin. viable IRAK4 inhibitors.  Finally, a view of knowledge gained and remaining challenges is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1K6ExwztfCLVg90H21EOLACvtfcHk0ljQ2hQrtMDIOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCjsLzL&md5=795797f7f3f07597ecd0b5899498804b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm5016044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5016044%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520small%2520molecule%2520inhibitors%2520of%2520interleukin-1%2520receptor-associated%2520kinase%25204%2520%2528IRAK4%2529%2520as%2520a%2520therapeutic%2520target%2520for%2520inflammation%2520and%2520oncology%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D1%26spage%3D96%26epage%3D110%26doi%3D10.1021%2Fjm5016044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawagoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uematsu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akira, S.</span></span> <span> </span><span class="NLM_article-title">Essential role of IRAK-4 protein and its kinase activity in toll-like receptorâmediated immune responses but not in TCR signaling</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>204</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1013</span>â <span class="NLM_lpage">1024</span>, <span class="refDoi">Â DOI: 10.1084/jem.20061523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1084%2Fjem.20061523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=17485511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFSjsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2007&pages=1013-1024&issue=5&author=T.+Kawagoeauthor=S.+Satoauthor=A.+Jungauthor=M.+Yamamotoauthor=K.+Matsuiauthor=H.+Katoauthor=S.+Uematsuauthor=O.+Takeuchiauthor=S.+Akira&title=Essential+role+of+IRAK-4+protein+and+its+kinase+activity+in+toll-like+receptor%E2%80%93mediated+immune+responses+but+not+in+TCR+signaling&doi=10.1084%2Fjem.20061523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling</span></div><div class="casAuthors">Kawagoe, Tatsukata; Sato, Shintaro; Jung, Andreas; Yamamoto, Masahiro; Matsui, Kosuke; Kato, Hiroki; Uematsu, Satoshi; Takeuchi, Osamu; Akira, Shizuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1013-1024</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Interleukin-1 receptor-assocd. kinase 4 (IRAK-4) was reported to be essential for the Toll-like receptor (TLR)- and T cell receptor (TCR)-mediated signaling leading to the activation of nuclear factor ÎºB (NF-ÎºB).  However, the importance of kinase activity of IRAK family members is unclear.  In this study, we investigated the functional role of IRAK-4 activity in vivo by generating mice carrying a knockin mutation (KK213AA) that abrogates its kinase activity.  IRAK-4KN/KN mice were highly resistant to TLR-induced shock response.  The cytokine prodn. in response to TLR ligands was severely impaired in IRAK-4KN/KN as well as IRAK-4-/- macrophages.  The IRAK-4 activity was essential for the activation of signaling pathways leading to mitogen-activated protein kinases.  TLR-induced IRAK-4/IRAK-1-dependent and -independent pathways were involved in early induction of NF-ÎºB-regulated genes in response to TLR ligands such as tumor necrosis factor Î± and IÎºBÎ¶.  In contrast to a previous paper, the TCR signaling was not impaired in IRAK-4-/- and IRAK-4KN/KN mice.  Thus, the kinase activity of IRAK-4 is essential for the regulation of TLR-mediated innate immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDdu13L0FMrVg90H21EOLACvtfcHk0ljQ2hQrtMDIOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFSjsbY%253D&md5=902905464ef0cba41a3fda070fc982f5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1084%2Fjem.20061523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20061523%26sid%3Dliteratum%253Aachs%26aulast%3DKawagoe%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DUematsu%26aufirst%3DS.%26aulast%3DTakeuchi%26aufirst%3DO.%26aulast%3DAkira%26aufirst%3DS.%26atitle%3DEssential%2520role%2520of%2520IRAK-4%2520protein%2520and%2520its%2520kinase%2520activity%2520in%2520toll-like%2520receptor%25E2%2580%2593mediated%2520immune%2520responses%2520but%2520not%2520in%2520TCR%2520signaling%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2007%26volume%3D204%26issue%3D5%26spage%3D1013%26epage%3D1024%26doi%3D10.1084%2Fjem.20061523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdollahi-Roodsaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netea, M. G.</span></span> <span> </span><span class="NLM_article-title">Toll-like receptors and chronic inflammation in rheumatic diseases: new developments</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">344</span>â <span class="NLM_lpage">357</span>, <span class="refDoi">Â DOI: 10.1038/nrrheum.2016.61</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1038%2Fnrrheum.2016.61" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=27170508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvV2ntb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=344-357&author=L.+A.+B.+Joostenauthor=S.+Abdollahi-Roodsazauthor=C.+A.+Dinarelloauthor=L.+O%E2%80%99Neillauthor=M.+G.+Netea&title=Toll-like+receptors+and+chronic+inflammation+in+rheumatic+diseases%3A+new+developments&doi=10.1038%2Fnrrheum.2016.61"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptors and chronic inflammation in rheumatic diseases: new developments</span></div><div class="casAuthors">Joosten, Leo A. B.; Abdollahi-Roodsaz, Shahla; Dinarello, Charles A.; O'Neill, Luke; Netea, Mihai G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">344-357</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the past few years, new developments have been reported on the role of Toll-like receptors (TLRs) in chronic inflammation in rheumatic diseases.  The inhibitory function of TLR10 has been demonstrated.  Receptors that enhance the function of TLRs, and several TLR inhibitors, have been identified.  In addn., the role of the microbiome and TLRs in the onset of rheumatic diseases has been reported.  We review novel insights on the role of TLRs in several inflammatory joint diseases, including rheumatoid arthritis, systemic lupus erythematosus, gout and Lyme arthritis, with a focus on the signalling mechanisms mediated by the Toll-IL-1 receptor (TIR) domain, the exogenous and endogenous ligands of TLRs, and the current and future therapeutic strategies to target TLR signalling in rheumatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBPDFqhEIq1rVg90H21EOLACvtfcHk0lil82uO5ngL9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvV2ntb8%253D&md5=a561bbe778204e8e57d599efdbec093a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2016.61&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2016.61%26sid%3Dliteratum%253Aachs%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2BB.%26aulast%3DAbdollahi-Roodsaz%26aufirst%3DS.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%26aulast%3DNetea%26aufirst%3DM.%2BG.%26atitle%3DToll-like%2520receptors%2520and%2520chronic%2520inflammation%2520in%2520rheumatic%2520diseases%253A%2520new%2520developments%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D344%26epage%3D357%26doi%3D10.1038%2Fnrrheum.2016.61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudhgaonkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karunanithi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariappan, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetsko, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carman, J. A.</span></span> <span> </span><span class="NLM_article-title">Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>198</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1308</span>â <span class="NLM_lpage">1319</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1600583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.4049%2Fjimmunol.1600583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=28003376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlaitb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2017&pages=1308-1319&issue=3&author=S.+Dudhgaonkarauthor=S.+Ranadeauthor=J.+Nagarauthor=S.+Subramaniauthor=D.+S.+Prasadauthor=P.+Karunanithiauthor=R.+Srivastavaauthor=K.+Venkateshauthor=S.+Selvamauthor=P.+Krishnamurthyauthor=T.+T.+Mariappanauthor=A.+Saxenaauthor=L.+Fanauthor=D.+K.+Stetskoauthor=D.+A.+Hollowayauthor=X.+Liauthor=J.+Zhuauthor=W.-P.+Yangauthor=S.+Rueppauthor=S.+Nairauthor=J.+Santellaauthor=J.+Dunciaauthor=J.+Hynesauthor=K.+W.+McIntyreauthor=J.+A.+Carman&title=Selective+IRAK4+inhibition+attenuates+disease+in+murine+lupus+models+and+demonstrates+steroid+sparing+activity&doi=10.4049%2Fjimmunol.1600583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity</span></div><div class="casAuthors">Dudhgaonkar, Shailesh; Ranade, Sourabh; Nagar, Jignesh; Subramani, Siva; Prasad, Durga Shiv; Karunanithi, Preethi; Srivastava, Ratika; Venkatesh, Kamala; Selvam, Sabariya; Krishnamurthy, Prasad; Mariappan, T. Thanga; Saxena, Ajay; Fan, Li; Stetsko, Dawn K.; Holloway, Deborah A.; Li, Xin; Zhu, Jun; Yang, Wen-Pin; Ruepp, Stefan; Nair, Satheesh; Santella, Joseph; Duncia, John; Hynes, John; McIntyre, Kim W.; Carman, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1308-1319</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The serine/threonine kinase IL-1R-assocd. kinase (IRAK)4 is a crit. regulator of innate immunity.  We have identified BMS-986126, a potent, highly selective inhibitor of IRAK4 kinase activity that demonstrates equipotent activity against multiple MyD88-dependent responses both in vitro and in vivo.  BMS-986126 failed to inhibit assays downstream of MyD88-independent receptors, including the TNF receptor and TLR3.  Very little activity was seen downstream of TLR4, which can also activate an MyD88-independent pathway.  In mice, the compd. inhibited cytokine prodn. induced by injection of several different TLR agonists, including those for TLR2, TLR7, and TLR9.  The compd. also significantly suppressed skin inflammation induced by topical administration of the TLR7 agonist imiquimod.  BMS-986126 demonstrated robust activity in the MRL/lpr and NZB/NZW models of lupus, inhibiting multiple pathogenic responses.  In the MRL/lpr model, robust activity was obsd. with the combination of suboptimal doses of BMS-986126 and prednisolone, suggesting the potential for steroid sparing activity.  BMS-986126 also demonstrated synergy with prednisolone in assays of TLR7- and TLR9-induced IFN target gene expression using human PBMCs.  Lastly, BMS-986126 inhibited TLR7- and TLR9-dependent responses using cells derived from lupus patients, suggesting that inhibition of IRAK4 has the potential for therapeutic benefit in treating lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs4ZWIchaO6rVg90H21EOLACvtfcHk0lil82uO5ngL9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlaitb8%253D&md5=340ba834510cd04eb0e984e212731e17</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1600583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1600583%26sid%3Dliteratum%253Aachs%26aulast%3DDudhgaonkar%26aufirst%3DS.%26aulast%3DRanade%26aufirst%3DS.%26aulast%3DNagar%26aufirst%3DJ.%26aulast%3DSubramani%26aufirst%3DS.%26aulast%3DPrasad%26aufirst%3DD.%2BS.%26aulast%3DKarunanithi%26aufirst%3DP.%26aulast%3DSrivastava%26aufirst%3DR.%26aulast%3DVenkatesh%26aufirst%3DK.%26aulast%3DSelvam%26aufirst%3DS.%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DMariappan%26aufirst%3DT.%2BT.%26aulast%3DSaxena%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DStetsko%26aufirst%3DD.%2BK.%26aulast%3DHolloway%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DW.-P.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DSantella%26aufirst%3DJ.%26aulast%3DDuncia%26aufirst%3DJ.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DCarman%26aufirst%3DJ.%2BA.%26atitle%3DSelective%2520IRAK4%2520inhibition%2520attenuates%2520disease%2520in%2520murine%2520lupus%2520models%2520and%2520demonstrates%2520steroid%2520sparing%2520activity%26jtitle%3DJ.%2520Immunol.%26date%3D2017%26volume%3D198%26issue%3D3%26spage%3D1308%26epage%3D1319%26doi%3D10.4049%2Fjimmunol.1600583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">The TLR and IL-1 signalling network at a glance</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2383</span>â <span class="NLM_lpage">2390</span>, <span class="refDoi">Â DOI: 10.1242/jcs.149831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1242%2Fjcs.149831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=24829146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsrbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2014&pages=2383-2390&issue=11&author=P.+Cohen&title=The+TLR+and+IL-1+signalling+network+at+a+glance&doi=10.1242%2Fjcs.149831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The TLR and IL-1 signalling network at a glance</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2383-2390</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Toll-like receptors (TLRs) and the receptors for interleukin (IL)-1, IL-18 and IL-33 are required for defense against microbial pathogens but, if hyper-activated or not switched off efficiently, can cause tissue damage and inflammatory and autoimmune diseases.  Understanding how the checks and balances in the system are integrated to fight infection without the network operating out of control will be crucial for the development of improved drugs to treat these diseases in the future.  In this Cell Science at a Glance article and the accompanying poster, I provide a brief overview of how one of these intricate networks is controlled by the interplay of protein phosphorylation and protein ubiquitylation events, and the mechanisms in myeloid cells that restrict and terminate its activation to prevent inflammatory and autoimmune diseases.  Finally, I suggest a few protein kinases that have been neglected as drug targets, but whose therapeutic potential should be explored in the light of recent advances in our understanding of their roles in the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Hfw28mAkmrVg90H21EOLACvtfcHk0lil82uO5ngL9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsrbK&md5=b86f588378be962309bad302139543c6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1242%2Fjcs.149831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.149831%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DThe%2520TLR%2520and%2520IL-1%2520signalling%2520network%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2014%26volume%3D127%26issue%3D11%26spage%3D2383%26epage%3D2390%26doi%3D10.1242%2Fjcs.149831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rokosz, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appell, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M. L.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">883</span>â <span class="NLM_lpage">903</span>, <span class="refDoi">Â DOI: 10.1517/14728222.12.7.883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1517%2F14728222.12.7.883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=18554156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=883-903&issue=7&author=L.+L.+Rokoszauthor=J.+R.+Beasleyauthor=C.+D.+Carrollauthor=T.+Linauthor=J.+Zhaoauthor=K.+C.+Appellauthor=M.+L.+Webb&title=Kinase+inhibitors+as+drugs+for+chronic+inflammatory+and+immunological+diseases%3A+progress+and+challenges&doi=10.1517%2F14728222.12.7.883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span></div><div class="casAuthors">Rokosz, Laura L.; Beasley, James R.; Carroll, Carolyn DiIanni; Lin, Tsung; Zhao, Jiuqiao; Appell, Kenneth C.; Webb, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-903</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  At the time of writing, there are seven marketed kinase inhibitor drugs.  The first kinase inhibitor, imatinib mesilate (Gleevec, Novartis), came to market in 2001, an inhibitor of the breakpoint cluster region (BCR)/Abelson murine leukemia oncogene homolog (ABL) fusion, platelet-derived growth factor (PDGF) receptor, and c-kit kinases.  The most recent kinase inhibitor to come to market, disatinib (Sprycel, Bristol-Myers Squibb), acts on c-SRC, ABL and Bruton's tyrosine kinase.  To date, kinase inhibitor drugs are approved for oncol. and demonstrate that it is possible to develop compds. with relative selectivity for the target kinase against the broader kinome.  However, the use of kinase inhibitors in chronic inflammatory and immunol. diseases may require greater selectivity for the target kinase.  This review addresses the opportunities and challenges of kinase inhibition as a therapeutic approach in chronic immune and inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq458NGQKTbcbVg90H21EOLACvtfcHk0li2Ztw2ypQe3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D&md5=6db3fdcc34b3ec97394c9dc6cdca8b99</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.7.883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.7.883%26sid%3Dliteratum%253Aachs%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DBeasley%26aufirst%3DJ.%2BR.%26aulast%3DCarroll%26aufirst%3DC.%2BD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26atitle%3DKinase%2520inhibitors%2520as%2520drugs%2520for%2520chronic%2520inflammatory%2520and%2520immunological%2520diseases%253A%2520progress%2520and%2520challenges%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2008%26volume%3D12%26issue%3D7%26spage%3D883%26epage%3D903%26doi%3D10.1517%2F14728222.12.7.883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W.-C.</span></span> <span> </span><span class="NLM_article-title">IRAK-4 inhibitors for inflammation</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">724</span>â <span class="NLM_lpage">737</span>, <span class="refDoi">Â DOI: 10.2174/156802609789044407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.2174%2F156802609789044407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=19689377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=724-737&issue=8&author=Z.+Wangauthor=H.+Wescheauthor=T.+Stevensauthor=N.+Walkerauthor=W.-C.+Yeh&title=IRAK-4+inhibitors+for+inflammation&doi=10.2174%2F156802609789044407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">IRAK-4 inhibitors for inflammation</span></div><div class="casAuthors">Wang, Zhulun; Wesche, Holger; Stevens, Tracey; Walker, Nigel; Yeh, Wen-Chen</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">724-737</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Interleukin-1 receptor-assocd. kinases (IRAKs) are key components in the signal transduction pathways utilized by interleukin-1 receptor (IL-1R), interleukin-18 receptor (IL-18R), and Toll-like receptors (TLRs).  Out of four members in the mammalian IRAK family, IRAK-4 is considered to be the "master IRAK", the only family member indispensable for IL-1R/TLR signaling.  In humans, mutations resulting in IRAK-4 deficiency have been linked to susceptibility to bacterial infections, esp. recurrent pyogenic bacterial infections.  Furthermore, knock-in expts. by several groups have clearly demonstrated that IRAK-4 requires its kinase activity for its function.  Given the crit. role of IRAK-4 in inflammatory processes, modulation of IRAK-4 kinase activity presents an attractive therapeutic approach for the treatment of immune and inflammatory diseases.  The recent success in the detn. of the 3-dimensional structure of the IRAK-4 kinase domain in complex with inhibitors has facilitated the understanding of the mechanistic role of IRAK-4 in immunity and inflammation as well as the development of specific IRAK-4 kinase inhibitors.  In this article, we review the biol. function of IRAK-4, the structural characteristics of the kinase domain, and the development of small mol. inhibitors targeting the kinase activity.  We also review the key pharmacophores required for several classes of inhibitors as well as important features for optimal protein/inhibitor interactions.  Lastly, we summarize how these insights can be translated into strategies to develop potent IRAK-4 inhibitors with desired properties as new anti-inflammatory therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRhyk3FnIbSrVg90H21EOLACvtfcHk0li2Ztw2ypQe3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnO&md5=c6a1278c9b9647aa8ce21edac373ddaa</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F156802609789044407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789044407%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWesche%26aufirst%3DH.%26aulast%3DStevens%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DYeh%26aufirst%3DW.-C.%26atitle%3DIRAK-4%2520inhibitors%2520for%2520inflammation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26issue%3D8%26spage%3D724%26epage%3D737%26doi%3D10.2174%2F156802609789044407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors for the treatment of immunological disorders: recent advances</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">9030</span>â <span class="NLM_lpage">9058</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00667</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00667" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9030-9058&issue=20&author=M.+C.+Bryanauthor=N.+S.+Rajapaksa&title=Kinase+inhibitors+for+the+treatment+of+immunological+disorders%3A+recent+advances&doi=10.1021%2Facs.jmedchem.8b00667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span></div><div class="casAuthors">Bryan, Marian C.; Rajapaksa, Naomi S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9030-9058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry.  Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways.  While this focus has led to over 30 FDA-approved small mol. kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases.  Despite this lack of success, there remains tremendous reason for excitement.  Our growing understanding of the biol. involved in the inflammatory response, the factors that lead to safer small mol. kinase inhibitors, and the availability of selective tool mols. for interrogating specific nodes and pathways are all pushing the field forward.  This article focuses on recent developments requiring novel approaches to create safe and effective small mol. kinase inhibitors and where further work is needed to realize the promise of small mol. kinase inhibitors for patient benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVucOE4LCJALVg90H21EOLACvtfcHk0li2Ztw2ypQe3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI&md5=aff62adff54c9152d2b2156b05d67400</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DRajapaksa%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520immunological%2520disorders%253A%2520recent%2520advances%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058%26doi%3D10.1021%2Facs.jmedchem.8b00667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelinsky, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korver, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawtin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.-L.</span></span> <span> </span><span class="NLM_article-title">IRAK4 kinase activity controls Toll-like receptorâinduced inflammation through the transcription factor IRF5 in primary human monocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">18689</span>â <span class="NLM_lpage">18698</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M117.796912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1074%2Fjbc.M117.796912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=28924041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2jurjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=18689-18698&issue=45&author=L.+Cushingauthor=A.+Winklerauthor=S.+A.+Jelinskyauthor=K.+Leeauthor=W.+Korverauthor=R.+Hawtinauthor=V.+R.+Raoauthor=M.+Flemingauthor=L.-L.+Lin&title=IRAK4+kinase+activity+controls+Toll-like+receptor%E2%80%93induced+inflammation+through+the+transcription+factor+IRF5+in+primary+human+monocytes&doi=10.1074%2Fjbc.M117.796912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes</span></div><div class="casAuthors">Cushing, Leah; Winkler, Aaron; Jelinsky, Scott A.; Lee, Katherine; Korver, Wouter; Hawtin, Rachael; Rao, Vikram R.; Fleming, Margaret; Lin, Lih-Ling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18689-18698</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Interleukin-1 receptor-assocd. kinase 4 (IRAK4) plays a crit. role in innate immune signaling by Toll-like receptors (TLRs), and loss of IRAK4 activity in mice and humans increases susceptibility to bacterial infections and causes defects in TLR and IL1 ligand sensing.  However, the mechanism by which IRAK4 activity regulates the prodn. of downstream inflammatory cytokines is unclear.  Using transcriptomic and biochem. analyses of human monocytes treated with a highly potent and selective inhibitor of IRAK4, we show that IRAK4 kinase activity controls the activation of interferon regulatory factor 5 (IRF5), a transcription factor implicated in the pathogenesis of multiple autoimmune diseases.  Following TLR7/8 stimulation by its agonist R848, chem. inhibition of IRAK4 abolished IRF5 translocation to the nucleus and thus prevented IRF5 binding to and activation of the promoters of inflammatory cytokines in human monocytes.  We also found that IKKÎ², an upstream IRF5 activator, is phosphorylated in response to the agonist-induced TLR signaling.  Of note, IRAK4 inhibition blocked IKKÎ² phosphorylation but did not block the nuclear translocation of NFÎºB, which was surprising, given the canonical role of IKKÎ² in phosphorylating IÎºB to allow NFÎºB activation.  Moreover, pharmacol. inhibition of either IKKÎ² or the serine/threonine protein kinase TAK1 in monocytes blocked TLR-induced cytokine prodn. and IRF5 translocation to the nucleus, but not nuclear translocation of NFÎºB.  Taken together, our data suggest a mechanism by which IRAK4 activity regulates TAK1 and IKKÎ² activation, leading to the nuclear translocation of IRF5 and induction of inflammatory cytokines in human monocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSuWx97aRdRrVg90H21EOLACvtfcHk0liVDRdqrb1xRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2jurjE&md5=0de08402791155c147cfebdeb6ab768e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.796912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.796912%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DL.%26aulast%3DWinkler%26aufirst%3DA.%26aulast%3DJelinsky%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DKorver%26aufirst%3DW.%26aulast%3DHawtin%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DFleming%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DL.-L.%26atitle%3DIRAK4%2520kinase%2520activity%2520controls%2520Toll-like%2520receptor%25E2%2580%2593induced%2520inflammation%2520through%2520the%2520transcription%2520factor%2520IRF5%2520in%2520primary%2520human%2520monocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26issue%3D45%26spage%3D18689%26epage%3D18698%26doi%3D10.1074%2Fjbc.M117.796912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscoe, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bree, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dower, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisbie, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hope, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaioannou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samardjiev, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soutter, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapf, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5521</span>â <span class="NLM_lpage">5542</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5521-5542&issue=13&author=K.+L.+Leeauthor=C.+M.+Amblerauthor=D.+R.+Andersonauthor=B.+P.+Boscoeauthor=A.+G.+Breeauthor=J.+I.+Brodfuehrerauthor=J.+S.+Changauthor=C.+Choiauthor=S.+Chungauthor=K.+J.+Curranauthor=J.+E.+Dayauthor=C.+M.+Dehnhardtauthor=K.+Dowerauthor=S.+E.+Drozdaauthor=R.+K.+Frisbieauthor=L.+K.+Gavrinauthor=J.+A.+Goldbergauthor=S.+Hanauthor=M.+Hegenauthor=D.+Hepworthauthor=H.+R.+Hopeauthor=S.+Kamtekarauthor=I.+C.+Kiltyauthor=A.+Leeauthor=L.-L.+Linauthor=F.+E.+Loveringauthor=M.+D.+Loweauthor=J.+P.+Mathiasauthor=H.+M.+Morganauthor=E.+A.+Murphyauthor=N.+Papaioannouauthor=A.+Patnyauthor=B.+S.+Pierceauthor=V.+R.+Raoauthor=E.+Saiahauthor=I.+J.+Samardjievauthor=B.+M.+Samasauthor=M.+W.+H.+Shenauthor=J.+H.+Shinauthor=H.+H.+Soutterauthor=J.+W.+Strohbachauthor=P.+T.+Symanowiczauthor=J.+R.+Thomasonauthor=J.+D.+Trzupekauthor=R.+Vargasauthor=F.+Vincentauthor=J.+Yanauthor=C.+W.+Zapfauthor=S.+W.+Wright&title=Discovery+of+clinical+candidate+1-%7B%5B%282S%2C3S%2C4S%29-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%5Dmethoxy%7D-7-methoxyisoquinoline-6-carboxamide+%28PF-06650833%29%2C+a+potent%2C+selective+inhibitor+of+interleukin-1+receptor+associated+kinase+4+%28IRAK4%29%2C+by+fragment-based+drug+design&doi=10.1021%2Facs.jmedchem.7b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design</span></div><div class="casAuthors">Lee, Katherine L.; Ambler, Catherine M.; Anderson, David R.; Boscoe, Brian P.; Bree, Andrea G.; Brodfuehrer, Joanne I.; Chang, Jeanne S.; Choi, Chulho; Chung, Seungwon; Curran, Kevin J.; Day, Jacqueline E.; Dehnhardt, Christoph M.; Dower, Ken; Drozda, Susan E.; Frisbie, Richard K.; Gavrin, Lori K.; Goldberg, Joel A.; Han, Seungil; Hegen, Martin; Hepworth, David; Hope, Heidi R.; Kamtekar, Satwik; Kilty, Iain C.; Lee, Arthur; Lin, Lih-Ling; Lovering, Frank E.; Lowe, Michael D.; Mathias, John P.; Morgan, Heidi M.; Murphy, Elizabeth A.; Papaioannou, Nikolaos; Patny, Akshay; Pierce, Betsy S.; Rao, Vikram R.; Saiah, Eddine; Samardjiev, Ivan J.; Samas, Brian M.; Shen, Marina W. H.; Shin, Julia H.; Soutter, Holly H.; Strohbach, Joseph W.; Symanowicz, Peter T.; Thomason, Jennifer R.; Trzupek, John D.; Vargas, Richard; Vincent, Fabien; Yan, Jiangli; Zapf, Christoph W.; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5521-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topol. in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays.  The medicinal chem. effort featured the judicious placement of lipophilicity, informed by cocrystal structures with IRAK4 and optimization of ADME properties to deliver clin. candidate I.  This compd. benefitted from a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYrCep64bhMbVg90H21EOLACvtfcHk0liVDRdqrb1xRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D&md5=9771ad2d33089f6ef3dba3556536ff1a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DBree%26aufirst%3DA.%2BG.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%2BI.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDower%26aufirst%3DK.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DGoldberg%26aufirst%3DJ.%2BA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DL.-L.%26aulast%3DLovering%26aufirst%3DF.%2BE.%26aulast%3DLowe%26aufirst%3DM.%2BD.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DH.%2BM.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DPapaioannou%26aufirst%3DN.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSamardjiev%26aufirst%3DI.%2BJ.%26aulast%3DSamas%26aufirst%3DB.%2BM.%26aulast%3DShen%26aufirst%3DM.%2BW.%2BH.%26aulast%3DShin%26aufirst%3DJ.%2BH.%26aulast%3DSoutter%26aufirst%3DH.%2BH.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DR.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%25201-%257B%255B%25282S%252C3S%252C4S%2529-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%255Dmethoxy%257D-7-methoxyisoquinoline-6-carboxamide%2520%2528PF-06650833%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%2520%2528IRAK4%2529%252C%2520by%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5521%26epage%3D5542%26doi%3D10.1021%2Facs.jmedchem.7b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span> <span> </span><span class="NLM_article-title">Mapping the efficiency and physicochemical trajectories of successful optimizations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6421</span>â <span class="NLM_lpage">6467</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00180</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00180" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6421-6467&issue=15&author=R.+J.+Youngauthor=P.+D.+Leeson&title=Mapping+the+efficiency+and+physicochemical+trajectories+of+successful+optimizations&doi=10.1021%2Facs.jmedchem.8b00180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations</span></div><div class="casAuthors">Young, Robert J.; Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6421-6467</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The practices and tactics employed in successful optimizations are examd., judged from the trajectories of ligand efficiency and property evolution.  A wide range of targets is analyzed, encompassing a variety of hit finding methods (HTS, fragments, encoded library technol.) and types of mols., including those beyond the rule of five.  The wider employment of efficiency metrics and lipophilicity control is evident in contemporary practice and the impact on quality demonstrable.  What is clear is that while targets are different, successful mols. are almost invariably among the most efficient for their target, even at the extremes.  Trajectory mapping, based on principles rather than rules, is useful in assessing quality and progress in optimizations while benchmarking against competitors and assessing property-dependent risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCQtcLKSk7q7Vg90H21EOLACvtfcHk0ljZorJ7XrdZmw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmu7Y%253D&md5=f040ef02d161e070bb5021fde1585e66</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DMapping%2520the%2520efficiency%2520and%2520physicochemical%2520trajectories%2520of%2520successful%2520optimizations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467%26doi%3D10.1021%2Facs.jmedchem.8b00180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KeserÃ¼, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi">Â DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105&author=A.+L.+Hopkinsauthor=G.+M.+Keser%C3%BCauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0ljZorJ7XrdZmw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapeller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Selective interleukin-1 receptorâassociated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>212</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2189</span>â <span class="NLM_lpage">2201</span>, <span class="refDoi">Â DOI: 10.1084/jem.20151074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1084%2Fjem.20151074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=26621451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2015&pages=2189-2201&issue=13&author=P.+N.+Kellyauthor=D.+L.+Romeroauthor=Y.+Yangauthor=A.+L.+Shafferauthor=D.+Chaudharyauthor=S.+Robinsonauthor=W.+Miaoauthor=L.+Ruiauthor=W.+F.+Westlinauthor=R.+Kapellerauthor=L.+M.+Staudt&title=Selective+interleukin-1+receptor%E2%80%93associated+kinase+4+inhibitors+for+the+treatment+of+autoimmune+disorders+and+lymphoid+malignancy&doi=10.1084%2Fjem.20151074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span></div><div class="casAuthors">Kelly, Priscilla N.; Romero, Donna L.; Yang, Yibin; Shaffer, Arthur L., III; Chaudhary, Divya; Robinson, Shaughnessy; Miao, Wenyan; Rui, Lixin; Westlin, William F.; Kapeller, Rosana; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2189-2201</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Pathol. activation of the Toll-like receptor signaling adaptor protein MYD88 underlies many autoimmune and inflammatory disease states.  In the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLB CL), the oncogenic MYD88 L265P mutation occurs in 29% of cases, making it the most prevalent activating mutation in this malignancy.  IRAK4 kinase accounts for almost all of the biol. functions of MYD88, highlighting IRAK4 as a therapeutic target for diseases driven by aberrant MYD88 signaling.  Using innovative structure-based drug design methodologies, we report the development of highly selective and bioavailable small mol. IRAK4 inhibitors, ND-2158 and ND-2110.  These small mols. suppressed LPS-induced TNF prodn., alleviated collagen-induced arthritis, and blocked gout formation in mouse models.  IRAK4 inhibition promoted killing of ABC DLB CL lines harboring MYD88 L265P, by down-modulating survival signals, including NF-ÎºB and autocrine IL-6/IL-10 engagement of the JAK-STAT3 pathway.  In ABC DLB CL xenograft models, IRAK4 inhibition suppressed tumor growth as a single agent, and in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or the Bcl-2 inhibitor ABT-199.  Our findings support pharmacol. inhibition of IRAK4 as a therapeutic strategy in autoimmune disorders, in a genetically defined population of ABC DLB CL, and possibly other malignancies dependent on aberrant MYD88 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJuS2v8AyXXrVg90H21EOLACvtfcHk0ljZorJ7XrdZmw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D&md5=cf477aff5f649644017cbe5330995a70</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1084%2Fjem.20151074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20151074%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DP.%2BN.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DW.%26aulast%3DRui%26aufirst%3DL.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DSelective%2520interleukin-1%2520receptor%25E2%2580%2593associated%2520kinase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520autoimmune%2520disorders%2520and%2520lymphoid%2520malignancy%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2015%26volume%3D212%26issue%3D13%26spage%3D2189%26epage%3D2201%26doi%3D10.1084%2Fjem.20151074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milletti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goracci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span> <span> </span><span class="NLM_article-title">Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4270</span>â <span class="NLM_lpage">4279</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2010.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1016%2Fj.ejmech.2010.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=20633962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=4270-4279&issue=9&author=F.+Millettiauthor=L.+Storchiauthor=L.+Goracciauthor=S.+Bendelsauthor=B.+Wagnerauthor=M.+Kansyauthor=G.+Cruciani&title=Extending+pKa+prediction+accuracy%3A+high-throughput+pKa+measurements+to+understand+pKa+modulation+of+new+chemical+series&doi=10.1016%2Fj.ejmech.2010.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Extending pKa prediction accuracy: High-throughput pKa measurements to understand pKa modulation of new chemical series</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Goracci, Laura; Bendels, Stefanie; Wagner, Bjoern; Kansy, Manfred; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4270-4279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We have recently developed a tool, MoKÎ±, to predict the pKa of org. compds. using a large dataset of over 26,500 literature pKa values as a training set.  However, predicting accurately pKa (<0.5 pH units) remains challenging for novel series, and this can be a drawback in the optimization of activity and ADME properties of lead compds.  To address this issue it is important to expand our knowledge of pKa determinants, therefore we have conducted high-throughput pKa measurements by using Spectral Gradient Anal. (SGA) on novel series of compds. selected from vendor databases.  Here we report our findings on the effect of specific chem. groups and steric constraints on the pKa of common functionalities in medicinal chem., such as amines, sulfonamides, and amides.  Furthermore, we report the pKa of ionizable groups that were not well represented in the database of literature pKa of MoKÎ±, such as hydrazide derivs.  These findings helped us to enhance MoKÎ±, which is here benchmarked on a set of exptl. pKa values from the Roche inhouse library (N = 5581; RMSE = 1.09; R2 = 0.82).  The accuracy of the predictions was greatly improved (RMSE = 0.49, R2 = 0.96) after training the software by using the automated tool Kibitzer with 6226 pK a values taken from a different set of Roche compds. appropriately selected, and this demonstrates the value of using high-throughput pKa measurements to expand the training set of pKa values used by the software MoKÎ±.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxQ9UJOAhB-rVg90H21EOLACvtfcHk0lis5zgVjn04eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D&md5=e4c579032df7fa37ec3551c69a09257a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DGoracci%26aufirst%3DL.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DExtending%2520pKa%2520prediction%2520accuracy%253A%2520high-throughput%2520pKa%2520measurements%2520to%2520understand%2520pKa%2520modulation%2520of%2520new%2520chemical%2520series%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26issue%3D9%26spage%3D4270%26epage%3D4279%26doi%3D10.1016%2Fj.ejmech.2010.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulshian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bober, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlisi, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossetta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span> <span> </span><span class="NLM_article-title">Potent and selective amidopyrazole inhibitors of IRAK4 that are efficacious in a rodent model of inflammation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">677</span>â <span class="NLM_lpage">682</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=677-682&issue=6&author=W.+T.+McElroyauthor=Z.+Tanauthor=G.+Hoauthor=S.+Paliwalauthor=G.+Liauthor=W.+M.+Seganishauthor=D.+Tulshianauthor=J.+Tataauthor=T.+O.+Fischmannauthor=C.+Sondeyauthor=H.+Bianauthor=L.+Boberauthor=J.+Jacksonauthor=C.+G.+Garlisiauthor=K.+Devitoauthor=J.+Fossettaauthor=D.+Lundellauthor=X.+Niu&title=Potent+and+selective+amidopyrazole+inhibitors+of+IRAK4+that+are+efficacious+in+a+rodent+model+of+inflammation&doi=10.1021%2Facsmedchemlett.5b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation</span></div><div class="casAuthors">McElroy, William T.; Tan, Zheng; Ho, Ginny; Paliwal, Sunil; Li, Guoqing; Seganish, W. Michael; Tulshian, Deen; Tata, James; Fischmann, Thierry O.; Sondey, Christopher; Bian, Hong; Bober, Loretta; Jackson, James; Garlisi, Charles G.; Devito, Kristine; Fossetta, James; Lundell, Daniel; Niu, Xiaoda</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-682</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">IRAK4 is a crit. upstream kinase in the IL-1R/TLR signaling pathway.  Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders.  A screening campaign identified a pyrazole class of IRAK4 inhibitors that were detd. by X-ray crystallog. to exhibit an unusual binding mode.  SAR efforts focused on the identification of a potent and selective inhibitor with good aq. soly. and rodent pharmacokinetics.  Pyrazole C-3 piperidines were well tolerated, with N-sulfonyl analogs generally having good rodent oral exposure but poor soly.  N-Alkyl piperidines exhibited excellent soly. and reduced exposure.  Pyrazoles possessing N-1 pyridine and fluorophenyl substituents were among the most active.  Piperazine 32 was a potent enzyme inhibitor with good cellular activity.  Compd. 32 reduced the in vivo prodn. of proinflammatory cytokines and was orally efficacious in a mouse antibody induced arthritis disease model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSA2VYtAf07Vg90H21EOLACvtfcHk0lis5zgVjn04eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D&md5=2203ad720b478a6e415d7d9df3e82106</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00106%26sid%3Dliteratum%253Aachs%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DHo%26aufirst%3DG.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSeganish%26aufirst%3DW.%2BM.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DBober%26aufirst%3DL.%26aulast%3DJackson%26aufirst%3DJ.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DPotent%2520and%2520selective%2520amidopyrazole%2520inhibitors%2520of%2520IRAK4%2520that%2520are%2520efficacious%2520in%2520a%2520rodent%2520model%2520of%2520inflammation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D6%26spage%3D677%26epage%3D682%26doi%3D10.1021%2Facsmedchemlett.5b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective pyrazolopyrimidine Janus kinase 2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10090</span>â <span class="NLM_lpage">10107</span>, <span class="refDoi">Â DOI: 10.1021/jm3012239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7vO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10090-10107&issue=22&author=E.+J.+Hananauthor=A.+van+Abbemaauthor=K.+Barrettauthor=W.+S.+Blairauthor=J.+Blaneyauthor=C.+Changauthor=C.+Eigenbrotauthor=S.+Flynnauthor=P.+Gibbonsauthor=C.+A.+Hurleyauthor=J.+R.+Kennyauthor=J.+Kulagowskiauthor=L.+Leeauthor=S.+R.+Magnusonauthor=C.+Morrisauthor=J.+Murrayauthor=R.+M.+Pastorauthor=T.+Rawsonauthor=M.+Siuauthor=M.+Ultschauthor=A.+Zhouauthor=D.+Sampathauthor=J.+P.+Lyssikatos&title=Discovery+of+potent+and+selective+pyrazolopyrimidine+Janus+kinase+2+inhibitors&doi=10.1021%2Fjm3012239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors</span></div><div class="casAuthors">Hanan, Emily J.; van Abbema, Anne; Barrett, Kathy; Blair, Wade S.; Blaney, Jeff; Chang, Christine; Eigenbrot, Charles; Flynn, Sean; Gibbons, Paul; Hurley, Christopher A.; Kenny, Jane R.; Kulagowski, Janusz; Lee, Leslie; Magnuson, Steven R.; Morris, Claire; Murray, Jeremy; Pastor, Richard M.; Rawson, Tom; Siu, Michael; Ultsch, Mark; Zhou, Aihe; Sampath, Deepak; Lyssikatos, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10090-10107</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in discovering selective Jak2 inhibitors for use in treating these disorders.  A high-throughput screening effort identified the pyrazolo[1,5-a]pyrimidine scaffold as a potent inhibitor of Jak2.  Optimization of lead compds. in this chem. series for activity against Jak2, selectivity against other Jak family kinases, and good in vivo pharmacokinetic properties led to the discovery of (I).  In a SET2 xenograft model that is dependent on Jak2 for growth, I demonstrated a time-dependent knock-down of pSTAT5, a downstream target of Jak2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLsbJk8ilR07Vg90H21EOLACvtfcHk0lis5zgVjn04eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7vO&md5=b08cc250ae2498a164c6ce416743c968</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm3012239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012239%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBlaney%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFlynn%26aufirst%3DS.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKulagowski%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DMagnuson%26aufirst%3DS.%2BR.%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPastor%26aufirst%3DR.%2BM.%26aulast%3DRawson%26aufirst%3DT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520pyrazolopyrimidine%2520Janus%2520kinase%25202%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D22%26spage%3D10090%26epage%3D10107%26doi%3D10.1021%2Fjm3012239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N. P. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1835</span>â <span class="NLM_lpage">1844</span>, <span class="refDoi">Â DOI: 10.1016/j.str.2006.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1016%2Fj.str.2006.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=17161373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlShsrvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1835-1844&issue=12&author=Z.+Wangauthor=J.+Liuauthor=A.+Sudomauthor=M.+Ayresauthor=S.+Liauthor=H.+Wescheauthor=J.+P.+Powersauthor=N.+P.+C.+Walker&title=Crystal+structures+of+IRAK-4+kinase+in+complex+with+inhibitors%3A+a+serine%2Fthreonine+kinase+with+tyrosine+as+a+gatekeeper&doi=10.1016%2Fj.str.2006.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of IRAK-4 Kinase in Complex with Inhibitors: A Serine/Threonine Kinase with Tyrosine as a Gatekeeper</span></div><div class="casAuthors">Wang, Zhulun; Liu, Jinsong; Sudom, Athena; Ayres, Merrill; Li, Shyun; Wesche, Holger; Powers, Jay P.; Walker, Nigel P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1835-1844</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Interleukin-1 (IL-1) receptor-assocd. kinase-4 (IRAK-4) is a serine/threonine kinase that plays an essential role in signal transduction by Toll/IL-1 receptors (TIRs).  Here, we report the crystal structures of the phosphorylated human IRAK-4 kinase domain in complex with a potent inhibitor and with staurosporine to 2.0 and 2.2 Ã, resp.  The structures reveal that IRAK-4 has a unique tyrosine gatekeeper residue that interacts with the conserved glutamate from helix Î±C.  Consequently, helix Î±C is "pulled in" to maintain the active orientation, and the usual pre-existing hydrophobic back pocket of the ATP-binding site is abolished.  The peptide substrate-binding site is more open when compared with other protein kinases due to a marked movement of helix Î±G.  The pattern of phosphate ligand interactions in the activation loop bears a close resemblance to that of a tyrosine kinase.  Our results provide insights into IRAK-4 function and the design of selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1kW8-IrZf47Vg90H21EOLACvtfcHk0lg8QXHOEcXUGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlShsrvF&md5=6a8f14729eeb6776871ff632f0822f8f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2006.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2006.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWesche%26aufirst%3DH.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520IRAK-4%2520kinase%2520in%2520complex%2520with%2520inhibitors%253A%2520a%2520serine%252Fthreonine%2520kinase%2520with%2520tyrosine%2520as%2520a%2520gatekeeper%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26issue%3D12%26spage%3D1835%26epage%3D1844%26doi%3D10.1016%2Fj.str.2006.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, N.</span>; <span class="NLM_string-name">Chen, S.</span>; <span class="NLM_string-name">Hermann, J. C.</span>; <span class="NLM_string-name">Kuglstatter, A.</span>; <span class="NLM_string-name">Labadie, S. S.</span>; <span class="NLM_string-name">Lin, C. J. J.</span>; <span class="NLM_string-name">Lucas, M. C.</span>; <span class="NLM_string-name">Moore, A. G.</span>; <span class="NLM_string-name">Papp, E.</span>; <span class="NLM_string-name">Talamas, F. X.</span>; <span class="NLM_string-name">Wanner, J.</span>; <span class="NLM_string-name">Zhai, Y.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5<i>a</i>]pyrimidine and Thieno[3,2<i>b</i>]pyrimidine Derivatives As IRAK4 Modulators</span>. <span class="NLM_patent">WO2012007375A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+Arora&author=S.+Chen&author=J.+C.+Hermann&author=A.+Kuglstatter&author=S.+S.+Labadie&author=C.+J.+J.+Lin&author=M.+C.+Lucas&author=A.+G.+Moore&author=E.+Papp&author=F.+X.+Talamas&author=J.+Wanner&author=Y.+Zhai&title=Pyrazolo%5B1%2C5a%5Dpyrimidine+and+Thieno%5B3%2C2b%5Dpyrimidine+Derivatives+As+IRAK4+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DN.%26atitle%3DPyrazolo%255B1%252C5a%255Dpyrimidine%2520and%2520Thieno%255B3%252C2b%255Dpyrimidine%2520Derivatives%2520As%2520IRAK4%2520Modulators%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="note"><p class="first last">Compound <b>22</b> solubility in standard phosphate buffer: pH 2.0 = 17.2 ug/mL; pH 7.4 = 5.2 ug/mL. Precipitation was observed in thermodynamic solubility solutions at pH 2.0 and pH 7.4. Kinetic solubility in 2% DMSO = 1.00 uM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland 2: complexity and promiscuity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">515</span>â <span class="NLM_lpage">519</span>, <span class="refDoi">Â DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&issue=3&author=F.+Lovering&title=Escape+from+flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0lg8QXHOEcXUGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D3%26spage%3D515%26epage%3D519%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>â <span class="NLM_lpage">6756</span>, <span class="refDoi">Â DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lj2k5GY-a7OFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyota, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakura, Y.</span></span> <span> </span><span class="NLM_article-title">TLR9-dependent systemic interferon-Î² production by intravenous injection of plasmid DNA/cationic liposome complex in mice</span>. <i>J. Gene Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">708</span>â <span class="NLM_lpage">717</span>, <span class="refDoi">Â DOI: 10.1002/jgm.1348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1002%2Fjgm.1348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=19462411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFSqtbzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=708-717&issue=8&author=H.+Yoshidaauthor=M.+Nishikawaauthor=S.+Yasudaauthor=Y.+Mizunoauthor=H.+Toyotaauthor=T.+Kiyotaauthor=R.+Takahashiauthor=Y.+Takakura&title=TLR9-dependent+systemic+interferon-%CE%B2+production+by+intravenous+injection+of+plasmid+DNA%2Fcationic+liposome+complex+in+mice&doi=10.1002%2Fjgm.1348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">TLR9-dependent systemic interferon-Î² production by intravenous injection of plasmid DNA/cationic liposome complex in mice</span></div><div class="casAuthors">Yoshida, Hiroyuki; Nishikawa, Makiya; Yasuda, Sachiyo; Mizuno, Yumiko; Toyota, Hiroyasu; Kiyota, Tsuyoshi; Takahashi, Rei; Takakura, Yoshinobu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Gene Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">708-717</span>CODEN:
                <span class="NLM_cas:coden">JGMEFG</span>;
        ISSN:<span class="NLM_cas:issn">1099-498X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Background: The type I interferon (IFN) response to DNA/cationic liposome complex, or lipoplex, has been reported in cultured cells, but little is known about the response in vivo.  Studies of the pro-inflammatory cytokine response to lipoplex have shown the importance of the unmethylated CpG dinucleotide (CpG motif) and its receptor, Toll-like receptor (TLR)-9.  Methods: CpG- and non-CpG lipoplex consisting of CpG- or non-CpG plasmid DNA, resp., and N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride/cholesterol liposomes were i.v. injected into mice.  IFN-Î² and interleukin (IL)-6 in the serum and organs were measured by the ELISA.  The involvement of TLR9, phagocytic cells and the spleen in the responses was evaluated using TLR9-/-, clodronate liposome-treated-, and splenectomized mice, resp.  Accumulation of blood cells in the lung was evaluated histol.  Results: CpG lipoplex induced a large increase in the levels of IFN-Î² and IL-6 in the serum, liver, spleen, lung and kidney, whereas non-CpG lipoplex scarcely had any effect.  Neither formulation led to significant cytokine prodn. in TLR9-/- mice.  Clodronate liposome-treated mice showed a large redn. in both IFN-Î² and IL-6 levels.  Splenectomized mice receiving CpG lipoplex also showed a significantly low prodn. of IL-6 but a similar level of IFN-Î² prodn. to that of unsplenectomized mice.  A large no. of monocytes were found in the capillary vessels around the pulmonary alveoli of mice receiving lipoplex.  Conclusions: These findings indicate that, in contrast to the prodn. of IL-6 from splenic macrophages, IFN-Î² is produced from phagocytic cells other than splenic macrophages after the injection of CpG lipoplex through the TLR9-dependent pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpozxbmNsSDD7Vg90H21EOLACvtfcHk0lj2k5GY-a7OFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFSqtbzF&md5=57243eaa103b84accf55de7f7d539d3e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fjgm.1348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjgm.1348%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DNishikawa%26aufirst%3DM.%26aulast%3DYasuda%26aufirst%3DS.%26aulast%3DMizuno%26aufirst%3DY.%26aulast%3DToyota%26aufirst%3DH.%26aulast%3DKiyota%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DR.%26aulast%3DTakakura%26aufirst%3DY.%26atitle%3DTLR9-dependent%2520systemic%2520interferon-%25CE%25B2%2520production%2520by%2520intravenous%2520injection%2520of%2520plasmid%2520DNA%252Fcationic%2520liposome%2520complex%2520in%2520mice%26jtitle%3DJ.%2520Gene%2520Med.%26date%3D2009%26volume%3D11%26issue%3D8%26spage%3D708%26epage%3D717%26doi%3D10.1002%2Fjgm.1348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Means, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golenbock, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luster, A. D.</span></span> <span> </span><span class="NLM_article-title">Human lupus autoantibodyâDNA complexes activate DCs through cooperation of CD32 and TLR9</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">407</span>â <span class="NLM_lpage">417</span>, <span class="refDoi">Â DOI: 10.1172/JCI23025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1172%2FJCI23025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=15668740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyjsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=407-417&issue=2&author=T.+K.+Meansauthor=E.+Latzauthor=F.+Hayashiauthor=M.+R.+Muraliauthor=D.+T.+Golenbockauthor=A.+D.+Luster&title=Human+lupus+autoantibody%E2%80%93DNA+complexes+activate+DCs+through+cooperation+of+CD32+and+TLR9&doi=10.1172%2FJCI23025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9</span></div><div class="casAuthors">Means, Terry K.; Latz, Eicke; Hayashi, Fumitaka; Murali, Mandakolathur R.; Golenbock, Douglas T.; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">407-417</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by pathogenic autoantibodies against nucleoproteins and DNA.  Here we show that DNA-contg. immune complexes (ICs) within lupus serum (SLE-ICs), but not protein-contg. ICs from other autoimmune rheumatic diseases, stimulates plasmacytoid DCs (PDCs) to produce cytokines and chemokines via a cooperative interaction between Toll-like receptor 9 (TLR9) and FcÎ³RIIa (CD32).  SLE-ICs transiently colocalized to a subcellular compartment contg. CD32 and TLR9, and CD32+, but not CD32-, PDCs internalized and responded to SLE-ICs.  Our findings demonstrate a novel functional interaction between Fc receptors and TLRs, defining a pathway in which CD32 delivers SLE-ICs to intracellular lysosomes contg. TLR9, inducing a signaling cascade leading to PDC activation.  These data demonstrate that endogenous DNA-contg. autoantibody complexes found in the serum of patients with SLE activate the innate immune system and suggest a novel mechanism whereby these ICs contribute to the pathogenesis of this autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWojsiWfm8irVg90H21EOLACvtfcHk0lj2k5GY-a7OFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyjsbg%253D&md5=5c81dcafef8948f79969df3c3aa061c1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1172%2FJCI23025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI23025%26sid%3Dliteratum%253Aachs%26aulast%3DMeans%26aufirst%3DT.%2BK.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DHayashi%26aufirst%3DF.%26aulast%3DMurali%26aufirst%3DM.%2BR.%26aulast%3DGolenbock%26aufirst%3DD.%2BT.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DHuman%2520lupus%2520autoantibody%25E2%2580%2593DNA%2520complexes%2520activate%2520DCs%2520through%2520cooperation%2520of%2520CD32%2520and%2520TLR9%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26issue%3D2%26spage%3D407%26epage%3D417%26doi%3D10.1172%2FJCI23025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad-Nejad, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HÃ¤cker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vabulas, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, H.</span></span> <span> </span><span class="NLM_article-title">Bacterial CpG-DNA and lipopolysaccharides activate toll-like receptors at distinct cellular compartments</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1958</span>â <span class="NLM_lpage">1968</span>, <span class="refDoi">Â DOI: 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1002%2F1521-4141%28200207%2932%3A7%3C1958%3A%3AAID-IMMU1958%3E3.0.CO%3B2-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=12115616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFajurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=1958-1968&issue=7&author=P.+Ahmad-Nejadauthor=H.+H%C3%A4ckerauthor=M.+Rutzauthor=S.+Bauerauthor=R.+M.+Vabulasauthor=H.+Wagner&title=Bacterial+CpG-DNA+and+lipopolysaccharides+activate+toll-like+receptors+at+distinct+cellular+compartments&doi=10.1002%2F1521-4141%28200207%2932%3A7%3C1958%3A%3AAID-IMMU1958%3E3.0.CO%3B2-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments</span></div><div class="casAuthors">Ahmad-Nejad, Parviz; Hacker, Hans; Rutz, Mark; Bauer, Stefan; Vabulas, Ramunas M.; Wagner, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1958-1968</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">Recognition by innate immune cells of the pathogen assocd. mol. patterns (PAMP) lipopolysaccharide (LPS) from Gram-neg. bacteria and bacterial CpG-DNA depends on Toll-like receptor 4 (TLR4) and TLR9, resp.  To define differences in the response to these distinct PAMP, we compared a key intracellular event, namely recruitment of myeloid differentiation marker 88 (MyD88) to the resp. PAMP-initiated TLR signaling.  Using MyD88-GFP fusion protein expressing macrophages we demonstrate that LPS and CpG-DNA trigger signaling from two different cellular locations: the former at the cell membrane and the latter at the lysosomal compartment.  While LPS does not require endocytosis to functionally assoc. with the membrane expressed TLR4/MD2 complex, internalization and endosomal maturation is conditional for CpG-DNA to activate TLR9.  In support of these data, TLR9 is not localized at the cell surface, but intracellularly.  These data stress the need to characterize individual TLR at the very beginning of signal initiation in order to understand their diverse biol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNK_GJnjUIHbVg90H21EOLACvtfcHk0ljPNaTVj6oi0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFajurg%253D&md5=50c3a729b743d87586a35afec9a8777c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2F1521-4141%28200207%2932%3A7%3C1958%3A%3AAID-IMMU1958%3E3.0.CO%3B2-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-4141%2528200207%252932%253A7%253C1958%253A%253AAID-IMMU1958%253E3.0.CO%253B2-U%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad-Nejad%26aufirst%3DP.%26aulast%3DH%25C3%25A4cker%26aufirst%3DH.%26aulast%3DRutz%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DVabulas%26aufirst%3DR.%2BM.%26aulast%3DWagner%26aufirst%3DH.%26atitle%3DBacterial%2520CpG-DNA%2520and%2520lipopolysaccharides%2520activate%2520toll-like%2520receptors%2520at%2520distinct%2520cellular%2520compartments%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2002%26volume%3D32%26issue%3D7%26spage%3D1958%26epage%3D1968%26doi%3D10.1002%2F1521-4141%28200207%2932%3A7%3C1958%3A%3AAID-IMMU1958%3E3.0.CO%3B2-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gursel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gursel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinman, D. M.</span></span> <span> </span><span class="NLM_article-title">Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">17</span>â <span class="NLM_lpage">22</span>, <span class="refDoi">Â DOI: 10.1016/j.smim.2003.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1016%2Fj.smim.2003.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=14751759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntVOntg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=17-22&issue=1&author=F.+Takeshitaauthor=I.+Gurselauthor=K.+J.+Ishiiauthor=K.+Suzukiauthor=M.+Gurselauthor=D.+M.+Klinman&title=Signal+transduction+pathways+mediated+by+the+interaction+of+CpG+DNA+with+Toll-like+receptor+9&doi=10.1016%2Fj.smim.2003.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9</span></div><div class="casAuthors">Takeshita, Fumihiko; Gursel, Ihsan; Ishii, Ken J.; Suzuki, Koichi; Gursel, Mayda; Klinman, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-22</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Synthetic oligodeoxynucleotides (ODN) expressing non-methylated "CpG motifs" patterned after those present in bacterial DNA have characteristic immunomodulatory effects.  CpG DNA is recognized as a pathogen-assocd. mol. pattern, and triggers a rapid innate immune response.  CpG ODN are being harnessed for a variety of therapeutic uses, including as immune adjuvants, for cancer therapy, as anti-allergens, and as immunoprotective agents.  The signal transduction pathway mediated by the engagement of CpG DNA with Toll-like receptor 9 (TLR9) is shared with other members of the TLR family.  Recent studies demonstrate that formation and maturation of CpG DNA-contg. endosomes are regulated by phosphatidylinositol 3 kinases and the Ras-assocd. GTP-binding protein, Rab5, which are essential for the initiation of TLR9-mediated signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpcyyr_i_p2rVg90H21EOLACvtfcHk0ljPNaTVj6oi0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntVOntg%253D%253D&md5=114d24bad4ee7c00b231b03b827c5a57</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.smim.2003.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smim.2003.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DTakeshita%26aufirst%3DF.%26aulast%3DGursel%26aufirst%3DI.%26aulast%3DIshii%26aufirst%3DK.%2BJ.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DGursel%26aufirst%3DM.%26aulast%3DKlinman%26aufirst%3DD.%2BM.%26atitle%3DSignal%2520transduction%2520pathways%2520mediated%2520by%2520the%2520interaction%2520of%2520CpG%2520DNA%2520with%2520Toll-like%2520receptor%25209%26jtitle%3DSemin.%2520Immunol.%26date%3D2004%26volume%3D16%26issue%3D1%26spage%3D17%26epage%3D22%26doi%3D10.1016%2Fj.smim.2003.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anima, B.</span>; <span class="NLM_string-name">Hosahalli, S.</span>; <span class="NLM_string-name">Subhendu, M.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Heterocycles as IRAK4 Inhibitors</span>. <span class="NLM_patent">WO2013042137</span>, 28/03/2013, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=B.+Anima&author=S.+Hosahalli&author=M.+Subhendu&title=Bicyclic+Heterocycles+as+IRAK4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAnima%26aufirst%3DB.%26atitle%3DBicyclic%2520Heterocycles%2520as%2520IRAK4%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span> <span> </span><span class="NLM_article-title">Addition of amines to nitriles catalyzed by ytterbium amides: an efficient one-step synthesis of monosubstituted N-arylamidines</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">445</span>â <span class="NLM_lpage">448</span>, <span class="refDoi">Â DOI: 10.1021/ol702739c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol702739c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFyltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=445-448&issue=3&author=J.+Wangauthor=F.+Xuauthor=T.+Caiauthor=Q.+Shen&title=Addition+of+amines+to+nitriles+catalyzed+by+ytterbium+amides%3A+an+efficient+one-step+synthesis+of+monosubstituted+N-arylamidines&doi=10.1021%2Fol702739c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of Amines to Nitriles Catalyzed by Ytterbium Amides: An Efficient One-Step Synthesis of Monosubstituted N-Arylamidines</span></div><div class="casAuthors">Wang, Junfeng; Xu, Fan; Cai, Tao; Shen, Qi</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">445-448</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A one-step synthesis of monosubstituted N-arylamidinates via addn. of amines to nitriles catalyzed by ytterbium amides is reported.  The reactions with various substrates give the products in good to excellent yields with 5 mol % ytterbium at 100 Â°C under solvent-free conditions.  E.g., reaction of 2,6-diisopropylaniline and PhCN gave up to 97% N-(2,6-diisopropylphenyl)benzamidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYUfirKNAH2rVg90H21EOLACvtfcHk0ljPNaTVj6oi0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFyltQ%253D%253D&md5=23e0f1f9315088ef488e8d42755dd03f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fol702739c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol702739c%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DQ.%26atitle%3DAddition%2520of%2520amines%2520to%2520nitriles%2520catalyzed%2520by%2520ytterbium%2520amides%253A%2520an%2520efficient%2520one-step%2520synthesis%2520of%2520monosubstituted%2520N-arylamidines%26jtitle%3DOrg.%2520Lett.%26date%3D2008%26volume%3D10%26issue%3D3%26spage%3D445%26epage%3D448%26doi%3D10.1021%2Fol702739c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span>; <span class="NLM_string-name">Gobbi, A.</span>; <span class="NLM_string-name">Kiefer, J. R.</span>; <span class="NLM_string-name">Kolesnikov, A.</span>; <span class="NLM_string-name">Olivero, A.</span>; <span class="NLM_string-name">Drobnick, J.</span>; <span class="NLM_string-name">Liang, J.</span>; <span class="NLM_string-name">Rajapaksa, N.</span>; <span class="NLM_string-name">Ndubaka, C. I.</span>; <span class="NLM_string-name">Feng, J.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5<i>a</i>]pyrimidine Derivatives as IRAK4 Modulators</span>. <span class="NLM_patent">WO2017108723</span>, June 29, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+C.+Bryan&author=A.+Gobbi&author=J.+R.+Kiefer&author=A.+Kolesnikov&author=A.+Olivero&author=J.+Drobnick&author=J.+Liang&author=N.+Rajapaksa&author=C.+I.+Ndubaka&author=J.+Feng&title=Pyrazolo%5B1%2C5a%5Dpyrimidine+Derivatives+as+IRAK4+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26atitle%3DPyrazolo%255B1%252C5a%255Dpyrimidine%2520Derivatives%2520as%2520IRAK4%2520Modulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':[],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Kerstin Hiesinger, Dmitry Darâin, Ewgenij Proschak, <span class="NLM_string-name hlFld-ContribAuthor">Mikhail Krasavin</span>. </span><span class="cited-content_cbyCitation_article-title">Spirocyclic Scaffolds in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 150-183. <a href="https://doi.org/10.1021/acs.jmedchem.0c01473" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01473%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSpirocyclic%252BScaffolds%252Bin%252BMedicinal%252BChemistry%26aulast%3DHiesinger%26aufirst%3DKerstin%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D24082020%26date%3D31122020%26volume%3D64%26issue%3D1%26spage%3D150%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Venkateshwar Rao Gummadi, Anima Boruah, Bharathi Raja Ainan, Brahma Reddy Vare, Srinivas Manda, Hari Prakash Gondle, Shiva Nagendra Kumar, Subhendu Mukherjee, Suraj T. Gore, Narasimha Rao Krishnamurthy, Sivapriya Marappan, Shilpa S. Nayak, Kavitha Nellore, Wesley Roy Balasubramanian, Archana Bhumireddy, Sanjeev Giri, Sreevalsam Gopinath, Dodheri S. Samiulla, Girish Daginakatte, Aravind Basavaraju, Shekar Chelur, Rajesh Eswarappa, Charamanna Belliappa, Hosahalli S. Subramanya, Robert N. Booher, Murali Ramachandra, <span class="NLM_string-name hlFld-ContribAuthor">Susanta Samajdar</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (12)
                                     , 2374-2381. <a href="https://doi.org/10.1021/acsmedchemlett.0c00255" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00255%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BCA-4948%25252C%252Ban%252BOrally%252BBioavailable%252BIRAK4%252BInhibitor%252Bfor%252BTreatment%252Bof%252BHematologic%252BMalignancies%26aulast%3DGummadi%26aufirst%3DVenkateshwar%2BRao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D13052020%26date%3D06102020%26date%3D14102020%26volume%3D11%26issue%3D12%26spage%3D2374%26epage%3D2381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">John M. Hatcher, Guang Yang, Li Wang, Scott B. Ficarro, Sara Buhrlage, Hao Wu, Jarrod A. Marto, Steven P. Treon, <span class="NLM_string-name hlFld-ContribAuthor">Nathanael S. Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2238-2243. <a href="https://doi.org/10.1021/acsmedchemlett.0c00378" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00378</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00378%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BSelective%25252C%252BCovalent%252BIRAK1%252BInhibitor%252Bwith%252BAntiproliferative%252BActivity%252Bin%252BMYD88%252BMutated%252BB-Cell%252BLymphoma%26aulast%3DHatcher%26aufirst%3DJohn%2BM.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D08072020%26date%3D06102020%26date%3D09102020%26volume%3D11%26issue%3D11%26spage%3D2238%26epage%3D2243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Matthew D. Lloyd</span>. </span><span class="cited-content_cbyCitation_article-title">High-Throughput Screening for the Discovery of Enzyme Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10742-10772. <a href="https://doi.org/10.1021/acs.jmedchem.0c00523" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00523%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHigh-Throughput%252BScreening%252Bfor%252Bthe%252BDiscovery%252Bof%252BEnzyme%252BInhibitors%26aulast%3DLloyd%26aufirst%3DMatthew%2BD.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30032020%26date%3D10062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10742%26epage%3D10772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Naomi S. Rajapaksa, Alberto Gobbi, Joy Drobnick, Steven Do, Aleksandr Kolesnikov, Jun Liang, Yongsheng Chen, Swathi Sujatha-Bhaskar, Zhiyu Huang, Hans Brightbill, Ross Francis, Christine Yu, Edna F. Choo, Kevin DeMent, Yingqing Ran, Le An, Claire Emson, Jonathan Maher, John Wai, Brent S. McKenzie, Patrick J. Lupardus, Ali A. Zarrin, James R. Kiefer, <span class="NLM_string-name hlFld-ContribAuthor">Marian C. Bryan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 327-333. <a href="https://doi.org/10.1021/acsmedchemlett.9b00380" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00380</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00380%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%252BBenzolactam%252BIRAK4%252BInhibitors%252Bwith%252BRobust%252Bin%252BVivo%252BActivity%26aulast%3DRajapaksa%26aufirst%3DNaomi%2BS.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14082019%26date%3D11112019%26date%3D19112019%26date%3D11112019%26volume%3D11%26issue%3D3%26spage%3D327%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andres  Arias-GÃ³mez</span>, <span class="hlFld-ContribAuthor ">AndrÃ©s  Godoy</span>, <span class="hlFld-ContribAuthor ">Jaime  Portilla</span>. </span><span class="cited-content_cbyCitation_article-title">Functional Pyrazolo[1,5-a]pyrimidines: Current Approaches in Synthetic Transformations and Uses as an Antitumor Scaffold. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (9)
                                     , 2708. <a href="https://doi.org/10.3390/molecules26092708" title="DOI URL">https://doi.org/10.3390/molecules26092708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26092708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26092708%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DFunctional%252BPyrazolo%25255B1%25252C5-a%25255Dpyrimidines%25253A%252BCurrent%252BApproaches%252Bin%252BSynthetic%252BTransformations%252Band%252BUses%252Bas%252Ban%252BAntitumor%252BScaffold%26aulast%3DArias-G%25C3%25B3mez%26aufirst%3DAndres%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D9%26spage%3D2708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenqiang  Zhai</span>, <span class="hlFld-ContribAuthor ">Yongping  Lu</span>, <span class="hlFld-ContribAuthor ">Yabo  Zhu</span>, <span class="hlFld-ContribAuthor ">Mengguang  Zhou</span>, <span class="hlFld-ContribAuthor ">Cheng  Ye</span>, <span class="hlFld-ContribAuthor ">Zheng-Zheng  Shi</span>, <span class="hlFld-ContribAuthor ">Wenjian  Qian</span>, <span class="hlFld-ContribAuthor ">Taishan  Hu</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127686. <a href="https://doi.org/10.1016/j.bmcl.2020.127686" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127686%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252Boptimization%252Bof%252Ba%252Bpotent%252Band%252Bselective%252Bindazolamine%252Bseries%252Bof%252BIRAK4%252Binhibitors%26aulast%3DZhai%26aufirst%3DWenqiang%26date%3D2021%26volume%3D31%26spage%3D127686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia A.  Elkina</span>, <span class="hlFld-ContribAuthor ">Yanina V.  Burgart</span>, <span class="hlFld-ContribAuthor ">Evgeny V.  Shchegolkov</span>, <span class="hlFld-ContribAuthor ">Olga P.  Krasnykh</span>, <span class="hlFld-ContribAuthor ">Vera V.  Maslova</span>, <span class="hlFld-ContribAuthor ">Galina A.  Triandafilova</span>, <span class="hlFld-ContribAuthor ">Sergey S.  Solodnikov</span>, <span class="hlFld-ContribAuthor ">Anna A.  Muryleva</span>, <span class="hlFld-ContribAuthor ">Maria A.  Misiurina</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Slita</span>, <span class="hlFld-ContribAuthor ">Vladimir V.  Zarubaev</span>, <span class="hlFld-ContribAuthor ">Victor I.  Saloutin</span>. </span><span class="cited-content_cbyCitation_article-title">Competitive routes to cyclizations of polyfluoroalkyl-containing 2-tolylhydrazinylidene-1,3-diketones with 3-aminopyrazoles into bioactive pyrazoloazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2020,</strong> <em>240 </em>, 109648. <a href="https://doi.org/10.1016/j.jfluchem.2020.109648" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2020.109648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2020.109648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2020.109648%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DCompetitive%252Broutes%252Bto%252Bcyclizations%252Bof%252Bpolyfluoroalkyl-containing%252B2-tolylhydrazinylidene-1%25252C3-diketones%252Bwith%252B3-aminopyrazoles%252Binto%252Bbioactive%252Bpyrazoloazines%26aulast%3DElkina%26aufirst%3DNatalia%2BA.%26date%3D2020%26volume%3D240%26spage%3D109648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yun-Ti  Chen</span>, <span class="hlFld-ContribAuthor ">Cheng-Hsuan  Wu</span>, <span class="hlFld-ContribAuthor ">Yi-Cyun  Chen</span>, <span class="hlFld-ContribAuthor ">Yen-Chao  Hsu</span>, <span class="hlFld-ContribAuthor ">Yu-Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Jinn-Moon  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Configurational Differences and Binding Mechanisms of Interleukin-1 Receptor-Associated Kinase 1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 160-167. <a href="https://doi.org/10.1109/BIBE50027.2020.00034" title="DOI URL">https://doi.org/10.1109/BIBE50027.2020.00034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1109/BIBE50027.2020.00034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1109%2FBIBE50027.2020.00034%26sid%3Dliteratum%253Aachs%26atitle%3DConfigurational%252BDifferences%252Band%252BBinding%252BMechanisms%252Bof%252BInterleukin-1%252BReceptor-Associated%252BKinase%252B1%26aulast%3DChen%26aufirst%3DYun-Ti%26date%3D2020%26spage%3D160%26epage%3D167%26pub%3DIEEE%26atitle%3D2020%252BIEEE%252B20th%252BInternational%252BConference%252Bon%252BBioinformatics%252Band%252BBioengineering%252B%252528BIBE%252529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cesar A.  Corzo</span>, <span class="hlFld-ContribAuthor ">Eugene  Varfolomeev</span>, <span class="hlFld-ContribAuthor ">A. Francesca  Setiadi</span>, <span class="hlFld-ContribAuthor ">Ross  Francis</span>, <span class="hlFld-ContribAuthor ">Sha  Klabunde</span>, <span class="hlFld-ContribAuthor ">Kate  Senger</span>, <span class="hlFld-ContribAuthor ">Swathi  Sujatha-Bhaskar</span>, <span class="hlFld-ContribAuthor ">Joy  Drobnick</span>, <span class="hlFld-ContribAuthor ">Steven  Do</span>, <span class="hlFld-ContribAuthor ">Eric  Suto</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Huang</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Eastham-Anderson</span>, <span class="hlFld-ContribAuthor ">Arna  Katewa</span>, <span class="hlFld-ContribAuthor ">Jodie  Pang</span>, <span class="hlFld-ContribAuthor ">Melanie  Domeyer</span>, <span class="hlFld-ContribAuthor ">Christopher  Dela Cruz</span>, <span class="hlFld-ContribAuthor ">Andres  Paler-Martinez</span>, <span class="hlFld-ContribAuthor ">Vivian W. C.  Lau</span>, <span class="hlFld-ContribAuthor ">Azadeh  Hadadianpour</span>, <span class="hlFld-ContribAuthor ">Vladimir  Ramirez-Carrozi</span>, <span class="hlFld-ContribAuthor ">Yonglian  Sun</span>, <span class="hlFld-ContribAuthor ">Katherine  Bao</span>, <span class="hlFld-ContribAuthor ">Daqi  Xu</span>, <span class="hlFld-ContribAuthor ">Emily  Hunley</span>, <span class="hlFld-ContribAuthor ">Hans D.  Brightbill</span>, <span class="hlFld-ContribAuthor ">Soren  Warming</span>, <span class="hlFld-ContribAuthor ">Merone  Roose-Girma</span>, <span class="hlFld-ContribAuthor ">Alfred  Wong</span>, <span class="hlFld-ContribAuthor ">Lucinda  Tam</span>, <span class="hlFld-ContribAuthor ">Claire L.  Emson</span>, <span class="hlFld-ContribAuthor ">James J.  Crawford</span>, <span class="hlFld-ContribAuthor ">Wendy B.  Young</span>, <span class="hlFld-ContribAuthor ">Rajita  Pappu</span>, <span class="hlFld-ContribAuthor ">Brent S.  McKenzie</span>, <span class="hlFld-ContribAuthor ">Vida  Asghari</span>, <span class="hlFld-ContribAuthor ">Domagoj  Vucic</span>, <span class="hlFld-ContribAuthor ">Jason A.  Hackney</span>, <span class="hlFld-ContribAuthor ">Cary D.  Austin</span>, <span class="hlFld-ContribAuthor ">Wyne P.  Lee</span>, <span class="hlFld-ContribAuthor ">Annemarie  Lekkerkerker</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Marian C.  Bryan</span>, <span class="hlFld-ContribAuthor ">James R.  Kiefer</span>, <span class="hlFld-ContribAuthor ">Michael J.  Townsend</span>, <span class="hlFld-ContribAuthor ">Ali A.  Zarrin</span>. </span><span class="cited-content_cbyCitation_article-title">The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells. </span><span class="cited-content_cbyCitation_journal-name">Science Signaling</span><span> <strong>2020,</strong> <em>13 </em>
                                    (634)
                                     , eaaz1053. <a href="https://doi.org/10.1126/scisignal.aaz1053" title="DOI URL">https://doi.org/10.1126/scisignal.aaz1053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scisignal.aaz1053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscisignal.aaz1053%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Signaling%26atitle%3DThe%252Bkinase%252BIRAK4%252Bpromotes%252Bendosomal%252BTLR%252Band%252Bimmune%252Bcomplex%252Bsignaling%252Bin%252BB%252Bcells%252Band%252Bplasmacytoid%252Bdendritic%252Bcells%26aulast%3DCorzo%26aufirst%3DCesar%2BA.%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D634%26spage%3Deaaz1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yun  Chen</span>, <span class="hlFld-ContribAuthor ">Gang  Bai</span>, <span class="hlFld-ContribAuthor ">Yi  Ning</span>, <span class="hlFld-ContribAuthor ">Shi  Cai</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Peiran  Song</span>, <span class="hlFld-ContribAuthor ">Jinpei  Zhou</span>, <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Huibin  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>190 </em>, 112092. <a href="https://doi.org/10.1016/j.ejmech.2020.112092" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112092%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252BImidazo%25255B1%25252C2-b%25255Dpyridazine%252BIRAK4%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bmutant%252BMYD88%252BL265P%252Bdiffuse%252Blarge%252BB-cell%252Blymphoma%26aulast%3DChen%26aufirst%3DYun%26date%3D2020%26volume%3D190%26spage%3D112092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of IRAK4 kinase inhibitors PF-06650833 (<b>1</b>), indazole <b>2</b>, 1,6-naphthyridine <b>3</b>, and aminopyridine <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structures of IRAK4 initial lead inhibitors. The 2.5 Ã resolution cocrystal structure of <b>5</b> (A, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O9D">6O9D</a>) bound in the IRAK4 active site reveals three polarized functional groups forming hydrogen bonds to the protein. Further annotation (B) shows the subregions together with key molecule features and their interactions. The solvent-accessible surface of the binding site (C) shows substantial van der Waals contacts made between nonpolar (green mesh) protein residues and the inhibitor as well as focal polar (pink mesh) contact points. Regions above and below the plane of the quinoline ring (dotted circles) are potentially accessible through elaboration of the inhibitor linker. A 2.0 Ã resolution cocrystal structure of <b>17</b> (D, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O94">6O94</a>) shows that the inhibitor benzimidazole forms an additional polar interaction with the protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structures of dihydrobenzofuran IRAK4 inhibitors. (A, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8U">6O8U</a>) Cocrystal structure of <b>23</b> (1.8 Ã resolution) bound in the IRAK4 active site revealed three hydrogen bonds formed to the protein or solvent molecules and the protrusion of the <i>gem</i>-dimethyl moiety into the region of the site unoccupied by inhibitor atoms in the cocrystal structure of <b>5</b> with IRAK4. (B, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O95">6O95</a>) Crystal structure of <b>41</b> (1.8 Ã resolution) revealed additional polar contacts made by the hydroxymethyl substituent that further fills a previously unoccupied region, also adding 3-dimensional vectors to the compound. (C) Solvent-accessible surface for <b>41</b>, colored as in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cytokine inhibition upon treatment with <b>41</b> in a CpG-stimulated mouse PK/PD model. (A) IL-6 response, (B) TNFÎ± response, and (C) plasma compound PK. Model design: 5 mice per group were enrolled. Single dose of the compound or vehicle was given orally at â1 h; the stimulus CpG1826 or phosphate-buffered saline (PBS) was dosed intravenously at 0 h; and whole blood was collected at 1 h post CpG1826 for plasma PK and serum cytokines (IL-6 and TNFa) measured by MSD. Plasma compound PK is from blood samples collected from the same experiment of the cytokine analysis as shown in (A) and (B). One-way ANOVA analysis comparing all groups to the stimulus group (Group 2: vehicle + GpG1826) was performed. *<i>P</i> < 0.05; **<i>P</i> < 0.01; ***<i>P</i> < 0.001; ***<i>P</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Benzimidazole Intermediates and Final 5,6-Biaryl Molecules<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ytterbium triflate, xylenes, 140 Â°C, 48 h; (b) MeI/EtBr, Cs<sub>2</sub>CO<sub>3</sub>, dimethylformamide (DMF), 90 min; (c) NHR<sup>3</sup>R<sup>4</sup>, 100 Â°C, 4 h; (d) Pd/C, MeOH; (e) hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DMF.</p></p></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Initial Route for Generating Dihydrobenzofuran <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, MeCN, 55 Â°C, quant.; (b) K<sub>2</sub>CO<sub>3</sub>, DMSO, 100 Â°C, 30 min, 93% yield; (c) Î¼w, DMF, 220 Â°C, 60 min; (d) 35% aqueous HCl in MeOH, 65% yield; (e) H<sub>2</sub>, Pd/C, MeOH; (f) PyAOP, 2,4,6-trimethylpyridine, DMF (45% yield).</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/medium/jm-2019-00439x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Revised Route to Dihydrobenzofuran Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00439/20190705/images/large/jm-2019-00439x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00439&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) <i>m</i>CPBA, dichloromethane (DCM), 20% yield; (b) H<sub>2</sub>, Pd/C; (c) PyAOP, 65% yield; (d) Mg, cat. I<sub>2</sub>, Et<sub>2</sub>O, Î then methyl 2-oxopropanoate; tetrahydrofuran (THF), â78 Â°C to rt, 2 h, 51% yield; (e) <i>t</i>BuOK, THF, 60 Â°C, 12 h, 64% yield; (f) HNO<sub>3</sub>, DCM, rt, 5 min, 54% yield; (g) BH<sub>3</sub>, THF, rt, 2 h, 32% yield. Highest resolution shell; n.d., parameter not determined.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74456" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74456" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K.</span></span> <i>Janewayâs Immunobiology</i>, <span class="NLM_edition">8</span>th ed.; <span class="NLM_publisher-name">Garland Science, Taylor & Francis Group, LLC</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2012</span>; p  <span class="NLM_fpage">888</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=888&author=K.+Murphy&title=Janeway%E2%80%99s+Immunobiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DK.%26btitle%3DJaneway%25E2%2580%2599s%2520Immunobiology%26pub%3DGarland%2520Science%252C%2520Taylor%2520%2526%2520Francis%2520Group%252C%2520LLC%26date%3D2012%26spage%3D888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">96</span>â <span class="NLM_lpage">110</span>, <span class="refDoi">Â DOI: 10.1021/jm5016044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5016044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCjsLzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=96-110&issue=1&author=D.+Chaudharyauthor=S.+Robinsonauthor=D.+L.+Romero&title=Recent+advances+in+the+discovery+of+small+molecule+inhibitors+of+interleukin-1+receptor-associated+kinase+4+%28IRAK4%29+as+a+therapeutic+target+for+inflammation+and+oncology+disorders&doi=10.1021%2Fjm5016044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders</span></div><div class="casAuthors">Chaudhary, Divya; Robinson, Shaughnessy; Romero, Donna L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-110</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  IRAK4, a serine/threonine kinase, plays a key role in both inflammation and oncol. diseases.  Herein, we summarize the compelling biol. surrounding the IRAK4 signaling node in disease, review key structural features of IRAK4 including selectivity challenges, and describe efforts to discover clin. viable IRAK4 inhibitors.  Finally, a view of knowledge gained and remaining challenges is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1K6ExwztfCLVg90H21EOLACvtfcHk0lgQDoFmou8C0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCjsLzL&md5=795797f7f3f07597ecd0b5899498804b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm5016044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5016044%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520small%2520molecule%2520inhibitors%2520of%2520interleukin-1%2520receptor-associated%2520kinase%25204%2520%2528IRAK4%2529%2520as%2520a%2520therapeutic%2520target%2520for%2520inflammation%2520and%2520oncology%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D1%26spage%3D96%26epage%3D110%26doi%3D10.1021%2Fjm5016044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawagoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uematsu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akira, S.</span></span> <span> </span><span class="NLM_article-title">Essential role of IRAK-4 protein and its kinase activity in toll-like receptorâmediated immune responses but not in TCR signaling</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>204</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1013</span>â <span class="NLM_lpage">1024</span>, <span class="refDoi">Â DOI: 10.1084/jem.20061523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1084%2Fjem.20061523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=17485511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFSjsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2007&pages=1013-1024&issue=5&author=T.+Kawagoeauthor=S.+Satoauthor=A.+Jungauthor=M.+Yamamotoauthor=K.+Matsuiauthor=H.+Katoauthor=S.+Uematsuauthor=O.+Takeuchiauthor=S.+Akira&title=Essential+role+of+IRAK-4+protein+and+its+kinase+activity+in+toll-like+receptor%E2%80%93mediated+immune+responses+but+not+in+TCR+signaling&doi=10.1084%2Fjem.20061523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling</span></div><div class="casAuthors">Kawagoe, Tatsukata; Sato, Shintaro; Jung, Andreas; Yamamoto, Masahiro; Matsui, Kosuke; Kato, Hiroki; Uematsu, Satoshi; Takeuchi, Osamu; Akira, Shizuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1013-1024</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Interleukin-1 receptor-assocd. kinase 4 (IRAK-4) was reported to be essential for the Toll-like receptor (TLR)- and T cell receptor (TCR)-mediated signaling leading to the activation of nuclear factor ÎºB (NF-ÎºB).  However, the importance of kinase activity of IRAK family members is unclear.  In this study, we investigated the functional role of IRAK-4 activity in vivo by generating mice carrying a knockin mutation (KK213AA) that abrogates its kinase activity.  IRAK-4KN/KN mice were highly resistant to TLR-induced shock response.  The cytokine prodn. in response to TLR ligands was severely impaired in IRAK-4KN/KN as well as IRAK-4-/- macrophages.  The IRAK-4 activity was essential for the activation of signaling pathways leading to mitogen-activated protein kinases.  TLR-induced IRAK-4/IRAK-1-dependent and -independent pathways were involved in early induction of NF-ÎºB-regulated genes in response to TLR ligands such as tumor necrosis factor Î± and IÎºBÎ¶.  In contrast to a previous paper, the TCR signaling was not impaired in IRAK-4-/- and IRAK-4KN/KN mice.  Thus, the kinase activity of IRAK-4 is essential for the regulation of TLR-mediated innate immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDdu13L0FMrVg90H21EOLACvtfcHk0lgQDoFmou8C0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFSjsbY%253D&md5=902905464ef0cba41a3fda070fc982f5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1084%2Fjem.20061523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20061523%26sid%3Dliteratum%253Aachs%26aulast%3DKawagoe%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DUematsu%26aufirst%3DS.%26aulast%3DTakeuchi%26aufirst%3DO.%26aulast%3DAkira%26aufirst%3DS.%26atitle%3DEssential%2520role%2520of%2520IRAK-4%2520protein%2520and%2520its%2520kinase%2520activity%2520in%2520toll-like%2520receptor%25E2%2580%2593mediated%2520immune%2520responses%2520but%2520not%2520in%2520TCR%2520signaling%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2007%26volume%3D204%26issue%3D5%26spage%3D1013%26epage%3D1024%26doi%3D10.1084%2Fjem.20061523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdollahi-Roodsaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netea, M. G.</span></span> <span> </span><span class="NLM_article-title">Toll-like receptors and chronic inflammation in rheumatic diseases: new developments</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">344</span>â <span class="NLM_lpage">357</span>, <span class="refDoi">Â DOI: 10.1038/nrrheum.2016.61</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1038%2Fnrrheum.2016.61" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=27170508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvV2ntb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=344-357&author=L.+A.+B.+Joostenauthor=S.+Abdollahi-Roodsazauthor=C.+A.+Dinarelloauthor=L.+O%E2%80%99Neillauthor=M.+G.+Netea&title=Toll-like+receptors+and+chronic+inflammation+in+rheumatic+diseases%3A+new+developments&doi=10.1038%2Fnrrheum.2016.61"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptors and chronic inflammation in rheumatic diseases: new developments</span></div><div class="casAuthors">Joosten, Leo A. B.; Abdollahi-Roodsaz, Shahla; Dinarello, Charles A.; O'Neill, Luke; Netea, Mihai G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">344-357</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the past few years, new developments have been reported on the role of Toll-like receptors (TLRs) in chronic inflammation in rheumatic diseases.  The inhibitory function of TLR10 has been demonstrated.  Receptors that enhance the function of TLRs, and several TLR inhibitors, have been identified.  In addn., the role of the microbiome and TLRs in the onset of rheumatic diseases has been reported.  We review novel insights on the role of TLRs in several inflammatory joint diseases, including rheumatoid arthritis, systemic lupus erythematosus, gout and Lyme arthritis, with a focus on the signalling mechanisms mediated by the Toll-IL-1 receptor (TIR) domain, the exogenous and endogenous ligands of TLRs, and the current and future therapeutic strategies to target TLR signalling in rheumatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBPDFqhEIq1rVg90H21EOLACvtfcHk0lgQDoFmou8C0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvV2ntb8%253D&md5=a561bbe778204e8e57d599efdbec093a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2016.61&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2016.61%26sid%3Dliteratum%253Aachs%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2BB.%26aulast%3DAbdollahi-Roodsaz%26aufirst%3DS.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%26aulast%3DNetea%26aufirst%3DM.%2BG.%26atitle%3DToll-like%2520receptors%2520and%2520chronic%2520inflammation%2520in%2520rheumatic%2520diseases%253A%2520new%2520developments%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D344%26epage%3D357%26doi%3D10.1038%2Fnrrheum.2016.61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudhgaonkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karunanithi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariappan, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetsko, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carman, J. A.</span></span> <span> </span><span class="NLM_article-title">Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>198</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1308</span>â <span class="NLM_lpage">1319</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1600583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.4049%2Fjimmunol.1600583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=28003376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlaitb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2017&pages=1308-1319&issue=3&author=S.+Dudhgaonkarauthor=S.+Ranadeauthor=J.+Nagarauthor=S.+Subramaniauthor=D.+S.+Prasadauthor=P.+Karunanithiauthor=R.+Srivastavaauthor=K.+Venkateshauthor=S.+Selvamauthor=P.+Krishnamurthyauthor=T.+T.+Mariappanauthor=A.+Saxenaauthor=L.+Fanauthor=D.+K.+Stetskoauthor=D.+A.+Hollowayauthor=X.+Liauthor=J.+Zhuauthor=W.-P.+Yangauthor=S.+Rueppauthor=S.+Nairauthor=J.+Santellaauthor=J.+Dunciaauthor=J.+Hynesauthor=K.+W.+McIntyreauthor=J.+A.+Carman&title=Selective+IRAK4+inhibition+attenuates+disease+in+murine+lupus+models+and+demonstrates+steroid+sparing+activity&doi=10.4049%2Fjimmunol.1600583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity</span></div><div class="casAuthors">Dudhgaonkar, Shailesh; Ranade, Sourabh; Nagar, Jignesh; Subramani, Siva; Prasad, Durga Shiv; Karunanithi, Preethi; Srivastava, Ratika; Venkatesh, Kamala; Selvam, Sabariya; Krishnamurthy, Prasad; Mariappan, T. Thanga; Saxena, Ajay; Fan, Li; Stetsko, Dawn K.; Holloway, Deborah A.; Li, Xin; Zhu, Jun; Yang, Wen-Pin; Ruepp, Stefan; Nair, Satheesh; Santella, Joseph; Duncia, John; Hynes, John; McIntyre, Kim W.; Carman, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1308-1319</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The serine/threonine kinase IL-1R-assocd. kinase (IRAK)4 is a crit. regulator of innate immunity.  We have identified BMS-986126, a potent, highly selective inhibitor of IRAK4 kinase activity that demonstrates equipotent activity against multiple MyD88-dependent responses both in vitro and in vivo.  BMS-986126 failed to inhibit assays downstream of MyD88-independent receptors, including the TNF receptor and TLR3.  Very little activity was seen downstream of TLR4, which can also activate an MyD88-independent pathway.  In mice, the compd. inhibited cytokine prodn. induced by injection of several different TLR agonists, including those for TLR2, TLR7, and TLR9.  The compd. also significantly suppressed skin inflammation induced by topical administration of the TLR7 agonist imiquimod.  BMS-986126 demonstrated robust activity in the MRL/lpr and NZB/NZW models of lupus, inhibiting multiple pathogenic responses.  In the MRL/lpr model, robust activity was obsd. with the combination of suboptimal doses of BMS-986126 and prednisolone, suggesting the potential for steroid sparing activity.  BMS-986126 also demonstrated synergy with prednisolone in assays of TLR7- and TLR9-induced IFN target gene expression using human PBMCs.  Lastly, BMS-986126 inhibited TLR7- and TLR9-dependent responses using cells derived from lupus patients, suggesting that inhibition of IRAK4 has the potential for therapeutic benefit in treating lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs4ZWIchaO6rVg90H21EOLACvtfcHk0liiYTi8CCT0DQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlaitb8%253D&md5=340ba834510cd04eb0e984e212731e17</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1600583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1600583%26sid%3Dliteratum%253Aachs%26aulast%3DDudhgaonkar%26aufirst%3DS.%26aulast%3DRanade%26aufirst%3DS.%26aulast%3DNagar%26aufirst%3DJ.%26aulast%3DSubramani%26aufirst%3DS.%26aulast%3DPrasad%26aufirst%3DD.%2BS.%26aulast%3DKarunanithi%26aufirst%3DP.%26aulast%3DSrivastava%26aufirst%3DR.%26aulast%3DVenkatesh%26aufirst%3DK.%26aulast%3DSelvam%26aufirst%3DS.%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DMariappan%26aufirst%3DT.%2BT.%26aulast%3DSaxena%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DStetsko%26aufirst%3DD.%2BK.%26aulast%3DHolloway%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DW.-P.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DSantella%26aufirst%3DJ.%26aulast%3DDuncia%26aufirst%3DJ.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DCarman%26aufirst%3DJ.%2BA.%26atitle%3DSelective%2520IRAK4%2520inhibition%2520attenuates%2520disease%2520in%2520murine%2520lupus%2520models%2520and%2520demonstrates%2520steroid%2520sparing%2520activity%26jtitle%3DJ.%2520Immunol.%26date%3D2017%26volume%3D198%26issue%3D3%26spage%3D1308%26epage%3D1319%26doi%3D10.4049%2Fjimmunol.1600583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">The TLR and IL-1 signalling network at a glance</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2383</span>â <span class="NLM_lpage">2390</span>, <span class="refDoi">Â DOI: 10.1242/jcs.149831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1242%2Fjcs.149831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=24829146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsrbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2014&pages=2383-2390&issue=11&author=P.+Cohen&title=The+TLR+and+IL-1+signalling+network+at+a+glance&doi=10.1242%2Fjcs.149831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The TLR and IL-1 signalling network at a glance</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2383-2390</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Toll-like receptors (TLRs) and the receptors for interleukin (IL)-1, IL-18 and IL-33 are required for defense against microbial pathogens but, if hyper-activated or not switched off efficiently, can cause tissue damage and inflammatory and autoimmune diseases.  Understanding how the checks and balances in the system are integrated to fight infection without the network operating out of control will be crucial for the development of improved drugs to treat these diseases in the future.  In this Cell Science at a Glance article and the accompanying poster, I provide a brief overview of how one of these intricate networks is controlled by the interplay of protein phosphorylation and protein ubiquitylation events, and the mechanisms in myeloid cells that restrict and terminate its activation to prevent inflammatory and autoimmune diseases.  Finally, I suggest a few protein kinases that have been neglected as drug targets, but whose therapeutic potential should be explored in the light of recent advances in our understanding of their roles in the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Hfw28mAkmrVg90H21EOLACvtfcHk0liiYTi8CCT0DQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsrbK&md5=b86f588378be962309bad302139543c6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1242%2Fjcs.149831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.149831%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DThe%2520TLR%2520and%2520IL-1%2520signalling%2520network%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2014%26volume%3D127%26issue%3D11%26spage%3D2383%26epage%3D2390%26doi%3D10.1242%2Fjcs.149831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rokosz, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appell, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M. L.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">883</span>â <span class="NLM_lpage">903</span>, <span class="refDoi">Â DOI: 10.1517/14728222.12.7.883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1517%2F14728222.12.7.883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=18554156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=883-903&issue=7&author=L.+L.+Rokoszauthor=J.+R.+Beasleyauthor=C.+D.+Carrollauthor=T.+Linauthor=J.+Zhaoauthor=K.+C.+Appellauthor=M.+L.+Webb&title=Kinase+inhibitors+as+drugs+for+chronic+inflammatory+and+immunological+diseases%3A+progress+and+challenges&doi=10.1517%2F14728222.12.7.883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span></div><div class="casAuthors">Rokosz, Laura L.; Beasley, James R.; Carroll, Carolyn DiIanni; Lin, Tsung; Zhao, Jiuqiao; Appell, Kenneth C.; Webb, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-903</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  At the time of writing, there are seven marketed kinase inhibitor drugs.  The first kinase inhibitor, imatinib mesilate (Gleevec, Novartis), came to market in 2001, an inhibitor of the breakpoint cluster region (BCR)/Abelson murine leukemia oncogene homolog (ABL) fusion, platelet-derived growth factor (PDGF) receptor, and c-kit kinases.  The most recent kinase inhibitor to come to market, disatinib (Sprycel, Bristol-Myers Squibb), acts on c-SRC, ABL and Bruton's tyrosine kinase.  To date, kinase inhibitor drugs are approved for oncol. and demonstrate that it is possible to develop compds. with relative selectivity for the target kinase against the broader kinome.  However, the use of kinase inhibitors in chronic inflammatory and immunol. diseases may require greater selectivity for the target kinase.  This review addresses the opportunities and challenges of kinase inhibition as a therapeutic approach in chronic immune and inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq458NGQKTbcbVg90H21EOLACvtfcHk0liiYTi8CCT0DQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D&md5=6db3fdcc34b3ec97394c9dc6cdca8b99</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.7.883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.7.883%26sid%3Dliteratum%253Aachs%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DBeasley%26aufirst%3DJ.%2BR.%26aulast%3DCarroll%26aufirst%3DC.%2BD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26atitle%3DKinase%2520inhibitors%2520as%2520drugs%2520for%2520chronic%2520inflammatory%2520and%2520immunological%2520diseases%253A%2520progress%2520and%2520challenges%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2008%26volume%3D12%26issue%3D7%26spage%3D883%26epage%3D903%26doi%3D10.1517%2F14728222.12.7.883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W.-C.</span></span> <span> </span><span class="NLM_article-title">IRAK-4 inhibitors for inflammation</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">724</span>â <span class="NLM_lpage">737</span>, <span class="refDoi">Â DOI: 10.2174/156802609789044407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.2174%2F156802609789044407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=19689377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=724-737&issue=8&author=Z.+Wangauthor=H.+Wescheauthor=T.+Stevensauthor=N.+Walkerauthor=W.-C.+Yeh&title=IRAK-4+inhibitors+for+inflammation&doi=10.2174%2F156802609789044407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">IRAK-4 inhibitors for inflammation</span></div><div class="casAuthors">Wang, Zhulun; Wesche, Holger; Stevens, Tracey; Walker, Nigel; Yeh, Wen-Chen</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">724-737</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Interleukin-1 receptor-assocd. kinases (IRAKs) are key components in the signal transduction pathways utilized by interleukin-1 receptor (IL-1R), interleukin-18 receptor (IL-18R), and Toll-like receptors (TLRs).  Out of four members in the mammalian IRAK family, IRAK-4 is considered to be the "master IRAK", the only family member indispensable for IL-1R/TLR signaling.  In humans, mutations resulting in IRAK-4 deficiency have been linked to susceptibility to bacterial infections, esp. recurrent pyogenic bacterial infections.  Furthermore, knock-in expts. by several groups have clearly demonstrated that IRAK-4 requires its kinase activity for its function.  Given the crit. role of IRAK-4 in inflammatory processes, modulation of IRAK-4 kinase activity presents an attractive therapeutic approach for the treatment of immune and inflammatory diseases.  The recent success in the detn. of the 3-dimensional structure of the IRAK-4 kinase domain in complex with inhibitors has facilitated the understanding of the mechanistic role of IRAK-4 in immunity and inflammation as well as the development of specific IRAK-4 kinase inhibitors.  In this article, we review the biol. function of IRAK-4, the structural characteristics of the kinase domain, and the development of small mol. inhibitors targeting the kinase activity.  We also review the key pharmacophores required for several classes of inhibitors as well as important features for optimal protein/inhibitor interactions.  Lastly, we summarize how these insights can be translated into strategies to develop potent IRAK-4 inhibitors with desired properties as new anti-inflammatory therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRhyk3FnIbSrVg90H21EOLACvtfcHk0lgHxYE49ymTJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnO&md5=c6a1278c9b9647aa8ce21edac373ddaa</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F156802609789044407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789044407%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWesche%26aufirst%3DH.%26aulast%3DStevens%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DYeh%26aufirst%3DW.-C.%26atitle%3DIRAK-4%2520inhibitors%2520for%2520inflammation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26issue%3D8%26spage%3D724%26epage%3D737%26doi%3D10.2174%2F156802609789044407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors for the treatment of immunological disorders: recent advances</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">9030</span>â <span class="NLM_lpage">9058</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00667</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00667" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9030-9058&issue=20&author=M.+C.+Bryanauthor=N.+S.+Rajapaksa&title=Kinase+inhibitors+for+the+treatment+of+immunological+disorders%3A+recent+advances&doi=10.1021%2Facs.jmedchem.8b00667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span></div><div class="casAuthors">Bryan, Marian C.; Rajapaksa, Naomi S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9030-9058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry.  Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways.  While this focus has led to over 30 FDA-approved small mol. kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases.  Despite this lack of success, there remains tremendous reason for excitement.  Our growing understanding of the biol. involved in the inflammatory response, the factors that lead to safer small mol. kinase inhibitors, and the availability of selective tool mols. for interrogating specific nodes and pathways are all pushing the field forward.  This article focuses on recent developments requiring novel approaches to create safe and effective small mol. kinase inhibitors and where further work is needed to realize the promise of small mol. kinase inhibitors for patient benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVucOE4LCJALVg90H21EOLACvtfcHk0lgHxYE49ymTJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI&md5=aff62adff54c9152d2b2156b05d67400</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DRajapaksa%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520immunological%2520disorders%253A%2520recent%2520advances%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058%26doi%3D10.1021%2Facs.jmedchem.8b00667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelinsky, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korver, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawtin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.-L.</span></span> <span> </span><span class="NLM_article-title">IRAK4 kinase activity controls Toll-like receptorâinduced inflammation through the transcription factor IRF5 in primary human monocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">18689</span>â <span class="NLM_lpage">18698</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M117.796912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1074%2Fjbc.M117.796912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=28924041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2jurjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=18689-18698&issue=45&author=L.+Cushingauthor=A.+Winklerauthor=S.+A.+Jelinskyauthor=K.+Leeauthor=W.+Korverauthor=R.+Hawtinauthor=V.+R.+Raoauthor=M.+Flemingauthor=L.-L.+Lin&title=IRAK4+kinase+activity+controls+Toll-like+receptor%E2%80%93induced+inflammation+through+the+transcription+factor+IRF5+in+primary+human+monocytes&doi=10.1074%2Fjbc.M117.796912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes</span></div><div class="casAuthors">Cushing, Leah; Winkler, Aaron; Jelinsky, Scott A.; Lee, Katherine; Korver, Wouter; Hawtin, Rachael; Rao, Vikram R.; Fleming, Margaret; Lin, Lih-Ling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18689-18698</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Interleukin-1 receptor-assocd. kinase 4 (IRAK4) plays a crit. role in innate immune signaling by Toll-like receptors (TLRs), and loss of IRAK4 activity in mice and humans increases susceptibility to bacterial infections and causes defects in TLR and IL1 ligand sensing.  However, the mechanism by which IRAK4 activity regulates the prodn. of downstream inflammatory cytokines is unclear.  Using transcriptomic and biochem. analyses of human monocytes treated with a highly potent and selective inhibitor of IRAK4, we show that IRAK4 kinase activity controls the activation of interferon regulatory factor 5 (IRF5), a transcription factor implicated in the pathogenesis of multiple autoimmune diseases.  Following TLR7/8 stimulation by its agonist R848, chem. inhibition of IRAK4 abolished IRF5 translocation to the nucleus and thus prevented IRF5 binding to and activation of the promoters of inflammatory cytokines in human monocytes.  We also found that IKKÎ², an upstream IRF5 activator, is phosphorylated in response to the agonist-induced TLR signaling.  Of note, IRAK4 inhibition blocked IKKÎ² phosphorylation but did not block the nuclear translocation of NFÎºB, which was surprising, given the canonical role of IKKÎ² in phosphorylating IÎºB to allow NFÎºB activation.  Moreover, pharmacol. inhibition of either IKKÎ² or the serine/threonine protein kinase TAK1 in monocytes blocked TLR-induced cytokine prodn. and IRF5 translocation to the nucleus, but not nuclear translocation of NFÎºB.  Taken together, our data suggest a mechanism by which IRAK4 activity regulates TAK1 and IKKÎ² activation, leading to the nuclear translocation of IRF5 and induction of inflammatory cytokines in human monocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSuWx97aRdRrVg90H21EOLACvtfcHk0lgHxYE49ymTJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2jurjE&md5=0de08402791155c147cfebdeb6ab768e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.796912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.796912%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DL.%26aulast%3DWinkler%26aufirst%3DA.%26aulast%3DJelinsky%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DKorver%26aufirst%3DW.%26aulast%3DHawtin%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DFleming%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DL.-L.%26atitle%3DIRAK4%2520kinase%2520activity%2520controls%2520Toll-like%2520receptor%25E2%2580%2593induced%2520inflammation%2520through%2520the%2520transcription%2520factor%2520IRF5%2520in%2520primary%2520human%2520monocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26issue%3D45%26spage%3D18689%26epage%3D18698%26doi%3D10.1074%2Fjbc.M117.796912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscoe, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bree, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dower, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisbie, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hope, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaioannou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samardjiev, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soutter, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapf, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5521</span>â <span class="NLM_lpage">5542</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5521-5542&issue=13&author=K.+L.+Leeauthor=C.+M.+Amblerauthor=D.+R.+Andersonauthor=B.+P.+Boscoeauthor=A.+G.+Breeauthor=J.+I.+Brodfuehrerauthor=J.+S.+Changauthor=C.+Choiauthor=S.+Chungauthor=K.+J.+Curranauthor=J.+E.+Dayauthor=C.+M.+Dehnhardtauthor=K.+Dowerauthor=S.+E.+Drozdaauthor=R.+K.+Frisbieauthor=L.+K.+Gavrinauthor=J.+A.+Goldbergauthor=S.+Hanauthor=M.+Hegenauthor=D.+Hepworthauthor=H.+R.+Hopeauthor=S.+Kamtekarauthor=I.+C.+Kiltyauthor=A.+Leeauthor=L.-L.+Linauthor=F.+E.+Loveringauthor=M.+D.+Loweauthor=J.+P.+Mathiasauthor=H.+M.+Morganauthor=E.+A.+Murphyauthor=N.+Papaioannouauthor=A.+Patnyauthor=B.+S.+Pierceauthor=V.+R.+Raoauthor=E.+Saiahauthor=I.+J.+Samardjievauthor=B.+M.+Samasauthor=M.+W.+H.+Shenauthor=J.+H.+Shinauthor=H.+H.+Soutterauthor=J.+W.+Strohbachauthor=P.+T.+Symanowiczauthor=J.+R.+Thomasonauthor=J.+D.+Trzupekauthor=R.+Vargasauthor=F.+Vincentauthor=J.+Yanauthor=C.+W.+Zapfauthor=S.+W.+Wright&title=Discovery+of+clinical+candidate+1-%7B%5B%282S%2C3S%2C4S%29-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%5Dmethoxy%7D-7-methoxyisoquinoline-6-carboxamide+%28PF-06650833%29%2C+a+potent%2C+selective+inhibitor+of+interleukin-1+receptor+associated+kinase+4+%28IRAK4%29%2C+by+fragment-based+drug+design&doi=10.1021%2Facs.jmedchem.7b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design</span></div><div class="casAuthors">Lee, Katherine L.; Ambler, Catherine M.; Anderson, David R.; Boscoe, Brian P.; Bree, Andrea G.; Brodfuehrer, Joanne I.; Chang, Jeanne S.; Choi, Chulho; Chung, Seungwon; Curran, Kevin J.; Day, Jacqueline E.; Dehnhardt, Christoph M.; Dower, Ken; Drozda, Susan E.; Frisbie, Richard K.; Gavrin, Lori K.; Goldberg, Joel A.; Han, Seungil; Hegen, Martin; Hepworth, David; Hope, Heidi R.; Kamtekar, Satwik; Kilty, Iain C.; Lee, Arthur; Lin, Lih-Ling; Lovering, Frank E.; Lowe, Michael D.; Mathias, John P.; Morgan, Heidi M.; Murphy, Elizabeth A.; Papaioannou, Nikolaos; Patny, Akshay; Pierce, Betsy S.; Rao, Vikram R.; Saiah, Eddine; Samardjiev, Ivan J.; Samas, Brian M.; Shen, Marina W. H.; Shin, Julia H.; Soutter, Holly H.; Strohbach, Joseph W.; Symanowicz, Peter T.; Thomason, Jennifer R.; Trzupek, John D.; Vargas, Richard; Vincent, Fabien; Yan, Jiangli; Zapf, Christoph W.; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5521-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topol. in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays.  The medicinal chem. effort featured the judicious placement of lipophilicity, informed by cocrystal structures with IRAK4 and optimization of ADME properties to deliver clin. candidate I.  This compd. benefitted from a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYrCep64bhMbVg90H21EOLACvtfcHk0lhKxwAnPiexiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D&md5=9771ad2d33089f6ef3dba3556536ff1a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DBree%26aufirst%3DA.%2BG.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%2BI.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDower%26aufirst%3DK.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DGoldberg%26aufirst%3DJ.%2BA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DL.-L.%26aulast%3DLovering%26aufirst%3DF.%2BE.%26aulast%3DLowe%26aufirst%3DM.%2BD.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DH.%2BM.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DPapaioannou%26aufirst%3DN.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSamardjiev%26aufirst%3DI.%2BJ.%26aulast%3DSamas%26aufirst%3DB.%2BM.%26aulast%3DShen%26aufirst%3DM.%2BW.%2BH.%26aulast%3DShin%26aufirst%3DJ.%2BH.%26aulast%3DSoutter%26aufirst%3DH.%2BH.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DR.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%25201-%257B%255B%25282S%252C3S%252C4S%2529-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%255Dmethoxy%257D-7-methoxyisoquinoline-6-carboxamide%2520%2528PF-06650833%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520interleukin-1%2520receptor%2520associated%2520kinase%25204%2520%2528IRAK4%2529%252C%2520by%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5521%26epage%3D5542%26doi%3D10.1021%2Facs.jmedchem.7b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span> <span> </span><span class="NLM_article-title">Mapping the efficiency and physicochemical trajectories of successful optimizations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6421</span>â <span class="NLM_lpage">6467</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00180</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00180" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6421-6467&issue=15&author=R.+J.+Youngauthor=P.+D.+Leeson&title=Mapping+the+efficiency+and+physicochemical+trajectories+of+successful+optimizations&doi=10.1021%2Facs.jmedchem.8b00180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations</span></div><div class="casAuthors">Young, Robert J.; Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6421-6467</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The practices and tactics employed in successful optimizations are examd., judged from the trajectories of ligand efficiency and property evolution.  A wide range of targets is analyzed, encompassing a variety of hit finding methods (HTS, fragments, encoded library technol.) and types of mols., including those beyond the rule of five.  The wider employment of efficiency metrics and lipophilicity control is evident in contemporary practice and the impact on quality demonstrable.  What is clear is that while targets are different, successful mols. are almost invariably among the most efficient for their target, even at the extremes.  Trajectory mapping, based on principles rather than rules, is useful in assessing quality and progress in optimizations while benchmarking against competitors and assessing property-dependent risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCQtcLKSk7q7Vg90H21EOLACvtfcHk0lhKxwAnPiexiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmu7Y%253D&md5=f040ef02d161e070bb5021fde1585e66</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DMapping%2520the%2520efficiency%2520and%2520physicochemical%2520trajectories%2520of%2520successful%2520optimizations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467%26doi%3D10.1021%2Facs.jmedchem.8b00180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KeserÃ¼, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi">Â DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105&author=A.+L.+Hopkinsauthor=G.+M.+Keser%C3%BCauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lhKxwAnPiexiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapeller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Selective interleukin-1 receptorâassociated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>212</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2189</span>â <span class="NLM_lpage">2201</span>, <span class="refDoi">Â DOI: 10.1084/jem.20151074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1084%2Fjem.20151074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=26621451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2015&pages=2189-2201&issue=13&author=P.+N.+Kellyauthor=D.+L.+Romeroauthor=Y.+Yangauthor=A.+L.+Shafferauthor=D.+Chaudharyauthor=S.+Robinsonauthor=W.+Miaoauthor=L.+Ruiauthor=W.+F.+Westlinauthor=R.+Kapellerauthor=L.+M.+Staudt&title=Selective+interleukin-1+receptor%E2%80%93associated+kinase+4+inhibitors+for+the+treatment+of+autoimmune+disorders+and+lymphoid+malignancy&doi=10.1084%2Fjem.20151074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span></div><div class="casAuthors">Kelly, Priscilla N.; Romero, Donna L.; Yang, Yibin; Shaffer, Arthur L., III; Chaudhary, Divya; Robinson, Shaughnessy; Miao, Wenyan; Rui, Lixin; Westlin, William F.; Kapeller, Rosana; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2189-2201</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Pathol. activation of the Toll-like receptor signaling adaptor protein MYD88 underlies many autoimmune and inflammatory disease states.  In the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLB CL), the oncogenic MYD88 L265P mutation occurs in 29% of cases, making it the most prevalent activating mutation in this malignancy.  IRAK4 kinase accounts for almost all of the biol. functions of MYD88, highlighting IRAK4 as a therapeutic target for diseases driven by aberrant MYD88 signaling.  Using innovative structure-based drug design methodologies, we report the development of highly selective and bioavailable small mol. IRAK4 inhibitors, ND-2158 and ND-2110.  These small mols. suppressed LPS-induced TNF prodn., alleviated collagen-induced arthritis, and blocked gout formation in mouse models.  IRAK4 inhibition promoted killing of ABC DLB CL lines harboring MYD88 L265P, by down-modulating survival signals, including NF-ÎºB and autocrine IL-6/IL-10 engagement of the JAK-STAT3 pathway.  In ABC DLB CL xenograft models, IRAK4 inhibition suppressed tumor growth as a single agent, and in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or the Bcl-2 inhibitor ABT-199.  Our findings support pharmacol. inhibition of IRAK4 as a therapeutic strategy in autoimmune disorders, in a genetically defined population of ABC DLB CL, and possibly other malignancies dependent on aberrant MYD88 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJuS2v8AyXXrVg90H21EOLACvtfcHk0liGA9G9dti3vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D&md5=cf477aff5f649644017cbe5330995a70</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1084%2Fjem.20151074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20151074%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DP.%2BN.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DW.%26aulast%3DRui%26aufirst%3DL.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DSelective%2520interleukin-1%2520receptor%25E2%2580%2593associated%2520kinase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520autoimmune%2520disorders%2520and%2520lymphoid%2520malignancy%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2015%26volume%3D212%26issue%3D13%26spage%3D2189%26epage%3D2201%26doi%3D10.1084%2Fjem.20151074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milletti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goracci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span> <span> </span><span class="NLM_article-title">Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4270</span>â <span class="NLM_lpage">4279</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2010.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1016%2Fj.ejmech.2010.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=20633962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=4270-4279&issue=9&author=F.+Millettiauthor=L.+Storchiauthor=L.+Goracciauthor=S.+Bendelsauthor=B.+Wagnerauthor=M.+Kansyauthor=G.+Cruciani&title=Extending+pKa+prediction+accuracy%3A+high-throughput+pKa+measurements+to+understand+pKa+modulation+of+new+chemical+series&doi=10.1016%2Fj.ejmech.2010.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Extending pKa prediction accuracy: High-throughput pKa measurements to understand pKa modulation of new chemical series</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Goracci, Laura; Bendels, Stefanie; Wagner, Bjoern; Kansy, Manfred; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4270-4279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We have recently developed a tool, MoKÎ±, to predict the pKa of org. compds. using a large dataset of over 26,500 literature pKa values as a training set.  However, predicting accurately pKa (<0.5 pH units) remains challenging for novel series, and this can be a drawback in the optimization of activity and ADME properties of lead compds.  To address this issue it is important to expand our knowledge of pKa determinants, therefore we have conducted high-throughput pKa measurements by using Spectral Gradient Anal. (SGA) on novel series of compds. selected from vendor databases.  Here we report our findings on the effect of specific chem. groups and steric constraints on the pKa of common functionalities in medicinal chem., such as amines, sulfonamides, and amides.  Furthermore, we report the pKa of ionizable groups that were not well represented in the database of literature pKa of MoKÎ±, such as hydrazide derivs.  These findings helped us to enhance MoKÎ±, which is here benchmarked on a set of exptl. pKa values from the Roche inhouse library (N = 5581; RMSE = 1.09; R2 = 0.82).  The accuracy of the predictions was greatly improved (RMSE = 0.49, R2 = 0.96) after training the software by using the automated tool Kibitzer with 6226 pK a values taken from a different set of Roche compds. appropriately selected, and this demonstrates the value of using high-throughput pKa measurements to expand the training set of pKa values used by the software MoKÎ±.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxQ9UJOAhB-rVg90H21EOLACvtfcHk0liGA9G9dti3vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D&md5=e4c579032df7fa37ec3551c69a09257a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DGoracci%26aufirst%3DL.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DExtending%2520pKa%2520prediction%2520accuracy%253A%2520high-throughput%2520pKa%2520measurements%2520to%2520understand%2520pKa%2520modulation%2520of%2520new%2520chemical%2520series%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26issue%3D9%26spage%3D4270%26epage%3D4279%26doi%3D10.1016%2Fj.ejmech.2010.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulshian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bober, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlisi, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossetta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span> <span> </span><span class="NLM_article-title">Potent and selective amidopyrazole inhibitors of IRAK4 that are efficacious in a rodent model of inflammation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">677</span>â <span class="NLM_lpage">682</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=677-682&issue=6&author=W.+T.+McElroyauthor=Z.+Tanauthor=G.+Hoauthor=S.+Paliwalauthor=G.+Liauthor=W.+M.+Seganishauthor=D.+Tulshianauthor=J.+Tataauthor=T.+O.+Fischmannauthor=C.+Sondeyauthor=H.+Bianauthor=L.+Boberauthor=J.+Jacksonauthor=C.+G.+Garlisiauthor=K.+Devitoauthor=J.+Fossettaauthor=D.+Lundellauthor=X.+Niu&title=Potent+and+selective+amidopyrazole+inhibitors+of+IRAK4+that+are+efficacious+in+a+rodent+model+of+inflammation&doi=10.1021%2Facsmedchemlett.5b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation</span></div><div class="casAuthors">McElroy, William T.; Tan, Zheng; Ho, Ginny; Paliwal, Sunil; Li, Guoqing; Seganish, W. Michael; Tulshian, Deen; Tata, James; Fischmann, Thierry O.; Sondey, Christopher; Bian, Hong; Bober, Loretta; Jackson, James; Garlisi, Charles G.; Devito, Kristine; Fossetta, James; Lundell, Daniel; Niu, Xiaoda</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-682</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">IRAK4 is a crit. upstream kinase in the IL-1R/TLR signaling pathway.  Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders.  A screening campaign identified a pyrazole class of IRAK4 inhibitors that were detd. by X-ray crystallog. to exhibit an unusual binding mode.  SAR efforts focused on the identification of a potent and selective inhibitor with good aq. soly. and rodent pharmacokinetics.  Pyrazole C-3 piperidines were well tolerated, with N-sulfonyl analogs generally having good rodent oral exposure but poor soly.  N-Alkyl piperidines exhibited excellent soly. and reduced exposure.  Pyrazoles possessing N-1 pyridine and fluorophenyl substituents were among the most active.  Piperazine 32 was a potent enzyme inhibitor with good cellular activity.  Compd. 32 reduced the in vivo prodn. of proinflammatory cytokines and was orally efficacious in a mouse antibody induced arthritis disease model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSA2VYtAf07Vg90H21EOLACvtfcHk0liGA9G9dti3vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D&md5=2203ad720b478a6e415d7d9df3e82106</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00106%26sid%3Dliteratum%253Aachs%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DHo%26aufirst%3DG.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSeganish%26aufirst%3DW.%2BM.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DBober%26aufirst%3DL.%26aulast%3DJackson%26aufirst%3DJ.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DPotent%2520and%2520selective%2520amidopyrazole%2520inhibitors%2520of%2520IRAK4%2520that%2520are%2520efficacious%2520in%2520a%2520rodent%2520model%2520of%2520inflammation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D6%26spage%3D677%26epage%3D682%26doi%3D10.1021%2Facsmedchemlett.5b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective pyrazolopyrimidine Janus kinase 2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10090</span>â <span class="NLM_lpage">10107</span>, <span class="refDoi">Â DOI: 10.1021/jm3012239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7vO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10090-10107&issue=22&author=E.+J.+Hananauthor=A.+van+Abbemaauthor=K.+Barrettauthor=W.+S.+Blairauthor=J.+Blaneyauthor=C.+Changauthor=C.+Eigenbrotauthor=S.+Flynnauthor=P.+Gibbonsauthor=C.+A.+Hurleyauthor=J.+R.+Kennyauthor=J.+Kulagowskiauthor=L.+Leeauthor=S.+R.+Magnusonauthor=C.+Morrisauthor=J.+Murrayauthor=R.+M.+Pastorauthor=T.+Rawsonauthor=M.+Siuauthor=M.+Ultschauthor=A.+Zhouauthor=D.+Sampathauthor=J.+P.+Lyssikatos&title=Discovery+of+potent+and+selective+pyrazolopyrimidine+Janus+kinase+2+inhibitors&doi=10.1021%2Fjm3012239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors</span></div><div class="casAuthors">Hanan, Emily J.; van Abbema, Anne; Barrett, Kathy; Blair, Wade S.; Blaney, Jeff; Chang, Christine; Eigenbrot, Charles; Flynn, Sean; Gibbons, Paul; Hurley, Christopher A.; Kenny, Jane R.; Kulagowski, Janusz; Lee, Leslie; Magnuson, Steven R.; Morris, Claire; Murray, Jeremy; Pastor, Richard M.; Rawson, Tom; Siu, Michael; Ultsch, Mark; Zhou, Aihe; Sampath, Deepak; Lyssikatos, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10090-10107</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in discovering selective Jak2 inhibitors for use in treating these disorders.  A high-throughput screening effort identified the pyrazolo[1,5-a]pyrimidine scaffold as a potent inhibitor of Jak2.  Optimization of lead compds. in this chem. series for activity against Jak2, selectivity against other Jak family kinases, and good in vivo pharmacokinetic properties led to the discovery of (I).  In a SET2 xenograft model that is dependent on Jak2 for growth, I demonstrated a time-dependent knock-down of pSTAT5, a downstream target of Jak2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLsbJk8ilR07Vg90H21EOLACvtfcHk0lhI4N2ySvl7Gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7vO&md5=b08cc250ae2498a164c6ce416743c968</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm3012239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012239%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBlaney%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFlynn%26aufirst%3DS.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKulagowski%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DMagnuson%26aufirst%3DS.%2BR.%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPastor%26aufirst%3DR.%2BM.%26aulast%3DRawson%26aufirst%3DT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520pyrazolopyrimidine%2520Janus%2520kinase%25202%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D22%26spage%3D10090%26epage%3D10107%26doi%3D10.1021%2Fjm3012239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N. P. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1835</span>â <span class="NLM_lpage">1844</span>, <span class="refDoi">Â DOI: 10.1016/j.str.2006.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1016%2Fj.str.2006.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=17161373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlShsrvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1835-1844&issue=12&author=Z.+Wangauthor=J.+Liuauthor=A.+Sudomauthor=M.+Ayresauthor=S.+Liauthor=H.+Wescheauthor=J.+P.+Powersauthor=N.+P.+C.+Walker&title=Crystal+structures+of+IRAK-4+kinase+in+complex+with+inhibitors%3A+a+serine%2Fthreonine+kinase+with+tyrosine+as+a+gatekeeper&doi=10.1016%2Fj.str.2006.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of IRAK-4 Kinase in Complex with Inhibitors: A Serine/Threonine Kinase with Tyrosine as a Gatekeeper</span></div><div class="casAuthors">Wang, Zhulun; Liu, Jinsong; Sudom, Athena; Ayres, Merrill; Li, Shyun; Wesche, Holger; Powers, Jay P.; Walker, Nigel P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1835-1844</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Interleukin-1 (IL-1) receptor-assocd. kinase-4 (IRAK-4) is a serine/threonine kinase that plays an essential role in signal transduction by Toll/IL-1 receptors (TIRs).  Here, we report the crystal structures of the phosphorylated human IRAK-4 kinase domain in complex with a potent inhibitor and with staurosporine to 2.0 and 2.2 Ã, resp.  The structures reveal that IRAK-4 has a unique tyrosine gatekeeper residue that interacts with the conserved glutamate from helix Î±C.  Consequently, helix Î±C is "pulled in" to maintain the active orientation, and the usual pre-existing hydrophobic back pocket of the ATP-binding site is abolished.  The peptide substrate-binding site is more open when compared with other protein kinases due to a marked movement of helix Î±G.  The pattern of phosphate ligand interactions in the activation loop bears a close resemblance to that of a tyrosine kinase.  Our results provide insights into IRAK-4 function and the design of selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1kW8-IrZf47Vg90H21EOLACvtfcHk0lhI4N2ySvl7Gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlShsrvF&md5=6a8f14729eeb6776871ff632f0822f8f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2006.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2006.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWesche%26aufirst%3DH.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520IRAK-4%2520kinase%2520in%2520complex%2520with%2520inhibitors%253A%2520a%2520serine%252Fthreonine%2520kinase%2520with%2520tyrosine%2520as%2520a%2520gatekeeper%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26issue%3D12%26spage%3D1835%26epage%3D1844%26doi%3D10.1016%2Fj.str.2006.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, N.</span>; <span class="NLM_string-name">Chen, S.</span>; <span class="NLM_string-name">Hermann, J. C.</span>; <span class="NLM_string-name">Kuglstatter, A.</span>; <span class="NLM_string-name">Labadie, S. S.</span>; <span class="NLM_string-name">Lin, C. J. J.</span>; <span class="NLM_string-name">Lucas, M. C.</span>; <span class="NLM_string-name">Moore, A. G.</span>; <span class="NLM_string-name">Papp, E.</span>; <span class="NLM_string-name">Talamas, F. X.</span>; <span class="NLM_string-name">Wanner, J.</span>; <span class="NLM_string-name">Zhai, Y.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5<i>a</i>]pyrimidine and Thieno[3,2<i>b</i>]pyrimidine Derivatives As IRAK4 Modulators</span>. <span class="NLM_patent">WO2012007375A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+Arora&author=S.+Chen&author=J.+C.+Hermann&author=A.+Kuglstatter&author=S.+S.+Labadie&author=C.+J.+J.+Lin&author=M.+C.+Lucas&author=A.+G.+Moore&author=E.+Papp&author=F.+X.+Talamas&author=J.+Wanner&author=Y.+Zhai&title=Pyrazolo%5B1%2C5a%5Dpyrimidine+and+Thieno%5B3%2C2b%5Dpyrimidine+Derivatives+As+IRAK4+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DN.%26atitle%3DPyrazolo%255B1%252C5a%255Dpyrimidine%2520and%2520Thieno%255B3%252C2b%255Dpyrimidine%2520Derivatives%2520As%2520IRAK4%2520Modulators%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="note"><p class="first last">Compound <b>22</b> solubility in standard phosphate buffer: pH 2.0 = 17.2 ug/mL; pH 7.4 = 5.2 ug/mL. Precipitation was observed in thermodynamic solubility solutions at pH 2.0 and pH 7.4. Kinetic solubility in 2% DMSO = 1.00 uM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland 2: complexity and promiscuity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">515</span>â <span class="NLM_lpage">519</span>, <span class="refDoi">Â DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&issue=3&author=F.+Lovering&title=Escape+from+flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0lhI4N2ySvl7Gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D3%26spage%3D515%26epage%3D519%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>â <span class="NLM_lpage">6756</span>, <span class="refDoi">Â DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lhX9FvDT4g6Cg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyota, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakura, Y.</span></span> <span> </span><span class="NLM_article-title">TLR9-dependent systemic interferon-Î² production by intravenous injection of plasmid DNA/cationic liposome complex in mice</span>. <i>J. Gene Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">708</span>â <span class="NLM_lpage">717</span>, <span class="refDoi">Â DOI: 10.1002/jgm.1348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1002%2Fjgm.1348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=19462411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFSqtbzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=708-717&issue=8&author=H.+Yoshidaauthor=M.+Nishikawaauthor=S.+Yasudaauthor=Y.+Mizunoauthor=H.+Toyotaauthor=T.+Kiyotaauthor=R.+Takahashiauthor=Y.+Takakura&title=TLR9-dependent+systemic+interferon-%CE%B2+production+by+intravenous+injection+of+plasmid+DNA%2Fcationic+liposome+complex+in+mice&doi=10.1002%2Fjgm.1348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">TLR9-dependent systemic interferon-Î² production by intravenous injection of plasmid DNA/cationic liposome complex in mice</span></div><div class="casAuthors">Yoshida, Hiroyuki; Nishikawa, Makiya; Yasuda, Sachiyo; Mizuno, Yumiko; Toyota, Hiroyasu; Kiyota, Tsuyoshi; Takahashi, Rei; Takakura, Yoshinobu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Gene Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">708-717</span>CODEN:
                <span class="NLM_cas:coden">JGMEFG</span>;
        ISSN:<span class="NLM_cas:issn">1099-498X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Background: The type I interferon (IFN) response to DNA/cationic liposome complex, or lipoplex, has been reported in cultured cells, but little is known about the response in vivo.  Studies of the pro-inflammatory cytokine response to lipoplex have shown the importance of the unmethylated CpG dinucleotide (CpG motif) and its receptor, Toll-like receptor (TLR)-9.  Methods: CpG- and non-CpG lipoplex consisting of CpG- or non-CpG plasmid DNA, resp., and N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride/cholesterol liposomes were i.v. injected into mice.  IFN-Î² and interleukin (IL)-6 in the serum and organs were measured by the ELISA.  The involvement of TLR9, phagocytic cells and the spleen in the responses was evaluated using TLR9-/-, clodronate liposome-treated-, and splenectomized mice, resp.  Accumulation of blood cells in the lung was evaluated histol.  Results: CpG lipoplex induced a large increase in the levels of IFN-Î² and IL-6 in the serum, liver, spleen, lung and kidney, whereas non-CpG lipoplex scarcely had any effect.  Neither formulation led to significant cytokine prodn. in TLR9-/- mice.  Clodronate liposome-treated mice showed a large redn. in both IFN-Î² and IL-6 levels.  Splenectomized mice receiving CpG lipoplex also showed a significantly low prodn. of IL-6 but a similar level of IFN-Î² prodn. to that of unsplenectomized mice.  A large no. of monocytes were found in the capillary vessels around the pulmonary alveoli of mice receiving lipoplex.  Conclusions: These findings indicate that, in contrast to the prodn. of IL-6 from splenic macrophages, IFN-Î² is produced from phagocytic cells other than splenic macrophages after the injection of CpG lipoplex through the TLR9-dependent pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpozxbmNsSDD7Vg90H21EOLACvtfcHk0lhX9FvDT4g6Cg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFSqtbzF&md5=57243eaa103b84accf55de7f7d539d3e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fjgm.1348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjgm.1348%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DNishikawa%26aufirst%3DM.%26aulast%3DYasuda%26aufirst%3DS.%26aulast%3DMizuno%26aufirst%3DY.%26aulast%3DToyota%26aufirst%3DH.%26aulast%3DKiyota%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DR.%26aulast%3DTakakura%26aufirst%3DY.%26atitle%3DTLR9-dependent%2520systemic%2520interferon-%25CE%25B2%2520production%2520by%2520intravenous%2520injection%2520of%2520plasmid%2520DNA%252Fcationic%2520liposome%2520complex%2520in%2520mice%26jtitle%3DJ.%2520Gene%2520Med.%26date%3D2009%26volume%3D11%26issue%3D8%26spage%3D708%26epage%3D717%26doi%3D10.1002%2Fjgm.1348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Means, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golenbock, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luster, A. D.</span></span> <span> </span><span class="NLM_article-title">Human lupus autoantibodyâDNA complexes activate DCs through cooperation of CD32 and TLR9</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">407</span>â <span class="NLM_lpage">417</span>, <span class="refDoi">Â DOI: 10.1172/JCI23025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1172%2FJCI23025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=15668740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyjsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=407-417&issue=2&author=T.+K.+Meansauthor=E.+Latzauthor=F.+Hayashiauthor=M.+R.+Muraliauthor=D.+T.+Golenbockauthor=A.+D.+Luster&title=Human+lupus+autoantibody%E2%80%93DNA+complexes+activate+DCs+through+cooperation+of+CD32+and+TLR9&doi=10.1172%2FJCI23025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9</span></div><div class="casAuthors">Means, Terry K.; Latz, Eicke; Hayashi, Fumitaka; Murali, Mandakolathur R.; Golenbock, Douglas T.; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">407-417</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by pathogenic autoantibodies against nucleoproteins and DNA.  Here we show that DNA-contg. immune complexes (ICs) within lupus serum (SLE-ICs), but not protein-contg. ICs from other autoimmune rheumatic diseases, stimulates plasmacytoid DCs (PDCs) to produce cytokines and chemokines via a cooperative interaction between Toll-like receptor 9 (TLR9) and FcÎ³RIIa (CD32).  SLE-ICs transiently colocalized to a subcellular compartment contg. CD32 and TLR9, and CD32+, but not CD32-, PDCs internalized and responded to SLE-ICs.  Our findings demonstrate a novel functional interaction between Fc receptors and TLRs, defining a pathway in which CD32 delivers SLE-ICs to intracellular lysosomes contg. TLR9, inducing a signaling cascade leading to PDC activation.  These data demonstrate that endogenous DNA-contg. autoantibody complexes found in the serum of patients with SLE activate the innate immune system and suggest a novel mechanism whereby these ICs contribute to the pathogenesis of this autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWojsiWfm8irVg90H21EOLACvtfcHk0lhX9FvDT4g6Cg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyjsbg%253D&md5=5c81dcafef8948f79969df3c3aa061c1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1172%2FJCI23025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI23025%26sid%3Dliteratum%253Aachs%26aulast%3DMeans%26aufirst%3DT.%2BK.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DHayashi%26aufirst%3DF.%26aulast%3DMurali%26aufirst%3DM.%2BR.%26aulast%3DGolenbock%26aufirst%3DD.%2BT.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DHuman%2520lupus%2520autoantibody%25E2%2580%2593DNA%2520complexes%2520activate%2520DCs%2520through%2520cooperation%2520of%2520CD32%2520and%2520TLR9%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26issue%3D2%26spage%3D407%26epage%3D417%26doi%3D10.1172%2FJCI23025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad-Nejad, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HÃ¤cker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vabulas, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, H.</span></span> <span> </span><span class="NLM_article-title">Bacterial CpG-DNA and lipopolysaccharides activate toll-like receptors at distinct cellular compartments</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1958</span>â <span class="NLM_lpage">1968</span>, <span class="refDoi">Â DOI: 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1002%2F1521-4141%28200207%2932%3A7%3C1958%3A%3AAID-IMMU1958%3E3.0.CO%3B2-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=12115616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFajurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=1958-1968&issue=7&author=P.+Ahmad-Nejadauthor=H.+H%C3%A4ckerauthor=M.+Rutzauthor=S.+Bauerauthor=R.+M.+Vabulasauthor=H.+Wagner&title=Bacterial+CpG-DNA+and+lipopolysaccharides+activate+toll-like+receptors+at+distinct+cellular+compartments&doi=10.1002%2F1521-4141%28200207%2932%3A7%3C1958%3A%3AAID-IMMU1958%3E3.0.CO%3B2-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments</span></div><div class="casAuthors">Ahmad-Nejad, Parviz; Hacker, Hans; Rutz, Mark; Bauer, Stefan; Vabulas, Ramunas M.; Wagner, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1958-1968</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">Recognition by innate immune cells of the pathogen assocd. mol. patterns (PAMP) lipopolysaccharide (LPS) from Gram-neg. bacteria and bacterial CpG-DNA depends on Toll-like receptor 4 (TLR4) and TLR9, resp.  To define differences in the response to these distinct PAMP, we compared a key intracellular event, namely recruitment of myeloid differentiation marker 88 (MyD88) to the resp. PAMP-initiated TLR signaling.  Using MyD88-GFP fusion protein expressing macrophages we demonstrate that LPS and CpG-DNA trigger signaling from two different cellular locations: the former at the cell membrane and the latter at the lysosomal compartment.  While LPS does not require endocytosis to functionally assoc. with the membrane expressed TLR4/MD2 complex, internalization and endosomal maturation is conditional for CpG-DNA to activate TLR9.  In support of these data, TLR9 is not localized at the cell surface, but intracellularly.  These data stress the need to characterize individual TLR at the very beginning of signal initiation in order to understand their diverse biol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNK_GJnjUIHbVg90H21EOLACvtfcHk0ljBMdkb_bycpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFajurg%253D&md5=50c3a729b743d87586a35afec9a8777c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2F1521-4141%28200207%2932%3A7%3C1958%3A%3AAID-IMMU1958%3E3.0.CO%3B2-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-4141%2528200207%252932%253A7%253C1958%253A%253AAID-IMMU1958%253E3.0.CO%253B2-U%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad-Nejad%26aufirst%3DP.%26aulast%3DH%25C3%25A4cker%26aufirst%3DH.%26aulast%3DRutz%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DVabulas%26aufirst%3DR.%2BM.%26aulast%3DWagner%26aufirst%3DH.%26atitle%3DBacterial%2520CpG-DNA%2520and%2520lipopolysaccharides%2520activate%2520toll-like%2520receptors%2520at%2520distinct%2520cellular%2520compartments%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2002%26volume%3D32%26issue%3D7%26spage%3D1958%26epage%3D1968%26doi%3D10.1002%2F1521-4141%28200207%2932%3A7%3C1958%3A%3AAID-IMMU1958%3E3.0.CO%3B2-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gursel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gursel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinman, D. M.</span></span> <span> </span><span class="NLM_article-title">Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">17</span>â <span class="NLM_lpage">22</span>, <span class="refDoi">Â DOI: 10.1016/j.smim.2003.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=10.1016%2Fj.smim.2003.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=14751759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntVOntg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=17-22&issue=1&author=F.+Takeshitaauthor=I.+Gurselauthor=K.+J.+Ishiiauthor=K.+Suzukiauthor=M.+Gurselauthor=D.+M.+Klinman&title=Signal+transduction+pathways+mediated+by+the+interaction+of+CpG+DNA+with+Toll-like+receptor+9&doi=10.1016%2Fj.smim.2003.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9</span></div><div class="casAuthors">Takeshita, Fumihiko; Gursel, Ihsan; Ishii, Ken J.; Suzuki, Koichi; Gursel, Mayda; Klinman, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-22</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Synthetic oligodeoxynucleotides (ODN) expressing non-methylated "CpG motifs" patterned after those present in bacterial DNA have characteristic immunomodulatory effects.  CpG DNA is recognized as a pathogen-assocd. mol. pattern, and triggers a rapid innate immune response.  CpG ODN are being harnessed for a variety of therapeutic uses, including as immune adjuvants, for cancer therapy, as anti-allergens, and as immunoprotective agents.  The signal transduction pathway mediated by the engagement of CpG DNA with Toll-like receptor 9 (TLR9) is shared with other members of the TLR family.  Recent studies demonstrate that formation and maturation of CpG DNA-contg. endosomes are regulated by phosphatidylinositol 3 kinases and the Ras-assocd. GTP-binding protein, Rab5, which are essential for the initiation of TLR9-mediated signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpcyyr_i_p2rVg90H21EOLACvtfcHk0ljBMdkb_bycpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntVOntg%253D%253D&md5=114d24bad4ee7c00b231b03b827c5a57</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.smim.2003.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smim.2003.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DTakeshita%26aufirst%3DF.%26aulast%3DGursel%26aufirst%3DI.%26aulast%3DIshii%26aufirst%3DK.%2BJ.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DGursel%26aufirst%3DM.%26aulast%3DKlinman%26aufirst%3DD.%2BM.%26atitle%3DSignal%2520transduction%2520pathways%2520mediated%2520by%2520the%2520interaction%2520of%2520CpG%2520DNA%2520with%2520Toll-like%2520receptor%25209%26jtitle%3DSemin.%2520Immunol.%26date%3D2004%26volume%3D16%26issue%3D1%26spage%3D17%26epage%3D22%26doi%3D10.1016%2Fj.smim.2003.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anima, B.</span>; <span class="NLM_string-name">Hosahalli, S.</span>; <span class="NLM_string-name">Subhendu, M.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Heterocycles as IRAK4 Inhibitors</span>. <span class="NLM_patent">WO2013042137</span>, 28/03/2013, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=B.+Anima&author=S.+Hosahalli&author=M.+Subhendu&title=Bicyclic+Heterocycles+as+IRAK4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAnima%26aufirst%3DB.%26atitle%3DBicyclic%2520Heterocycles%2520as%2520IRAK4%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span> <span> </span><span class="NLM_article-title">Addition of amines to nitriles catalyzed by ytterbium amides: an efficient one-step synthesis of monosubstituted N-arylamidines</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">445</span>â <span class="NLM_lpage">448</span>, <span class="refDoi">Â DOI: 10.1021/ol702739c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol702739c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFyltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=445-448&issue=3&author=J.+Wangauthor=F.+Xuauthor=T.+Caiauthor=Q.+Shen&title=Addition+of+amines+to+nitriles+catalyzed+by+ytterbium+amides%3A+an+efficient+one-step+synthesis+of+monosubstituted+N-arylamidines&doi=10.1021%2Fol702739c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of Amines to Nitriles Catalyzed by Ytterbium Amides: An Efficient One-Step Synthesis of Monosubstituted N-Arylamidines</span></div><div class="casAuthors">Wang, Junfeng; Xu, Fan; Cai, Tao; Shen, Qi</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">445-448</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A one-step synthesis of monosubstituted N-arylamidinates via addn. of amines to nitriles catalyzed by ytterbium amides is reported.  The reactions with various substrates give the products in good to excellent yields with 5 mol % ytterbium at 100 Â°C under solvent-free conditions.  E.g., reaction of 2,6-diisopropylaniline and PhCN gave up to 97% N-(2,6-diisopropylphenyl)benzamidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYUfirKNAH2rVg90H21EOLACvtfcHk0ljBMdkb_bycpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFyltQ%253D%253D&md5=23e0f1f9315088ef488e8d42755dd03f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fol702739c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol702739c%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DQ.%26atitle%3DAddition%2520of%2520amines%2520to%2520nitriles%2520catalyzed%2520by%2520ytterbium%2520amides%253A%2520an%2520efficient%2520one-step%2520synthesis%2520of%2520monosubstituted%2520N-arylamidines%26jtitle%3DOrg.%2520Lett.%26date%3D2008%26volume%3D10%26issue%3D3%26spage%3D445%26epage%3D448%26doi%3D10.1021%2Fol702739c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span>; <span class="NLM_string-name">Gobbi, A.</span>; <span class="NLM_string-name">Kiefer, J. R.</span>; <span class="NLM_string-name">Kolesnikov, A.</span>; <span class="NLM_string-name">Olivero, A.</span>; <span class="NLM_string-name">Drobnick, J.</span>; <span class="NLM_string-name">Liang, J.</span>; <span class="NLM_string-name">Rajapaksa, N.</span>; <span class="NLM_string-name">Ndubaka, C. I.</span>; <span class="NLM_string-name">Feng, J.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5<i>a</i>]pyrimidine Derivatives as IRAK4 Modulators</span>. <span class="NLM_patent">WO2017108723</span>, June 29, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+C.+Bryan&author=A.+Gobbi&author=J.+R.+Kiefer&author=A.+Kolesnikov&author=A.+Olivero&author=J.+Drobnick&author=J.+Liang&author=N.+Rajapaksa&author=C.+I.+Ndubaka&author=J.+Feng&title=Pyrazolo%5B1%2C5a%5Dpyrimidine+Derivatives+as+IRAK4+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26atitle%3DPyrazolo%255B1%252C5a%255Dpyrimidine%2520Derivatives%2520as%2520IRAK4%2520Modulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O9D" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O9D','PDB','6O9D'); return false;">PDB: 6O9D</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O94" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O94','PDB','6O94'); return false;">PDB: 6O94</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8U" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8U','PDB','6O8U'); return false;">PDB: 6O8U</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O95" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O95','PDB','6O95'); return false;">PDB: 6O95</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i54"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00439">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_85303"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00439">10.1021/acs.jmedchem.9b00439</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings, synthetic procedures, biochemical and cellular assay conditions, metabolic stability assay conditions, kinase selectivity data, crystallography details, pharmacokinetic study conditions, and PK/PD study conditions (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00439/suppl_file/jm9b00439_si_001.pdf">PDF</a>)</p></li><li><p class="inline">List of compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00439/suppl_file/jm9b00439_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00439/suppl_file/jm9b00439_si_001.pdf">jm9b00439_si_001.pdf (2.19 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00439/suppl_file/jm9b00439_si_002.csv">jm9b00439_si_002.csv (2.2 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates and structure factors are deposited at the Protein Data Bank with codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O9D">6O9D</a> (<b>5</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O94">6O94</a> (<b>17</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8U">6O8U</a> (<b>23</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O95">6O95</a> (<b>41</b>).</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00439" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00439" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667988e8fc17d1cf","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
